Reagent Categories

Select Sub Section

Only applies to some categories


CodeReagent TitleDescription
0001 H9 Cloned cell line derived from HUT78 cell line; Widely used for the propagation of HIV.
0002 HUT78 Human cutaneous T-cell lymphoma. Secretes IL-2 and migration inhibition factor.
0005 CEM-CCRF (CAMR) Human T-lymphoblastoid cell line.
0006 CEM4 High level of cell surface CD4 expression. Closely related to CEM-CCRF by fingerprint analysis. CEM derived clone
0010 Molt 3 From the peripheral blood of a 19 year old male with acute lymphoblastic leukeamia.
0011 Molt 4 From the peripheral blood of a 19 year old male with acute lymphoblastic leukeamia.
0012 U937 Suitable for the growth of macrophage-tropic strains of HIV (CD14+, CD15+)
0013 C8166 Human T-lymphoblastoid cell. Reported to carry but not express HTLV-1; expresses tat sequence.
0014 MT2 Human T-cell transformed by co-cultivating with leukaemia lymphocytes harbouring HTLV-1. Sheds HTLV-1 in culture
0016 MT4(P) May shed HTLV-1 in culture. Stable sub-population of MT4 suitable for plaque assays
0017 MT4(S) Human T-cell transformed co-cultivating with leukaemia lymphocytes harbouring HTLV-1. May shed HTLV-1 in culture. Sub population of MT4 that are suitable for the induction of syncytia
0018 C91-PL Human cord-blood T-cells infected with co-cultivation with HTLV-positive T-cell lines. Sheds HTLV-1 in culture
0019 HeLa T4+ Transfected with CD4 cDNA. Supports infection with HIV and induction of syncytia.
0020 HeLa T8+ Transfected with CD8 cDNA. Does not support infection by HIV
0021 HeLa CD4 (HT4-C6) HeLa cells infected with a retrovirus vector expressing CD4. Support infection by HIV and induction of syncytia. Cells contain amphotropic MuLV and when co-infected with HIV may give rise to pseudotype virus particle formation.
0024 Sup-T1 Cells are TdT positive, CALLA negative and DR negative. They express pan T antigens, high levels of surface CD4 and lack sheep erythrocyte receptors. Morphology - Native lymphocyte.
0025 Jurkat tat III Jurkat cell line expressing the HIV-1 tat protein. Useful for growth of poorly replicating strains of HIV. Related to JM cells by DNA fingerprint analysis.
0026 LC5 HIV susceptible clone of Human embryonic lung fibroblasts. Used for neutralisation assays and for screening anti-viral compounds.
0027 Jurkat Clone E6-1 Clone of jurkat-FHCRC producing large amounts of IL-2 after stimulation. Cells may be induced to secrete gamma interferon and are CD4+. Related to JM cells (#0008) by DNA fingerprint analysis.
0028 U138MG Human glioblastoma cell line. Adherent cells growing as a monolayer with polygonal morphology
0029 U373MG Human glioblastoma/astrocytoma cell line. Epithelial-like cells growing as a monolayer.
0030 HL60 Human myeloid leukaemia cell line. From macrophage lineage (CD15+)
0031 THP1 Human acute monocytic leukaemia cell line. From macrophage lineage (CD14+, CD15+)
0032 Kas 45 T-cell line Human T-cell leukaemia cell line. Susceptible to infection with HIV-1/2 and can be used for the detection of antibodies to HIV.
0033 M8166 Human T-lymphoblastoid cell. Cloned from C8166 by K Mulder for increased susceptibility to SIV syncytium formation.
0034 HeLa-T4 pBK-LTRLac Transfected with LTR-LacZ. Supports infection by HIV with production of blue foci.
0035 HeLa env C Produces HIV-1 env, tat and presumably also rev gene products.
0036 HL2/3 Human Epithelial cells. Stably integrated copies of HXB2/3gpt. High level production of gag, env, tat, rev and nef but no RT or infectious virus produced.
0037 HLCD4-CAT HeLa Epithelial-like cells.. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene (HeLa T4+)
0039 U38 U937 Monocyte-like cells. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene.
0040 H938 H9 Lymphocyte-like cells. Contains integrated copies of HIV-1 LTR promotor linked to CAT gene (H938). When infected by HIV-1, H938 produces high levels of CAT.
0041 MV-1-lu Original CD4-negative mink lung cell line. (CCL64)
0042 MV-1-lu/CD4 Infected with an amphotropic retrovirus encoding the cDNA of the CD4 message downstream from the MoMLV LTR promoter as well as a neomycin resistance-selectable marker. Cells bind gp120 but are resistant to infection with HIV.
0043 U87.MG Original CD4-negative human glioma cells
0044 U87.MG/CD4 Human glioma cells expressing human CD4, infected with an amphotropic retrovirus encoding the cDNA of the CD4 message. Cells bind gp120, are resistant to infection by HIV-1 but sensitive to infection by HIV-2 and SIV.
0045 TE671/RD Human rhabdomyosarcoma cell line. Original CD4-negative cell line
0046 TE671/RD/CD4 Rhabdomyosarcoma cells were infected with an amphotropic retrovirus encoding the cDNA of the CD4 message downstream from the MoMLV LTR promoter as well as a neomycin resistance-selectable marker. Cells bind gp120 and are sensitive to infection with HIV-1
0047 HeLa CD4 + Clone 1022 HeLa cells were infected with a retroviral vector expressing CD4 and Neo resistance. Clone 1022 cells ezpress human CD4 protein on the cell surface and can be infected by most isolates of HIV.
0048 CEM SS Human T4-lymphoblastoid cell line. These cells have been cloned for both poly-L-lysine induced adherence to microtitre plates and viral-induced syncytial fusigenic sensitivity following infection with either cell-free or cell-associated HIV-1 and HIV-2.
0049 174 x CEM Fusion product of human B cell line 721.174 and human T cell line CEM. Found to be particularly useful for studies with SIV as it can be easily infected.
0050 CEM-A Fusion product of CEM-A and normal PBMC. Highly susceptible to HIV infection, 69% CD4+, 18% CD3+ and 1% CD20+
0052 Molt4 Clone8 High susceptibility to HIV-1 infection. Can be used to isolate and produce SIVagm
0053 HL tat Contains stably integrated copies of the HIV-1 LTR promoter linked tp a synthetic one-exon tat gene. This cell line was generated by co-transfection of HeLa cells with pSV2neo and with pL3tat, which contains the HIV-1 LTR promoter, synthetic first tat exo
0054 AA-2 Lymphoblastoid-like. AK- dCK- subclone of AA cells. Highly permissive to HIV-1 infection, useful for producing high titre virus stocks.
0055 HeLa/CD4-LTR-Beta-gal Express high levels of CD4 and contain one integrated copy of the HIV-1 LTR linked to the B-galactosidase gene.
0056 1A2 Secretes HIV-1 rev and tat proteins. Suited to viability endpoint assays for determining anti-HIV activity with the replication defective HIV-1 strain HIV-1 MC99Dtat-rev
0057 PM1 Permissive for growth of macrophage and t-tropic viruses
0058 FC36 cl.22 Adherent cells. Secretes HIV suppressive factors RANTES, MIP-1 alpha and beta after IL-2 stimulation.
0064 HOS.CD4 Adherent cells. CD4 control cell, low level expression of CXCR4.
0065 HOS.CD4 (Chemokine Receptor Transfectants) Adherant cells expressing chemokine receptors on the cell surface.
0066 HOS.CD4-pBABE-puro HOS-CD4 cells stably transformed with pBABE-puro. Can be used as a negative control for other p-BABE-puro derived HOS CD4 cell lines.
0067 A3.01/CCR5-A5 Clones of A3.01(A5) , expressing CCR5. Resistant to 2mg/ml G418 and is infectable by different NSI viruses. Also fuses in the presence of different NSI envelope
0068 A3.01/CCR5-F7 Clones of A3.01 (F7) expressing CCR5.Resistant to 2mg/ml G418 and is infectable by different NSI viruses. Also fuses in the presence of different NSI envelope
0069 U87/CD4 or CCR1 Adherent cells expressing human CD4 (0069c) or CCR1 (0069) on cell surface.
0070 U87.CD4/CCR2b Adherent cells expressing CCR2b on cell surface
0071 U87.CD4.CCR3 Adherent cells expressing CCR3 on cell surface
0072 U87.CD4.CCR5 Adherent cells expressing CCR5 on cell surface
0074 GHOST cell CCR1 Express CCR1 , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0075 GHOST cell CCR2 Express CCR2 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0076 GHOST cell CCR3 Express CCR3 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0077 GHOST cell CCR4 Express CCR4 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0078 GHOST cell CCR5 Express CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0079 GHOST cell CXCR4 Express CXCR4 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0080 GHOST cell BOB/GPR15 Express chemokines on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0081 GHOST cell BONZO/STRL33 Express chemokines on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0082 GHOST Parental cells Parental CD4 + cell line
0083 GHOST cell CCR8 Express CCR8 , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0084 GHOST cell X4/R5 Express CXCR4 and CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0085 GHOST cell R3/X4/R5 Express CCR3, CXCR4 and CCR5 on surface , also contain an HIV-2 ltr linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0086 GHOST cell Hi5 Express high levels of CCR5 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0087 GHOST cell V28 CXCR1 Express CX3CR1 on surface , also contain an HIV-2 LTR linked to a green fluorescent protein (GFP) gene. CD4, co-receptors and GFP are each under a different selection.
0088 Hos.CD4.CXCR4 Human CD4 cell expressing Simian CXCR4. HOS.CD4 cells have been stably transfected with pTARGET and cynomolgus macaque CXCR4. Co-receptor selected with G418.
0089 Hos.CD4.CCR5 Human CD4 cell expressing Simian CCR5. HOS.CD4 cells have been stably transfected with pTARGET and cynomolgus macaque CCR5. Co-receptor selected with G418.
0090 A2.01 Clonally selected natural CD4 negative mutant and resistant to HIV infection. May serve as a CD4 negative control.
0091 A2.01-CCR5 Clonally selected natural CD4 negative mutant, transfected to stably express CCR5. May be used in conjunction with #0090 and #0067/068
0092 HPBALL.CD4-CCR5 CD4+ T cell line with endogenous CXCR4 and stably transfected to express human CCR5. Susceptible to infection by R5, X4 & R5X4 using HIV-1 isolates.
0094 Jurkat-CD4.CCR5 CD4+ T cell line with endogenous CXCR4 and stably transfected to express human CCR5. Susceptible to infection by R5, X4 & R5X4 using HIV-1 isolates.
0097 RAW N5 & N7 Raw - N5 (0097.1) and - N7 (0097.2) Transfection with pSC NEF 51. Transfected to express low levels of NEF that are inducible by exposure of cells to cadmium chloride.
0098 A3.01 HAT sensitive derivative of CEM, a human T-cell line derived from the peripheral blood buffy coat of a four -year old Caucasian female with acute lymphoblastic leaukemia. Morphology is mature lymphocytic.
0099 CEM-NKR-CCR5 CEM-NKR cells were transduced with a retroviral vector to express human CCR5. Cells do not secrete infectious virus. Suitable for infection with primary HIV isolates and for neutralization assays.
0101 IIIB Original isolate of HIV-1 from Dr Robert Gallo's lab. Grows to high titre.
0102 MN Early isolate of HIV-1 from Dr Robet Gallo's lab
0103 RF Early isolate of HIV-1 from Dr Gallo laboratory
0104 LAI (BRU) First strain of HIV-1 to be isolated in 1983
0109 CBL-4 Tanzania, 1985, African isolate of HIV-1 originally called RUT.
0110 8E5/LAV Subclone of A3.01, a CD4+ CEM derived human T-cell line. Each cell contains a single integrated copy of LAV proviral DNA directing synthesis of defective virus particles.
0111 u455 Rapid virus production leading to syncytia and high levels of RT activity. Genome is divergent from other HIV-1 isolates including those from neighbouring Zaire.
0112 SF2 Early isolate from San Francico, easily neutralised
0113 SF162 Macrophage tropic strain
0114 SF2 mc Molecular clone of SF2
0115 A012B/D (AZT Resistant) Pair of sequential virus isolates from a patient with ARC/AIDS taken at 2 and 26 months after commencing AZT chemotherapy. Peripheral blood lymphocytes from the patient were co-cultivated with MT2 cells and drug sensitivity was examined using HeLa CD4+ ce
0116 A018A/C (AZT Resistant) Pair of sequential virus isolates from a patient with ARC/AIDS taken at 0 (A018A) and 14 (A018C) months after commencing AZT chemotherapy. Peripheral blood lymphocytes from the patient were co-cultivated with MT2 cells and drug sensitivity was examined us
0117 HIV-1 ELI Early African isolate, Zaire 1983.
0118 Ba-L Macrophage-monocyte-tropic strain, orginally identified as HTLVIII Ba-L in 1986.
0119 Ada-M Macrophage-monocyte-tropic strain. Drived from seropositive AIDS patient in 1986
0120 C-HIV-1 Original cambridege isolate isolated in 1984. Lacks Xhol, BamH1 and EcoR1 restriction sites.
0121 HIV-2 ROD ROD was one of the first reported isolates of HIV-2
0122 HIV-2 CBL-20 Rapid growing, produces syncytia in primary culture. Isolated from a patient with AIDS. Grows rapidly in culture producing high levels of RT. Produces syncytia in primary culture.
0123 HIV-2 CBL-21 Rapid growing, produces syncytia in primary culture. Isolated from a patient with AIDS. Grows rapidly in culture producing high levels of RT. Produces syncytia in primary culture.
0124 HIV-2 CBL-22 Isolated from a patient with ARC. Sensitive to neutralisation by antibodiesin HIV-2 positive sera and some cross reactivity with HIV-1 positive sera.. Slow growing , produces syncytia.
0125 HIV-2 CBL-23 Isolated from a patient without symptoms of HIV-related disease. Grows slowly and produces syncytia in primary cultures.
0126 HIV-2 CAM2 Full length lambda clone of HIV-2CAM2 is available (0225) as are a number of plasmid sub-clones (0212-0218)
0127 HIV-2 MIR One of the first reported isolates of HIV-2
0128 EHC91 Virus isolate from the Edinburgh heamophiliac cohort.
0129 EHC98 Isolate from the edinburgh heamophiliac cohort.
0131 GB8 Four sequential isolates. Produce distict syncytial morphologies in JM cells. Supplid as infected JM cells
0132 HIV-2 EHO Diverse strain of HIV-2 markedly different from HIV-2 ROD.
0135 Z129 Isolate from Zaire.
0136 HIV-1 MAL Isolated from a 7 year old boy with ARC from Zaire.
0137 105A-F (AZT Resistant) Series of 6 sequential isolates from a patient in Amsterdam. First isolate taken before commencement on AZT, then at 24, 60, 86, 115 and 136 weeks of therapy. Patient progressed to AIDS at week 80.
0138 ACH-2 Subclone of A3.01 producing low levels of RT and p24. Can be induced with phorbol myristate acetate or TNF-a to secrete high levels of HIV-1.
0139 U1/HIV-1 Sub-clone of the U937 chronically infected with HIV-1 with minimal constitutive expression of virus. U937 is a promonocyte obtained from a pleural effusion of a two year old Caucasian male with diffuse histiocytic lymphoma. Large semi-granular cells.
0140 OM-10.1 Cloned from HL60 infected with HIV-1. Each cell contains single integrated provirus. Expression can be induced. OM-10.1 cells show minimum, constitutive HIV-1 production and remain CD4+ under normal conditions.
0141 RTMC (AZT Resistant) In HeLa CD4+ cell assay, this virus has an IC50 value for AZT around 100 fold that of the wild type parental virus, HXB2.
0142 RTMF (AZT Resistant) In HeLa CD4+ cell assay, this virus has an IC50 value for AZT around 15-20-fold that of the wild type parental virus, HXB2.
0143 RTMN (AZT Resistant) In HeLa CD4+ cell assay this virus has an IC50 value for AZT around 60-70 fold that of the wild type parental virus HXB2.
0144 74V (DDI Resistant) In HeLa CD4+ cell assay this virus has an IC50 value for ddI and ddC around 6-10 fold that of the wild type parental virus HXB2. Derived by co-transfection of MT-2 cells with M13 RT clone containing 74V plus RT deleted proviral clone pHIVdRTBstEII
0145 184V (3TC/FTC Resistant) In HeLa CD4+ cell assay this virus has an IC50 value for 3TC and FTC around 1000 fold that of the wild type parental virus HXB2. Derived by co-transfection of MT-2 cells with M13 RT clone containing 184V plus RT deleted proviral clone pHIVdRTBstEII
0146 RTMDR1 (Triple Drug Resistant) In HeLa CD4+ cell assay this virus displays co-resistance to AZT, ddI and nevirapine. Derived by co-transfection of MT-2 cells with M13 RT clone containing 4IL, 74V, 106A, 215Y plus RT deleted proviral clone pHIVdRTBstEII
0147 JR-CSF Infects human brain primary glioma explant cells, producing persistant low levels of virus. The virus is non-cytopathic.
0148 JR-FL This virus was isolated from the same patient as JR-CSF (#0147), but has been found to be phenotypically distinct.Will not replicate in Jurkat , HUT78 or U937. Weekly cytopathic in PBL
0149 Primary isolates South Africa Clade C, NSI isolate SA/93/454 and Clade B, SI isolate SA/93/506.
0151 SIVmac251 (32H Isolate) Isolated from rhesus macaque given SIVmac251.
0156 FIV E77 Capable of inducing clinical signs of typical acute syndrome in 12 week old kittens, FeSFV has not been isolated from this stock.
0157 Purified SIVmac251 (32H isolate) SIVmac251 grown on C8166 cells for 3 days. Virus recovered by ultracentrifugation and purified.. Virus was 8-9 passages on from the 11/88 challenge stock. Reacts with Mab's to p26 (KK33) and gp120 (KK8) in western blot.
0158 Euro HIV-1 Field isolate - Han2 Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0159 Euro HIV-1 Field isolate - 4830 Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0160 Euro HIV-1 Field isolate - ACH168 (Q17BC) Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0161 Euro HIV-1 Field isolate - Ach320 (W6BC) Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0163 Euro HIV-1 Field isolate - 4803cll2mc Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0165 Euro HIV-1 Field isolate - ACH320.3.1.mc Low passage field isolates passaged only in Human PBMC's and their corresponding infectious molecular clones.
0166 SAQr (Saquinvir Resistant) HIV-1 GB8 sequentially passaged in the presence of Saquinvir produced this double mutant which has reduced sensitivity to the , Saquinvir (Roche proteinase inhibitor, Ro 31-8959) in vitro.
0167 MVP-5180 (Subtype O) A prototype HIV-1 subtype O virus, induces syncytia. Supplied as cell free supernatant from H9's or infected H9 cells.
0168 Ca-9 (Subtype O) Replicates in human PBMCs and CEMSS, but not in MT2, MOLT, U937,THP or Jurkat. NSI phenotype.
0169 HIV-1 primary isolates (env Subtypes A-F) Isolates of env subtypes A-F from HIV-1 seropositive, asymptomatic individuals in Brazil, Rwanda, Thailand and Uganda. Both SI and NSI viruses are provided. Genetic clones of the env regions are available for some of these viruses.
0170 MC99IIIBTat-Rev was generated by transfection of the proviral plasmid IIIB, an HXB-3 derivative. Oligonucleotidedirected mutagenesis with the bacteriophage M13 system (Amersham) was used to introduce five point mutations into the coding regions of tat and rev. Alows stud
0171 xxHIV-1LAI/ xxHIV-1 LAI M184V (3TC Resistant) 3TC-sensitive virus. Produced by electroporation of MT-2 cells with pxxHIV-1Lai proviral DNA. The virus was expanded once in MT-2 cells, harvested , aliquoted, and stored at -80°C.
0173 RU570 (Subtype G) env subtype G, slow growimg
0174 R132 (Subtype G) env subtype G, slow growing
0175 VI557 (Subtype H) env subtype H
0176 VI525 (Subtype G/H) subtype G (env)/subtype H (gag)
0177 HIV-1 primary isolates Uganda Isolated from seropositive individuals from Uganda. For known Genotype and Phenotype see datasheet .
0178 HIV-1 Primary isolates Rwanda Isolated from seropositive individuals from Rwanda. For known Genotype and Phenotype see datasheet .
0179 HIV-1 Primary isolates Brazil Isolated from seropositive individuals from Brazil. For known Genotype and Phenotype see datasheet
0180 HIV-1 primary isolates Thailand Isolated from seropositive individuals from Thialand. For known Genotype and Phenotype see datasheet.
0182 SHIV W61D Constructed by the replacement of gp120-Δgp41 region of SHIV-4 with the equivalent region of the HIV-1 clone ACH320.3.1. Infectious virus recovered by transfection into CEMx174 cells.
0183 SHIV HAN2 Constructed by the replacement of gp120-Δgp41 region of SHIV-4 with the equivalent region of the HIV-1 clone HAN2. Infectious virus recovered by transfection into human PBMC's
0187 SHIV-33 (CL18) DNA fragment encoding tat,rev,env (gp160) and vpu of HIV-1sf33 inserted into SIVmac239 to produce chimaeric recombinant SHIVsf33
0188 SHIV-162 (CL28) DNA fragment encoding tat,rev,env (gp160) and vpu of HIV-1sf162 inserted into SIVmac239 to produce chimaeric recombinant SHIVsf162.
0189 89.6 Replicates to high titres in primary human lymphocytes, macrophages, CEMx174 and MT4 cells; syncytium forming and extremely cytopathic. Uses chemokine co-receptors CCR1, CCR2, CCR3, CXCR4 & CCR5.
0190 YBF30 (Subtype N) Representative group N isolate. Shows genetic divergence, which suggests strain lies equidistant between HIV-1 group M and SIVcpz-gab. NSI, CCR5 using.
0191 BCF01 (Subtype O) Representative group O isolate. NSI, CCR5 using.
0192 BCF02 (Subtype O) Representative group O isolate. NSI, CCR5 using
0193 BCF06 (Subtype O) Representative group O isolate. SI, CXCR4, MT2 using.
0194 BCF07 (Subtype O) Representative group O isolate. NSI, CCR5 using
0195 BCF011 (Subtype O) Representative group O isolate. NSI, CCR5 using.
0196 Nucleoside RT Inhibitor Resistant Virus Sequential NNRTI & NRTI resistant isolates taken from a single patient.
0197 SE12808 & SE14784 Sub-type C isolates, SI, MT2 positive. Will infect U87.CD4-CXCR4.
0198 B117 Replicates on U87.CD4 cells expressing CCR1, CCR2b, CCR3, CXCR4 & CCR5.
0201 pNIBSC (SIV p26) pNIBSCI is dsM13mp18 containing a 744 base pair insert composed of the last 60 bases of p17 and the full length p27 gene from SIVmac251 (32H isolate).
0202 pLAI2 Full length insert of HIV-1 LAI. Produces infectious virus in PBL's, CD4+ t-cell lines and U937's
0204 pBK28-SIV Full length SIV infectious clone. Derived from SIVmac251
0205 pBH10 9Kb insert of BH-10 (III B), with 150bp deletion in both LTR's, subcloned into Sst1 site of SP64
0206 pHXB2D 12.5 Kb Xba I fragment of lambda HXB2 (HIV-1 IIIB). Complete provirus with flanking cellular sequences. Infectious when transfected into approprate cell line.
0207 pNIBSC2 (SIV gp32) Contains the full length gp32 env transmembrane protein from SIVmac251 (32H isolate). Fully sequenced.
0210 pGB8.C4 Full length insert of env gp160 from GB8.C4
0211 pGB8B.C9 Full length insert of env gp160 from GB8B.C9
0219 pNIBSC8 (SIV gp120) pNIBSC8 is dsM13 mp18 bacteriophage containing the entire env gene of SIVmac251 (32H isolate). The genomic DNA was extracted from C8166 cells infected with SIVmac251 (32H) and digested with Sal1. Primers were used to insert RE sites SalI and EcoRV at the
0220 pNIBSC7 (SIV gag) pNIBSC7 is dsM13 mp19 containing the entire gag gene of SIVmac251 (32H isolate). The genomic DNA was extracted from C8166 cells infected with SIVmac251 (32H) and digested with EcoR1. Primers were used to insert RE sites EcoR1 and Sma1 at the 5’ end and Hi
0221 pKA 27 (replaces pOGS247) pNIBSC1 was subcloned into pUC19 inframe with lacZ gene. Permits IPTG inducilble expression of SIV p27 (plus 20aa of p17) in a suitable E.coli host.
0222 pNIBSC9 (SIV rev) Contains a 343 bp insert of full length rev gene of SIVmac251 (32H isolate).
0223 pNIBSC4 (SIV pol) Spans the 3' end of gag and 5' end of pol including the entire proteinase gene.
0229 pJ5 del T-KS- (SIVmac32H) Full length infectious clone. Xhol sites at both ends of provirus. These clones are derivatives from the original SIVmac32H (pJ5) and SIVmac32H (pC8) clones. BamH1 to Xhol sites removed, BamH1, EcoR1, Xhol linker added. Sac1 site eliminated after cloni
0230 pC8 Del T-KS (SIVmac32H) Full length infectious clone with a 4 aa deletion in nef. xhoI sites at both ends of the virus. Derived from original C8 clones.
0231 pHIVdRTBstE11 Complete provirus except for a 1.4 Kb deletion at the RT region and the introduction of a BstEII restriction enzyme site at the deletion junction.
0232 pROD 10 Complete proviral sequence of HIV-2 ROD constructed from λROD27, λROD35 and pSPE2. Flanked by 200bp of cellular DNA at the 5’ end and 10bp at the 3’ end. Insert 10.5Kb; Vector 2Kb.Ampicillin Resistance Marker. 232.1 has SV40 ori inserted to assist trans
0233 pLTR/CAT Contains 5' LTR from HIV-1, Sub-clone of pNL4
0235 pC63.4.1 (tat) Retroviral vector for the expression of tat in mammalian cells
0237 ACH320 molecular clones 4 full length infectious clones with distinct biological phenotypes derived from a single individual infected with HIV.
0238 HIV-gpt Contains intact HIV-1HXB2 rev and tat genes. Deletion of sequences encoding gp160 has rendered HIV-gpt replication -defective. The pvuII-Dra1 SV2gpt fragment contains the SV40 origin of replication and coding sequences for the gpt gene.
0239 HIV-1 160 and 120 clones Envelope genes (gp160 and gp120) were PCR amplified from PBMC grown HIV-1 obtained from asymptomatic individuals within 2 years of sero-conversion. Amplification products were cloned by T/A overhang. These clones represent HIV-1 sequence subtypes A-E.
0240 CHO-pEE6HCMVgp120 GS Secretes rec HIV-1 IIIB gp120 into culture medium.
0242 CHO ST4.2 Secreates soluble CD4 (mycoplasma positve)
0243 CHO-6.2 (SIV gp120) Transfected with pSIV1 (SIV gp120) derived fron pNIBSC8 supplied by Dr N Almond. Secretes SIVmac251 (32H) rgp120
0244 CHO-P5 (SIV sgp160 cleavable) CHO cells transfected with pSIV3 (SIV gp160 with primary and secondary cleavage sites retained). Secretes SIVmac251 (32H) soluble gp160
0245 CHO -M5 (SIV sgp160 uncleavable) CHO cells transfected with pSIV3 (SIV gp160 with primary and secondary cleavage sites abolished). Secretes SIVmac251 (32H) soluble gp160 (uncleavable)
0246 CHO-4.4 (HIV-1 GB8 gp120) Secretes HIV-1 GB8 gp120 . Contains glutamine synthetase gene as a selectable marker.
0253 Vaccinia gag-vac Contains the HIV-1 gag-gene of pHIII 5.5 under the the control of the 7.5K early late promoter. Cells infected with this virus express the p55 gag protein.
0254 Vaccinia gag p17 vac Contains the HIV-1 gag p17 fragment of pHIII 5.5 under the control of the 7.5K early late promoter. Cells infected with this virus express the p17 gag protein
0255 Vaccinia env 2 Contains the env gene from HIV-1 IIIB. Cells infected with this virus express gp160
0256 Vaccinia v120 Contains the env gp120 from HIV-1 BRU.Cells infected with this virus express gp120
0257 Vaccinia v gag 1 Contains the gag p55 from hIV-1 IIIB. Cells infected with this virus express HIV-1 gag p55
0258 Vaccinia v gag 2 Contains the gag p57 gene from HIV-1 BRU. Cells infected with this virus express HIV-1 gag p57
0259 Vaccinia v gag F1 Contains the gag p40 gene fragment of HIV-1 IIIB. Cells infected with this virus express HIV-1 gag p40
0260 Vaccinia vp27 Infected cells express SIV gag p27
0261 Vaccinia vv SIV gag Contains gag of SIVmac (BK28). The myristylated p57 gag is expressed and targeted to the plasma membrane where budding occurs.
0262 Vaccinia vv SIV env Contains env gene of SIVmac (BK28). Gp 160 will be inserted into the plasma membrane. Will form syncytia with CD4+ cells
0263 Vaccinia vv SIV pol Express RT and integrase (Fused) protein approx. 90Kd
0264 HIV-1 env specific Riboprobe Complementary to highly conserved regions of HIV-1
0265 HIV-1 gag-specific Riboprobe Complementary to highly conserved regions of HIV-1
0266 HIV-1 pol-specific Riboprobe Complementary to highly conserved regions of HIV-1
0267 Vaccinia vRF222 Full length HIV-1 RF env gene expressed under the control of the vaccinia virus 7.5k promoter. Env gp160 is expressed in infected cells and syncitium formation may be observed.
0268 Vaccinia vMN462 Full length HIV-1 MN env gene expressed under the control of the 7.5 promoter. Env gp160 is expressed in infected cells , cleavage to gp120 and pg41 does not occur and syncitium formation not observed.
0269 Vaccinia vv 9001 (SIVmac vpx) vpx gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot.
0270 Vaccinia vv 9002 (SIVmac env gp160) env gene from SIVmac32H (pJ5 clone) not PCR derived . Expression confirmed by immunoblot.
0271 Vaccinia vv 9003 (SIVmac vif) vif gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot.
0272 Vaccinia vv 9001 (SIVmac vpr) vpr gene from SIVmac32H (pJ5 clone). Expression confirmed by immunoblot.
0273 Vaccinia vv 9001 (SIVmac rev) rev gene from SIVmac32H (pJ5 clone).
0274 Vaccinia vv9011 (SIVmac nef pJ5) nef gene from SIVmac32H (pJ5) clone. Expression confirmed by T-cell reactivity of infected mice to nef peptides
0275 Vaccinia vv9012 (SIVmac nef pC8) nef gene from SIVmac32H (pC8) clone. Expression confirmed by T-cell reactivity of infected mice to nef peptides
0276 Vaccinia vv9013 (SIVmac RT) RT PCR amplified from SIVmac32H (pJ5). Added EEF motif for purification. RT activity, Immunoblot reactive, IFA
0277 Vaccinia vv9015 (SIVmac tat) tat gene from SIVmac32H (pJ5) clone. tat gene product active on HIV LTR
0278 Vaccinia vv9019 (SIVmac gag/pol) gag/pol gene from SIVmac32H (pJ5) clone. Not PCR amplified. Genes active in a HERPES virus construct.
0279 Baculovirus- HIV-1 nef GST Baculovirus expressing HIV-1 nef
0280 Baculovirus-p17-GST GST with myristoylation sequence of HIV-1 p17 gag at the N-terminus MGARAS-GST.
0281 Baculovirus- human CD4 Baculovirus expressing CD4. 281.1 Full length human CD4. 281.2 Human CD4 with deletion of cytoplasmic domain, produces CD4 molecule truncated at aa394.
0282 GST-SIV-Pk expression vectors Contain various SIV genes derived from pBK28-SIV. The combination of two tags (GST or HIS and Pk) permits the purification of expressed proteins by a two step procedure or their assembly onto a solid matrix for immunisation.
0283 His-SIV-Pk Expression vectors Contain various SIV genes derived from pBK28-SIV. Genes encoding rev and tat were derived from SIVmac 32H (pJ5).The combination of two tags (GST or HIS and Pk) permits the purification of expressed proteins by a two step procedure or their assembly onto a
0284 HIV HXB2-env Contains HXB2 env fragment from pHXB2 gpt. HIV-1 gp160 is expressed, though no other viral products. Provides high levels of gp160 in COS cells.
0285 CHO-SIVmac 239 gp130 Clone 3 Cells secrete SIVmac 239 gp130.
0288 Baculovirus- SIV J5 nef GST Baculovirus expressing SIV J5 nef GST.
0289 Vaccinia HIV-1 env Envelope genes (#0239.1,2,3 and 11) pcr amplified by Dr B Hahn from primary isolates. Expression confirmed by immunoblot.
0290 MVA SIV recombinants Env, gag-pol, tat, rev, and nef genes from SIVmac J5. Expression confirmed by immunoblot.
0297 CHO pEE14/tpa/HIV-1 env PR1-16 Three sets of gp120 or gp160 inserts :- a) N Terminal truncates b) Loop deletions starting at aa93. Do not bind sCD4 or IIIB mabs recognising conformation dependant epitopes. c)As b) but bind sCD4 and confirmation dependant Mabs. Secreation of env dir
0298 CHO pEE14/tpa/HIV-2 env ROD CHO cells stably transfected with pEE14/tpa/HIV-2 ROD. Signal sequence of env replaced by tpa to direct secreation of rgp105 into culture medium
0299 Vaccinia p55 gag A clade p55 DNA from a Ugandan patient was PCR amplified and cloned into a modified plasmid (supplied by Dr P Balfe, UCLMS) expression is regulated by the vaccinia virus P7.5 promoter
0301 Mab to HIV-1 gp160/gp120 Binds to native gp120 weakly. Binds to denatured gp120 (SDS-DTT treated) more strongly. Mapped to peptide #0740.45 at gp120 carboxy terminus.
0302 Mab to CD4 (RFT4) Suitable for Immunoabsorption and as a diagnostic antibody for suspension and tissue culture work
0304 Mab to HIV-1 gp160/gp41 Mapped to peptide #0740.14 with some overlap with peptide #0740.13
0305 Mab to HIV-1 gp160/gp41 Specific to HIV-1 gp160/gp41
0306 Mab to HIV-1 gp160/gp41 Specific to HIV-1 gp160/gp41 by Immunoblot / ELISA.
0307 Mab to HIV-1 p24 Mapped to aa 284-289 and aa 351-356
0308 Mab to HIV-1 p55 Mapped to aa 357-362
0309 Mab to HIV-1 p24 mapped to aa288-295 and aa 351-356. reacts with peptide #0788.22
0310 Mab to CD4 (Q4084) Blocked by sCD4, inhibits syncitium formation (IIIB)
0311 Mab to CD4 (Q4116) Weakly inhibits syncitia (IIIB). Mapped to V3 domain
0313 Mab to HIV-1 p55/24 Reacts with peptides #0788 .7,.8,.13. Broadly reactive. Also availble conjugated to a/p or Biotinylated.
0314 Mab to HIV-1 p55/24 HIV-1 p55/p24 by immunoblot. Mapped to 177-182 (HIV-1 LAI). Reacts with peptide #0788.5
0315 Mab to HIV-1 p55/p18 HIV-1 p55/p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2)
0316 Mab to HIV-1 p18 HIV-1 p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2).
0317 Mab to HIV-1 gp41 Neutralises range of HIV-1 isolates.
0318 Mab to CD4 (Q4120) Blocked by sCD4; inhibits syncitia (IIIB) formation. Mapped to V1 domain of CD4
0319 Mab to HIV-1 p55/p24 Mapped to aa 275-280. reacts with peptide #0788.17
0320 Mab to HIV-1 p55/p24 Mapped to aa 363-368
0321 Mab to HIV-1 p24 Mapped to aa 358-363. reacts with peptide #0788.22
0322 Mab to HIV-1 p24 Mapped to aa281-286
0323 Mab to HIV-1 gp160/120 (CRA1) Recognises the 50K but not the 70K cleavage product of CHO gp120. Binds weakley to native gp120 (IIIB), but strongley to denatured gp120
0324 Mab to HIV-1 gp120 (CRA3) Does not immunoblot, binds native not denatured gp120. Neutralises HIV-1 (IIIB)
0325 Mab to HIV-1 gp120 (CRA4) Does not immunoblot, binds native not denatured gp120. Neutralises HIV-1 (IIIB)
0326 Mab to HIV-1 gp120 (CRA5) Does not immunoblot. Blocks CD4 binding. Binds native but not denatured gp120. Optimal binding in the presence of non-ionic detergent.
0327 Mab to HIV-1 gp120/gp160 (37.1.1) Binds native gp120 (IIIB) weakly, but denatured strongly.
0328 Mab to HIV-1 gp160/gp41 (60.1.1) Binds to denatured but not native gp120
0329 Mab to HIV-1 gp160/gp120 (136.1) Binds to denatured but not native gp120
0330 Mab to HIV-1 gp160/gp120 (140.1.1.1) Specific to HIV-1 gp160/gp41 by RIPA/Immunoblot/ELISA
0331 Mab to HIV-1 gp160/gp120 (178.1.1.1) Strongly binds to native gp120 (IIIB), but not to HXB2 gp120 (KRIRI sequence)
0332 Mab to HIV-1 gp160/gp120 (187.2.1) Moderate binding to native gp120, strong binding to denatured gp120
0333 Mab to HIV-1 gp160/gp120 (190.1.1) Specific to HIV-1 gp160/gp120 by RIPA/Immunoblot/ELISA
0334 Mab to HIV-1 gp160/gp120 (213.1) Weak binding to native gp120, but strong to denatured gp120.
0335 Mab to HIV-1 gp160/gp120 (H339.1.1) SPECIFICITY: HIV-1 gp160/gp120 by RIPA/ELISA; HOST: BALB/C mouse; IMMUNOGEN: HIV-1 IIIB; MYELOMA: Sp2
0337 Mab to CD4 High functional affinity equivalent to a Leu3a. Blocks gp120/CD4 binding and inhibits syncitia formation. Cross competes with #0386, 351, 357, a Leu3a, OKT4D or MT151. Similar to OKT4A. 1ml culture supernatant, 100ul ascitic fluid.
0338 Mab to HIV-1 gp120 (CRA2) Specific to HIV-1 gp120 by IRMA. Does not immunoblot.
0339 Mab to HIV-1 gp120 (CRA6) Specific to HIV-1 gp120 by IRMA. Does not immunoblot.
0340 Mab to HIV-1 gp120 (CRA7) Specific to HIV-1 gp120 by IRMA. Does not immunoblot.
0342 Mab to HIV-1 p18 HIV-1 p18 by immunoblot. Mapped to 121-134 (HIV-1 SF2)
0343 Mab to HIV-1 p18 HIV-1 p18. Mapped to 121-134 (HIV-1 SF2)
0344 Mab to HIV-1 p55/p18 HIV-1 p55/p18. Mapped to 101-115 (HIV-1 SF2).
0345 Mab to HIV-1 p55/p24 HIV-1 p55/p24. Mapped to 253-267 (HIV-1 LAI).. Reacts with peptide #0788.13
0346 Mab to HIV-1 p55/p24 HIV-1 p55/p24. Mapped to 303-317 (HIV-1 LAI)
0347 Mab to HIV-1 p55/p24
0348 Mab to HIV-1 p55/p24 HIV-1 p55/p24. Mapped to 143-157 (HIV-1 LAI). Reacts with peptide #0788.2
0350 Mab to HIV-1 p55/p24 HIV-1 p55/p24 by immunoblot (weak reactivity). Mapped to 133-147 (HIV-1 LAI).Reported to react with. Reacts with peptrides #0788.1,7 and 14
0351 Mab to CD4 Blocks gp120 binding.
0352 Mab to MAb anti HIV-1 tat (NT3 2D1.1) Immunoprecipitates and Immunoblots HIV-1 tat. mAb to N-terminal peptide.
0355 Mab to MAb anti HIV-1 rev (NR4-3C4.22) Reacts with HIV-1 rev in an immunoblot
0356 Mab to CD4 Does not block syncitium formation or rgp120 binding. Probably binds to V2 domain.
0357 Mab to CD4 Strongly blocks syncitium formation and blocks gp120 binding.
0364 Mab to CD4 Reacts with sCD4 and inhibits HIV- induced fusion.
0365 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 aa 253-282
0366 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 gag aa273-302
0367 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 gag aa 273-302
0368 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 gag aa 308-322. Reacts with peptides #0788.18 and 19
0369 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 gag aa308-322
0370 Mab to HIV-1 p24 Mapped to HIV-1 HXB2 gag aa 331-354. Reacts with peptide #0788.21
0372 Mab to CD4 A mouse monoclonal antibody to the V4 domain of human CD4. Cross-blocks L120 and MT429. Binds strongly to sCD4. Does not inhibit gp120 binding and HIV- induced fusion.
0373 Mab to SIV env gp120 (KK8) SIV env gp160/gp120. Maps to V1/V2 region.. Suitable for ELISA, immunoblotting , RIPA and IF. Purified antibody also available Cat# 100402
0380 Mab to HIV-1 RT Reacts with p66/p51 in Immunoblots, confirmational epitope.
0381 Mab to HIV-1 RT Reacts with p66/p51 in immunoblots and inhibits the reaction of RT enzyme in a Biological assay. Confirmational epitope possibly reacting with central region of RT aa231-430
0384 Mab to HIV-1 RT Reacts with p66/p51 in immunoblot. Mapped to C-terminus (aa 431-531)
0385 Mab to MAb anti HIV-1 nef (FL4) Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting
0386 Mab to anti HIV-1 nef (18FL7) Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting
0387 Mab to MAb anti HIV-1 nef (3FL4) Recognises aa 179-195 of HIV-1 IIIB nef. Suitable for ELISA/immunoblotting
0388 Mab to HIV-1 gp120 (ICR 38.1a) Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA
0389 Mab to HIV-1 gp120 (ICR 38.8f) Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA
0390 Mab to HIV-1 gp120 (ICR 39.13g) Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA
0391 Mab to HIV-1 gp120 (ICR 39.3b) Blocks CD4 binding. Neutralises HIV-1 IIIB/RF/MN/ at high concentrations. Suitable for ELISA
0392 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0393 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0394 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0395 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0396 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0397 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0398 Mab to SIV p27 Reacts in Immunoblot with SIV lysate
0401 Antiserum to HIV-1 rgp120 (CHO) Type specific to HIV-1 IIIB. The antiserum reacts strongly in a Western blot with native viral gp160 and gp120 and with both uncleaved and cleaved CH derived gp120.It has a type specific (HIV-I strain IIIB) virus-neutralisation titre of 1:80.
0403 Antiserum to HIV-1 rgp120 (CHO) Does not neutralise HIV-1 strain IIIB
0404 Antiserum to sCD4 (CHO)
0405 Antiserum to sCD4 (Baculovirus)
0406 Antisrum to HIV-1 rp24 (baculovirus)
0407 Antiserum to HIV-1 rgp160 (Baculovirus) Neutralising antobody titre of 1:20 against HIV-1 IIIB
0408 Antiserum to HIV-1 gp160 (Vaccinia)
0409 Antiserum to HIV-1 rgp160 (Vaccinia)
0410 Antiserum to HIV-1 p24 peptides For use in twin site ELISA for p24.
0411 Antiserum to HIV-1 rgp120 (Baculovirus)
0412 Antiserum to HIV-1 rgp120 (Baculovirus)
0413 Antiserum to HIV-1 protease
0414 Antiserum to SIV p27
0415 Antiserum to SIV env C-terminal peptide
0416 Antiserum to SIVmac251 (32H) Pooled antiserum from monkeys infected with live SIV. Antibodies to env, gag and pol are seen in an immunoblot
0418 Antiserum to HIV-2 gp105 (baculovirus)
0419 Antiserum to HIV-1 integrase peptide 1
0420 Antiserum to HIV-1 integrase peptide 2
0421 Antiserum to HIV-1 gp120 #20 (CHO) Neutralises IIIB at a titre of 1:20
0422 Antiserum to HIV-1 gp120#42 (CHO) Neutralises IIIB at a titre of 1:320
0423 Antiserum to HIV-1 gp120 #52 (CHO) Neutralises IIIB at a titre of 1:20
0424 Antiserum to SIV gp140 Neutralises SIVmac251 at a titre of 1:240
0425 Antiserum to HIV-1 gp120 #52 (CHO)
0426 Antiserum toHIV-2 gp105 #12
0427 Antiserum to NFk beta The cellular transcription factor NF-kB consists of two DNA-binding subunits of 50K and 65K and is believed to play an important role in stimulating transcriptional activation of HIV-1 in latently infected T-cells
0428 Antiserum to HIV-1 RT
0429 Antiserum to HIV-1 SF2 gp120 Neutralises SF2 at a titre of 1:10,000
0430 Antiserum to SIV gp140
0431 Antiserum to HIV-1 p17
0432 Antiserum to HIV-1 p24
0433 Antiserum to HIV-1 LAI V3 loop
0434 Antiserum to HIV-1 V3 Consensus group A
0435 Antiserum to HIV-1 V3 Consensus group B
0436 Antiserum to HIV-1 V3 Consensus group C
0437 Antiserum to HIV-1 V3 Consensus group D
0438 Antiserum to HIV-1 V3 Consensus group A_E
0439 Antiserum to HIV-1 MN gp120 Inhibits syncitium formation of IIIB and 4 clinical isolates
0440 Antiserum to HIV-1 GB8 gp120 (CHO) ELISA titre >10,000, neutralises GB8- titre 1:460 and R336 neutralises SF2 at a titre of 1:40
0441 Antiserum to SIV gp120 (CHO) Reacts with SIV gp120 in ELISA and Immunoblots
0443 Antiserum to HIV-1 GB8 rgp120 Reacts in ELISA (titre >10,000), immunoblot and neutralises HIV-1-see cat.
0444 Antiserum to HIV-1 nef-GST Reacts in ELISA, western blot and immunofluorescence. Will immunoprecipitate from in vitro translation assays but not from cell lysates.
0446 Antiserum to HIV-2 ST gp120 ELISA titre 1:250,000, western blots 1:2000 or 1:5000 with enhanced chemi-luminescence detection.
0452 Alkaline Phosphatase conjugated anti p24 Suitable for use in twin site ELISA's for p24 as a detection antibody
0453 Alkaline Phosphatase conjugated anti-p18 Suitable for use in Immunoblots for p18 as a detection antibody.
0454 Biotinylated anti-p24 Suitable for use in ELISA's for p24 as a detection antibody.
0512 HIV-1 (genotypes A-F) Plasma (WHO Panel G) WHO panel G. Panel of 8 plasma samples (8 x 100μl), with at least one ffrom each subtype A - F.
0513 HIVIG 1031 Purified HIV Immunoglobulin (HIVIG). HIVIG was prepared from discarded HIV-positive units of blood collected from the National Blood Bank in Kampala, Uganda. The pooled plasma was inactivated using solvent/detergent and the IgG fraction purified using ion
0514 Inactivated HIV Plasma Pool This reagent was prepared from discarded HIV-positive units of blood collected from the National Blood Bank in Kampala, Uganda. The pooled plasma was inactivated using solvent/detergent.
0515 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0516 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0517 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0518 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0519 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0520 HIV Positive Sera HIV+ plasma, unknown subtype. Part of Neut Net Panel (515-522)
0522 HIV Positive Sera HIV+ plasma, subtype F. Part of Neut Net Panel (515-522)
0523 HIV Negative Plasma Negative control plasma
0526 HIV-1 Plasma (C) Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0527 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0528 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0529 HIV-1 Plasma (F) Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0530 HIV-1 Plasma (F) Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0531 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0532 HIV-1 Plasma (C) Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0533 HIV-1 Plasma (E) Subtype E plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0534 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0535 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0536 HIV-1 Plasma (B) Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0537 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0538 HIV-1 Plasma (F) Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0539 HIV-1 Plasma (B) Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0540 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0541 HIV-1 Plasma (B) Subtype B plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0542 HIV-1 Plasma (BBR) Subtype BBr plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil.
0543 HIV-1 Plasma (F) Subtype F plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil
0544 HIV-1 Plasma (C) Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil
0545 HIV-1 Plasma (C) Subtype C plasma. Part of a plasma panel of 20 samples from HIV-1 infected patients from Brazil
0547 Subtype B Positive Plasma (12033)
0548 Subtype B Positive Plasma (12033)
0549 Subtype B Positive Plasma (13975)
0550 Subtype B Positive Plasma (10875)
0551 Subtype B Positive Plasma (14997)
0552 Subtype B Positive Plasma (11704)
0553 Subtype F Positive Plasma (14812)
0554 Subtype CR47BF Positive Plasma (13767)
0555 Subtype B Positive Plasma (14622)
0556 Subtype BF1 Positive Plasma (15368)
0557 Subtype B Positive Plasma (14532)
0558 Subtype B Positive Plasma (14745)
0559 Subtype F1 Positive Plasma (14934)
0560 Subtype CR47BF Positive Plasma (13718)
0561 Subtype B Positive Plasma (15354)
0562 Subtype B Positive Plasma (14295)
0563 Subtype B Positive Plasma (13162)
0564 HIV-1 (URF CRF02_AG/B) EUR001 Plasma from HIV-1 infected patient, SUBTYPE: URF CRF02_AG/B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0565 HIV-1 (G) EUR002 Plasma from HIV-1 infected patient, SUBTYPE: Subtype G (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0566 HIV-1 (CRF02_AG) EUR003 Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0567 HIV-1 (C) EUR004 Plasma from HIV-1 infected patient, SUBTYPE: C (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0568 HIV-1 (C) EUR005 Plasma from HIV-1 infected patient, SUBTYPE: C (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0569 HIV-1 (B) EUR006 Plasma from HIV-1 infected patient, SUBTYPE: B (pol). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0570 HIV-1 (B) EUR007 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0571 HIV-1 (B) EUR008 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0572 HIV-1 (G) EUR009 Plasma from HIV-1 infected patient, SUBTYPE: G (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0573 HIV-1 (F1) EUR010 Plasma from HIV-1 infected patient, SUBTYPE: F1 (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0574 HIV-1 (C) EUR011 Plasma from HIV-1 infected patient, SUBTYPE: C (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0575 HIV-1 (B) EUR012 Plasma from HIV-1 infected patient, SUBTYPE:B (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0576 HIV-1 (URF_BF1) EUR013 Plasma from HIV-1 infected patient, SUBTYPE:URF BF1 (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0577 HIV-1 (F1) EUR014 Plasma from HIV-1 infected patient, SUBTYPE: F1 (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0578 HIV-1 (CRF26_AU) EUR015 Plasma from HIV-1 infected patient, SUBTYPE: CRF26_AU (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0579 HIV-1 (G) EUR016 Plasma from HIV-1 infected patient, SUBTYPE: G (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0580 HIV-1 (B) EUR017 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0581 HIV-1 (D) EUR018 Plasma from HIV-1 infected patient, SUBTYPE: D (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0582 HIV-1 (A1) EUR019 Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0583 HIV-1 (F1) EUR020 Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0584 HIV-1 (A1) EUR021 Plasma from HIV-1 infected patient, SUBTYPE: A1 (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0585 HIV-1 (B) EUR022 Plasma from HIV-1 infected patient, SUBTYPE: B (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0586 HIV-1 (B) EUR023 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0587 HIV-1 (B) EUR024 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0588 HIV-1 (URF_02_AG/A1) EUR025 Plasma from HIV-1 infected patient, SUBTYPE URF_02_AG/A1. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0589 HIV-1 (B) EUR026 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0590 HIV-1 (B) EUR027 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0591 HIV-1 (B) EUR028 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0591 HIV-1 (URF_02_AG/A1) EUR025 Plasma from HIV-1 infected patient, SUBTYPE: URF_02_AG/A1. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0592 HIV-1 (URF_BF1) EUR029 Plasma from HIV-1 infected patient, SUBTYPE: URF BF1 (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0593 HIV-1 (CRF20_BG) EUR030 Plasma from HIV-1 infected patient, SUBTYPE: CRF20_BG (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0594 HIV-1 (B) EUR031 Plasma from HIV-1 infected patient, SUBTYPE: B (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0595 HIV-1 (URF_BF1) EUR032 Plasma from HIV-1 infected patient, SUBTYPE: URF BF1 (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0596 HIV-1 (G) EUR033 Plasma from HIV-1 infected patient, SUBTYPE: G (NFLG). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0597 HIV-1 (F1) EUR034 Plasma from HIV-1 infected patient, SUBTYPE: F1 (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0598 HIV-1 (B) EUR035 Plasma from HIV-1 infected patient, SUBTYPE: B (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0599 HIV-1 (CRF02_AG) EUR036 Plasma from HIV-1 infected patient, SUBTYPE: CRF02_AG (pol and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
0607 HIV-1 IIIB gp120 (Baculo.) Full Length Recombinant HIV-1 IIIB gp120 produced in the Baculovirus Expression System. Binds to sCD4.
0609 Human sCD4 Full-length recombinant Human T-Cell Receptor sCD4, produced in Baculovirus expression system. This protein binds to native and recombinant HIV-1 gp120 and HIV-2 gp105 and neutralises HIV-1 infectivity in CD4- bearing, HIV-1 infected cell cultures and HIV
0620 Rec HIV-1 LAI p24 Rec HIV-1 IIIB p24 produced in the Baculovirus expression system.
0621 HIV-2 gp105 (Baculo.) Migrates as a 105Kd protein on SDS-PAGE
0630 HIV-1 Proteinase (E.coli) Recombinant HIV-1 proteinase produced in E.coli.
0635 FIV p17 Recombinant FIV GLASGOW8 p17-GST fusion protein produced in E.coli
0636 FIV p24 Recombinant FIV GLASGOW8 p24-GST fusion protein produced in E.coli
0643 SIV p27 Expressed by pGEX-3X as a GST fusion protein. Reacts in Immunoblot with monkey antiserum to SIV and with Mabs to SIV p27
0646 HIV-1 MN gp120 (Baculo.) Full length recombinant envelope gp120 from T-cell-tropic HIV-1 MN strain, produced in the Baculovirus Expression System. This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase captu
0648 HIV-1 W61D gp120 (CHO) HIV-1 rgp120 from the molecular clone W61D derived from a Dutch field isolate of HIV-1, produced in CHO cells.
0651 HIV-1 integrase (E.coli) Recombinant HIV-1 Integrase from (LAV/BRU) strain. Produced in E.Coli. Active in 3' end processing and strand transfer of HIV-1 LTR substrates.
0657 HIV-1 gp120 (CHO) This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4 -), in vitro, as measured by RNA synthesis during G0 to G1
0659 HIV-1 vif Recombinant HIV-1 vif from IIIB strain, expressed in E.coli
0660 SIV p17 SIVmac 251 gag p17 (His p17-Pk fusion Protein). Produced in E.coli.
0661 HIV-2 p26 Recombinant HIV-2 p26 with GST fusion protein.
0667 HIV-1 gp120 from 93TH975 (Baculo.) Can be detected in Western blot using sheep or goat antibodies to HIV-1 gp120. Production: The env gene from HIV-1 93TH975.15 (GenBank Accession #U08457, construct donated by Dr. Beatrice Hahn) was cloned into a baculovirus vector. The protein was purifie
0668 SIV nef Recombinant SIV J5 nef. Produced in the Baculovirus expression system. Works well in immunoassays with CFAR Mabs: 3092, 3093 and 3094.
0669 SIV C8 nef Recombinant SIV C8 nef-GST. Produced in the Baculovirus expression system.
0671 HIV-1 MN gp41 Produced as a fusion protein in an E.coli expression system. Truncated gp41 protein mol. Wt: 25kD.This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western
0675 HIV-1 nef Recombinant HIV-1 nef aa3-190, produced in E.coli. Expressed as a fusion protein, B-galactosidase at N-terminus.
0677 HIV-2 gp36 [aa390-702] (E.coli) HIV-2 env antigen (recombinant) a.a. 390 to a.a. 702 of the HIV-2 env region 34 kDa. Reacts strongly with human HIV positive serum.
0678 HIV-1 p24 (Pichia) Recombinant p24 from HxB2 strain produced in Pichia pastoris (entire p24 protein, total 231 amino acids).
0679 HIV-2 gp36 Recombinant ecto-domain of HIV-2 gp36 produced in Pichia pastoris. Reacts with AIDS sera and human monoclonal antibodies as determined by ELISA and Western blot.
0680 HIV-1 gp41(Pichia.) Glycosylated recombinant ecto-domain of gp41, from HXB2 strain, amino acids 546-682, produced in Pichia pastoris (without the membrane spanning and cytoplasmic domains).
0681 SIV tat (E.coli) Recombinant SIV GST-tat-Pk.His Produced in E.coli. Low endotoxin aliquots available.
0683 HIV-1 CN54 gp120 (Baculo.) Chinese B/C recombinant. The env gene is predominantly subtype C except for a short region at the 5’ end.
0684 SIV J5 rev Recombinant SIVmac Clone J5 rev protein is expressed as His tag-fusion protein in E.coli using expression vector pET24.
0685 SIV J5 tat Recombinant TAT protein is expressed as His tag-fusion protein in E.coli using expression vector pET24.
0686 SIV J5 RT Recombinant RT protein from SIVmac clone J5 protein is expressed as His tag-fusion protein in E.coli using expression vector pET24.
0688 SARS CoV-1 Spike S1 protein S1 Subunit of SARS CoV-1. Protein is 100 Kda, consisting of a combination of the FC fusion (25 Kda) and the SARS CoV-1 S1 domain (70 Kda).
0689 HIV-1 IIIB p17 (E.coli) Recombinant p17 with authentic N and C terminii.
0691 HIV-1 nef (Clade A) Clade A recombinant nef-protein, expressed as His-tag fusion protein in E. Coli using expression vector pET24 and purified using Ni-agarose columns
0692 HIV-1 nef (Clade B) Clade B recombinant Nef protein, expressed as a His-tag fusion protein in E. coli using expression vector pET24 and purified using Ni-agarose columns.
0693 HIV-1 nef (Clade C) Clade C recombinant nef protein, expressed as His-tag fusion protein in E. coli using expression vector pET24 and purified using Ni-agarose columns.
0694 HIV-1 p17/24 (Clade B) Clade B recombinant p17/24-B protein is expressed as His-tag fusion protein in E.coli using expression vector pET24 and purified using Talon Superflow metal affinity resin.
0695 HIV-1 p17/24 (Clade C) Clade C recombinant p17/24-B protein, expressed as His-tag fusion protein in E.coli using expression vector pET24 and purified using Talon Superflow metal affinity resin.
0698 HIV-1 UG37 gp140 (CHO) Recombinant protein from the HIV-1 clade A strain 92UG037. Terminating after 2F5 epitope, Accession No: AY494974
0699 HIV-1 CN54 gp140 (CHO) Recombinant gp140 envelope protein from the HIV-1 clade C/B' strain CN97001 (clone CN54); the envelope protein is of clade C origin, accession number AF286226, terminating at ALDSWKN.
0703 Overlapping peptides HIV-1 gag p17 N-terminal cystine for conjugation.
0704 HIV-1 gag p15 N-terminal cystine for conjugation.
0705 HIV-2 gag p26 Possible T-cell epitope
0706 SIV gag p27 SIV p27 (aa233-247). A possible T-cell epitope
0707 HIV-1 env gp41 Conserved neutralisation epitope
0708 HIV-1 env gp41
0709 HIV-1 env gp120 Peptide to the CD4 binding region.
0710 HIV-1 env gp120 C-terminal of gp120
0711 HIV-1 env gp41 N-terminal of gp41
0712 HIV-1 gag p24 N-terminal of p24
0713 HIV-1 gag p24 LAI version of SF2 overlapping peptide number 18
0714 SIV gag p26 Set of overlapping 20mers covering entire SIV p26 region. Peptide 15, 16 and 18 have an additional N-terminal cysteine
0715 HIV-1 env gp120 V3 loop (MN)
0716 HIV-1 gag p9 (p15) Most hydrophobic region of p9. IIIB version of the SF2 overlapping peptide number 5
0717 HIV-1 T-cell epitopes
0718 HIV-1 gag T cell epitope
0719 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0720 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0721 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0722 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0723 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0724 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0725 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0726 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0727 HIV-1 pol T-cell epitopes Peptide to T-cell epitopes.
0728 HIV-1 T-cell epitopes
0729 HIV-1 T-cell epitopes
0730 HIV-1 nef T-cell peptide
0731 HIV-1 nef T-cell peptide
0732 HIV-1 T-cell epitopes
0733 HIV-1 T-cell epitopes
0734 HIV-1 T-cell epitopes
0735 HIV-1 nef T-cell peptide
0738 SIV env gp120 V3 loop Region of SIV env that corresponds to the hypervariable V3 loop of HIV-1. This region in SIV is, however, relatively well conserved.
0739 SIV env gp120 C-terminal SIV env gp120 C-terminal (aa497-516) . Available as a free peptide and conjugated to KLH.
0740 HIV-1 env gp120 (IIIB) Overlapping series covering entire gp120
0741 HIV-1 T-cell epitopes peptides to a range of HIV-1 T-cell epitopes
0743 HIV-2 tat
0744 HIV-2 tat
0745 HIV-2 tat
0746 SIV tat SIV tat/rev (N and C-terminus). ETPLREQENSLESSN
0747 SIV tat SIV tat/rev (N and C-terminus). ETPLREQENSLESSN
0748 SIV rev SIV tat/rev (N and C-terminus). RSHTGEEELRRRLRL
0749 SIV rev SIV tat/rev (N and C-terminus) . EALCDPTENSRSPQA
0750 HIV-2 rev
0751 HIV-2 rev
0752 HTLV-I rex
0753 HTLV-I rex
0754 HIV-1 pol integrase/endonuclease Available in both an unconjugated form and conjugated to KLH
0755 HIV-1 pol integrase/endonuclease Available in both an unconjugated form and conjugated to KLH
0756 HIV-1 pol integrase/endonuclease Available in both an unconjugated form and conjugated to KLH
0757 HIV-1 pol integrase/endonuclease Available in both an unconjugated form and conjugated to KLH
0758 FIV env gp120
0759 FIV env gp120
0760 FIV env gp41
0761 FIV orf 3
0762 HIV-1 env gp120 V3 loop V3 peptide for African strain of HIV-1 from Zaire
0763 HIV-1 env gp120 V3 loop V3 peptide for African strain of HIV-1 from Zaire
0764 HIV-1 env gp120 V3 loop V3 peptide for African strain of HIV-1 from Zaire
0765 HIV-1 env gp120 V3 loop V3 peptide for African strain of HIV-1 from Zaire
0770 HIV-1 env gp120 V3 loop
0771 HIV-1 env gp120 V3 Variant of Japanese HIV-1 GUN (770)
0772 Peptide substrate for HIV proteinase Protected heptapeptide for use as a substrate for assaying proteinase activity and its inhibitors.
0773 Peptide substrate for HIV proteinase Chromogenic substrate for HIV-1 proteinase
0775 SIV gag p17 Peptide set homologous to the entire p17 of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin
0776 SIV gag p15 Peptide set homologous to the entire p15 of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin
0777 SIV nef Peptide set homologous to nef of SIVmac251 (32H isolate), 20mers with 10 amino acid overlap. Based on consensus sequences derived by Drs N Almond and P Kitchin
0779 HIV-1 tat
0780 HIV-1 rev
0781 COUP-TF Cellular transcription factor that interacts with the LTR and influences transcription of the viral genome
0782 SIV env gp41 (Gnann) Conserved immunoreactive epitope of gp41. Original peptide 5 from HIV-2 ROD has a serine in position 3
0783 HIV-1 env gp41
0784 HIV-1 nef Putative GTP binding site.
0785 HIV-2 nef Putative GTP binding site
0787 HIV-1 env V3 loop (Ugandan loop) Sequences partially conserved in serveral African isolates of HIV-1
0788 HIV-1 gag p24 Replacement for #0702, it differs in that the peptides are 20mers and do not have additional C-terminal cysteines added.
0789 HIV-1 gag p17-3 variant HIV-1 SF2 gag peptide p17-3 has been shown to be a CTL epitope in individuals with HLA-B8. These peptides represent strain variants of this region.
0790 HIV-1 tat Peptides have been shown to bind to tar RNA and show specifcity for sense RNA
0791 HIV-2 env V3 loop HIV-2 ROD equivalent to the HIV-1 V3 principle neutralisation domain
0792 HIV-1 env V3 loop
0793 SIV env gp120 Homologous to env gp120 (aa167-181).
0794 HIV-1 env gp120 peptide 18 (aa171-185) This region from SF2 has soon to be a neutralising epitope recognised by HIV-1 antibody positive serum
0795 SIV env gp120 Env peptide 18 has been shown to be a neutralising epitope recognised by patients sera. This set of peptides spans the equivalent region of SIV between the two cysteines.
0796 HIV-1 env V3 loop (RF) Principle neutralising domain.
0797 HIV-1 env V3 loop (SF2) Principle neutralising domain.
0798 SIVenv gp41 Based on consensus sequences derived by Drs N Almond and P Kitchin
0901 Interleukin-2 CTLL and similar cell lines should be subcultured 1:10 with medium supplemented with 1-5 IU/ml IL-2 every 3-4 days. T helper lines should be subcultured with medium supplemented with a similar concentration of IL-2 about every 10-14 days. Recombinant DNA
0902 Interferon Gamma (Human) Recombinant human interferon gamma diluted in PBS containing human serum albumin, 6mg/ml. Contains mannitol, sodium succinate and polysorbate 20
0903 Inteferon Gamma (Murine) Recombinant murine interferon gamma diluted in PBS containing human serum albumin, 6mg/ml. Contains TRIS-HCl
0904 TNF alpha (Human) Recombinant TNF-alpha (Human) diluted in PBS containing human serum albumin, 6mg/ml.
0905 TNF Alpha (Murine) Recombinant TNF-alpha (Murine) diluted in PBS containing human serum albumin, 6mg/ml.
0952 AZT (Zidovudine) Pure AZT, for use as positive control in antivial assays.
0956 HIV-1 DNA PCR standards A set of HIV-1 DNA standards for PCR consisting of coded samples containing from 0.1 -10,000 molecules of DNA per assay in carrier DNA.
0961 HMA genetic subtyping kit Two aliquots each of purified plasmid DNA's containing envelope sequence subtype refrenceThe plasmids in this kit are for use in HMA only.
0964 HMA kit HIV-1 gag The plasmids in this kit are for use in HMA only.
0965 OLA kit for NRTI Kit for the detection of HIV-1 resistance mutations to NRTl.
0966 OLA kit for NNRTI Kit for the detection of HIV-1 resistance mutations to NNRTI.
0967 OLA kit for Protease Inhibitors Kit for the detection of HIV-1 resistance mutations to Protease Inhibitors.
0968 TAK779 (CCR5) Small molecule, non-peptide CCR5 antagonist with potent and selective anti HIV-1 activity.
0969 Integrase Inhibitor Potent inhibitor of the strand transfer reaction catalyzed by HIV-1 integrase.
0970 Nevirapine Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1.
0971 GM-CSF Human Granulocyte monocyte colony growth factor produced in E.coli and purified via sequential chromatography.
0972 Indinavir Sulphate Indinavir sulphate is a selective, competitive inhibitor of HIV-1 protease.
0973 PCS-RANTES Amino-terminus modified RANTES. RANTES analogue inhibits entry of HIV-1 CCR5 tropic strains.
0974 AMD 3100 CXCR4 Antagonist. A symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4.
0975 Abacavir Abacavir is a carbocyclic nucleoside analogue.
0976 Atazanavir Atazanavir is an azapeptide HIV-1 protease inhibitor.
0977 Efavirenz Efavirenz is a non-nucleoside reverse transcriptase inhibitor of HIV-1.
0978 Lopinavir Lopinavir, is an inhibitor of the HIV-1 protease.
0979 Maraviroc Maraviroc is an entry inhibitor. Specifically, maraviroc blocks the chemokine receptor CCR5.
0980 Ralregravir Raltegravir is an HIV-1 integrase inhibitor.
0981 Tenofovir Tenofovir is a cyclic nucleoside phosphonate analogue of adenosine monophosphate.
0982 Zidovudine Zidovudine is a nucleoside analogue of the naturally occurring nucleoside, thymidine.
0983 Saquinavir Saquinavir is an inhibitor of HIV protease.
0984 Trimeris/Roche T-20 Fusion Inhibitor T-20 inhibitors target a sequence in the HIV gp41, preventing viral fusion.
0985 Emtricitabine [(-)FTC] Emtricitabine, a nucleoside analogue of cytidine.
0986 Tenofovir Disoprxil Fumarate Efavirenz is a non-nucleoside reverse transcriptase inhibitor.
0987 Nelfinavir Mesylate Nelfinavir mesylate is an inhibitor of HIV-1 protease.
0988 Amprenavir Amprenavir is an inhibitor of HIV-1 protease.
0989 Darunavir Darunavir, also known as Prezista or TMC 114, is a nonpeptidic protease inhibitor.
0990 Etravirine Etravirine, also known as Intelence or TMC125, is a NNRTI.
0991 Elvitegravir An integrase inhibitor. Inhibition in-vivo can be boosted when combined with Ritonavir.
0992 Rilpivirine NNRTI with higher potency, longer half-life and reduced side-effects compared with older NNRTIs.
0993 Ritinovir Ritonavir is a peptidomimetic inhibitor of both HIV-1 and HIV-2 proteases.
1000 HIV-1 Saquinavir Resistant - Molecular Clone HXB2 (48V) Proteinase mutation G→V at position 48. Derived by co-transfection of MT4 cells with PHXB 2 delta pro and PHXB2 proteinase coding region containing a single G→ V mutation at position 48.
100000 CFP10 IgG mAb ELISA kit The Lionex CFP10 IgG antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgG antibodies against CFP10 in serum and plasma.
100001 CFP10 IgA mAb ELISA kit The Lionex CFP10 IgA antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgA antibodies against CFP10 in serum and plasma.
100002 CFP10 IgM mAb ELISA kit The Lionex CFP10 IgM antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgM antibodies against CFP10 in serum and plasma.
100003 Mab to e137, neutralising mAb against HCV E2 Human recombinant antibody e137, binding to hepatitis C virus (HCV) E2 glycoprotein
100004 mAb66 (HIV-1 neutralising) expressing plasmid Plasmid expressing 2F5 like antibody m6
100005 mAb66.6 (HIV-1 neutralising) expressing plasmid Plasmid expressing 2F5 like antibody m66.6
100007 Panel of Global HIV-1 Env Clones A panel of 12 envelope clones designed to assess neutralization responses. These reference strains were chosen because they are representative of the global epidemic.
100008 TB recombinant protein MPT64 Immunogenic protein MPT64 of M. tuberculosis, fuction unknown
100009 M. tuberculosis 85B (Rv1886) Secreted antigen 85-B FbpB of M. tuberculosis
100010 M.tuberculosis ESAT6 (Rv3875) 6 kDa early secretory antigen ESAT6 of M. tuberculosis. Genebank accession number: AFN51904.1
100011 M.tuberculosis CFP10 (Rv3874) 10 kDa culture filtrate antigen EsxB of M. tuberculosis. Genebank accession number: AFN51903.1
100012 M.tuberculosis TB10.4 (Rv0288) Low molecular weight protein antigen 7 EsxH of M. tuberculosis. Genebank accession number: AFN48143.1
100013 M.tuberculosis Rv0569 Genebank accession number: AFN48431.1
100014 M.tuberculosis Rv1733 Probable conserved transmembrane protein of M. tuberculosis Genebank accession number: AFN49658.1
100015 M.tuberculosis Rv1735 Hypothetical membrane protein of M. tuberculosis Genebank accession number: AFN49661.
100016 M.tuberculosis Rv1737 Possible nitrate/nitrite transporter NarK2 of M. tuberculosis Genebank accession number: AFN49664.
100017 M.tuberculosis Rv2005 Universal stress protein family protein of M. tuberculosis Genebank accession number: AFN49945
100018 M.tuberculosis Rv2029 6-phosphofructokinase PfkB of M. tuberculosis Genebank accession number: AFN49970.1
100019 M.tuberculosis Rv2032 Conserved protein Acg. Genebank accession number: AFN49973.1
100020 M.tuberculosis Rv2626 Hypoxic response protein 1 of M. tuberculosis. Genebank accession number: AFN50598.1
100021 M.tuberculosis Rv2627 Conserved protein Genebank accession number: AFN50599.1
100022 M.tuberculosis Rv2628 Hypothetical protein, Genebank accession number: AFN50600.1
100023 M.tuberculosis Rv2034 ArsR repressor protein of M. tuberculosis Genebank accession number: AFN49975.1
100024 M.tuberculosis Rv3353 Conserved hypothetical protein Genebank accession number: AFN51364.1
100025 M.tuberculosis Rv0867 Possible resuscitation-promoting factor RpfA of M. tuberculosis Genebank accession number: AFN48747.1
100026 M.tuberculosis Rv1009 Probable resuscitation-promoting factor RpfB of M. tuberculosis Genebank accession number: AFN48899.1
100027 M.tuberculosis Rv2389 Probable resuscitation-promoting factor RpfD of M. tuberculosis Genebank accession number: AFN50353.1
100028 PSTS1 antigen Phosphate transport protein of M. tuberculosis (PBP-1, 38 kDa antigen, PhoS, PhoS homologue)
100029 ELISA kit ESAT6 IgM The LIONEX ESAT6 IgG antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgG antibodies against ESAT6 in serum and plasma.
100030 ELISA kit ESAT6 IgA The LIONEX ESAT6 IgM antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgM antibodies against ESAT6 in serum and plasma.
100031 ELISA kit ESAT6 IgG The LIONEX ESAT6 IgA antibody detection ELISA test kit is suitable for rapid and reliable detection and quantitative determination of IgA antibodies against ESAT6 in serum and plasma.
100032 85A antigen FbpA, secreted antigen 85-A, antigen 85 complex A, Mycolyl transferase 85A, Fibronectin-binding protein A of M. tuberculosis
100033 PepMix HBV Ultra HBV Core Protein, average coverage: 92.5%. 21peptides approx. 25ug/peptide/vial.
100034 PepMix ESAT-6 esxA 6 kDa early secretory antigenic target ESAT-6. 21 peptides, 15meric, approx. 25ug/peptide/vial
100035 Adjuvant C Recombinant Adjuvant C protein.
100036 M. tuberculosis 16 kDa (Rv2031c) 14 kDa antigen, 16 kDa antigen, HSP16.3, acr, hspX of M. tuberculosis
100037 Mab to HIV-1 nef (2F2) Mouse monoclonal antibody to HIV-1 Nef protein epitope mapped to amino acids 150-158
100038 Mab to HIV-1nef (N5) Mouse monoclonal antibody to HIV-1 Nef protein epitope mapped to amino acids 62-68
100039 Mab to HIV-1 p24 (N17) Mouse monoclonal antibody to HIV-1 p24 protein epitope mapped to C-terminus, a.a. 165- 231
100040 Mab to HIV-1 p24 (N29) Mouse monoclonal antibody to HIV-1 p24 protein epitope mapped to N-terminus, a.a. 1-104
100041 Recombinent HIV-1 tat concensus C HIV-1 recombinent tat concencus C protien
100042 Recombinant HIV-1 BaL tat HIV-1 recombinent BaL tat protien
100043 HIV-1 (A1) EUR 0061 Plasma from HIV-1 infected patient, SUBTYPE: A1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100044 HIV-1 (F1) EUR0062 Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100045 HIV-1 (B) EUR0064 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100046 HIV-1 (B) EUR0065 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100047 HIV-1 (G) EUR0068 Plasma from HIV-1 infected patient, SUBTYPE: G (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100048 HIV-1 (F1) EUR0069 Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100049 HIV-1 (C) EUR0070 Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100050 HIV-1 (C) EUR0071 Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100051 HIV-1 (B) EUR0072 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100052 HIV-1 (B) EUR0073 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.Plasma from HIV-1 infected patient, SUBTYPE: See datasheet for P
100053 HIV-1 (F1) EUR0075 Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100054 HIV-1 (B) EUR0076 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100055 HIV-1 (F1) EUR0077 Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3) See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100056 HIV-1 (B) EUR0078 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100057 HIV-1 (C) EUR0079 Plasma from HIV-1 infected patient, SUBTYPE: C (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100058 HIV-1 (B) EUR0080 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100059 HIV-1 (F1) EUR0081 Plasma from HIV-1 infected patient, SUBTYPE: F1 (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100060 HIV-1 (CRF45_cpx: PRT, CRF02_AG: V3) EUR0082 Plasma from HIV-1 infected patient, SUBTYPE: CRF45_cpx (PRT), CRF02_AG (V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100061 HIV-1 (CRF45_cpx: PRT, CRF02_AG: V3) EUR0083 Plasma from HIV-1 infected patient, SUBTYPE: CRF45_cpx (PRT), CRF02_AG (V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100062 HIV-1 (B) EUR0084 Plasma from HIV-1 infected patient, SUBTYPE: B (PRT and V3). See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100063 HIV-1 (CRF19_cpx ) EUR0040 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100064 HIV-1 (CRF19_cpx ) EUR0041 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100065 HIV-1 (B) EUR0043 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100066 HIV-1 (B) EUR0044 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100067 HIV-1 (B) EUR0045 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100068 HIV-1 (B) EUR0046 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100069 HIV-1 (URF 02_AG/A1 ) EUR0048 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100070 HIV-1 (B) EUR0050 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100071 HIV-1 (B) EUR0052 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100072 HIV-1 (B) EUR0053 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resis
100073 HIV-1 gp160 clone subtype A1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100074 HIV-1 gp160 clone subtype A1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100075 HIV-1 gp160 clone subtype A1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100076 HIV-1 gp160 clone subtype A1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100077 HIV-1 gp160 clone subtype A1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Russia has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100078 HIV-1 gp160 clone subtype BG in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample collected in Spain has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100079 HIV-1 gp160 clone subtype F1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100080 HIV-1 gp160 clone subtype F1 in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100081 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100082 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100083 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100084 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100085 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100086 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100087 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100088 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100089 HIV-1 gp160 clone subtype G in pcDNA3.1 The HIV-1 gp160 sequence derived from a clinical sample has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100090 M.tuberculosis Rv2660
100091 Mab to HIV-1 gp41 (m66.6) Broadly neutralising anitbody, from an HIV-1-infected patient with 2F5-like serum Abs. This antibody binds to the D664KW666 core 2F5 epitope but use entirely different germ line V genes from 2F5 and that are significantly less divergent than 2F5 from thei
100092 MSCV (Puro)-HA-Flag-AU1-SAMHD1 WT pMSC (purp) plasmid expressing codon optimised wild type human SAMHD1 protein
100093 MSCV (Puro)-HA-Flag-AU1-SAMHD1 VQ618AA pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein VQ618AA
100094 MSCV (purp)-HA-Flag-AU1-SAMHD1 LF620AA pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein LF620AA
100095 MSCV(puro)-HA-Flag-AU1-SAMHD1 T592A pMSC (purp) plasmid expressing codon optimised mutant human SAMHD1 protein T592A
100096 PepMix M.Tb CFP-10 M.Tb CFP-10, ESAT-6-like protein EsxB (P9WNK5). 23 peptides, 15meric; approx. 25 µg / peptide
100097 PepMix M.Tb TP10.4 M.Tb TP10.4, ESAT-6-like protein EsxH (P9WNK3). 22 peptides, 15meric; approx. 25 µg / peptide
100098 PepMix M.Tb AG85B M.Tb AG85B, Diacylglycerol acyltransferase/mycolyltransferase Ag85B (P9WQP1). 79 peptides, 15meric; approx. 25 µg / peptide.
100099 RepliTope Antigen Collection M.tb Ultra Microarray Microarray with a comprehensive collection of 6388 overlapping, nonredundant 15-meric peptides from antigenic proteins of M.tb. This array was produced by carefully selecting 40 antigens of M.tb reference strain H37Rv supplemented by 354 homologous antige
1001 HIV-1 Saquinavir Resistant - Molecular Clone HIV-1 Molecular Clone HXB2 with L→M mutation In proteinase at position 90. Derived by co-transfection of MT4 cells with PHXB 2 delta pro and PHXB2 proteinase coding region containing a single G→V mutation at position 90.
100100 Jtag Parental cell line Jurkat cells expressing the SV40 large T antigen, derived from Jurkat E6.1 clone
100101 Jtag KO Serinc5/3 Jurkat T-antigen cells (JTAg) in which the coding sequences of SERINC3 and SERINC5 were disrupted using CRISPR-Cas9 vectors (PX458).
100102 pcDNA3.1-SERINC5 SERINC5 human coding sequence, cloned into pcDNA3.1 BS(-) between NotI and EcoRI restriction sites. pcDNA3.1 BS(-) (#100 104) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistant.
100103 pcDNA3.1-SERINC3-HA SERINC3 human coding sequence with a C-terminal HA tag, cloned into pcDNA3.1 BS(-) between NotI and EcoRI restriction sites. pcDNA3.1 BS(-) (#100 104) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistan
100104 pcDNA3.1 BS(-) pcDNA3.1 BS(-) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistant.
100105 pcDNA3.1-SERINC5-HA SERINC5 human coding sequence with a C-terminal HA tag, cloned into pcDNA3.1 BS(-) between NotI and EcoRI restriction sites. pcDNA3.1 BS(-) (#100 104) is a derivative of pcDNA3.1(-) (Invitrogen) in which the NeoR was replaced with BsdR. Ampicilin resistan
100106 PBJ6-SERINC3-HA SERINC3 human coding sequence with a C-terminal HA tag, cloned into PBJ6 between NotI and EcoRI restriction sites. PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early pr
100107 PBJ6-SERINC5-HA SERINC 5 human coding with a C-terminal HA tag, cloned into PBJ6 between NotI and EcoRI restriction sites. PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early promote
100108 PBJ6 PBJ6 is a derivative of PBJ5 in which the original SV40 early promoter fused to RU5 of HTLV-1 LTR was modified by removing the SV40 early promoter and retaining only HTLV-1 RU5. Ampicilin resistant.
100109 peGFP-N1 peGFP-N1 (Clontech) empty vector control. Kanamycin resistant.
100110 peGFP-N1-SERINC5 SERINC5 human coding sequence fused at N-terminus of eGFP, cloned between NheI and EcoRI in peGFP-N1 (Clontech). Kanamycin resistant.
100111 peGFP-N1-SERINC3 SERINC3 human coding sequence fused at N-terminus of eGFP, cloned between NheI and EcoRI in peGFP-N1 (Clontech). Kanamycin resistant.
100112 HIV-1 (B) EUR0056 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100113 HIV-1 (F1) EUR0058 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100114 HIV-1 (B) EUR0060 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100115 HIV-1 (F1) EUR0062 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100116 HIV-1 (B) EUR0065 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100117 HIV-1 (A1) EUR0066 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100118 HIV-1 (C) EUR0067 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100119 HIV-1 (URF BG) EUR0068 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100120 HIV-1 (URF F1_CRF14 BG) EUR0069 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100121 HIV-1 (B) EUR0073 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
100122 HIV-1 (B) EUR0085 Plasma Plasma from HIV-1 infected patient, SUBTYPE : B
100123 HIV-1 (F1) EUR0101 Plasma Plasma from HIV-1 infected patient, SUBTY PE: F1
100124 HIV-1 (A1) EUR0103 Plasma Plasma from HIV-1 infected patient, SUBTYPE: A1
100125 HIV-1 (B) EUR0104 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100126 HIV-1 (B) EUR0110 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100127 HIV-1 (B) EUR0111 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100128 HIV-1 (F1) EUR0115 Plasma Plasma from HIV-1 infected patient, SUBTYPE: F1
100129 HIV-1 (B) EUR0116 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100130 HIV-1 (B) EUR0117 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100131 HIV-1 (B) EUR0118 Plasma Plasma from HIV-1 infected patient, SUBTYPE: B
100133 Hela HA-CPSF6-358 HeLa cell line stably expressing N-terminal HA-tagged CPSF6 truncated at position 358.
100134 Hela Nup358 shRNA HeLa cell line stably expressing Nup358 shRNA.
100135 CCR5-tropic NL4.3 (Ba-L Env) wt Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env wild type
100136 CCR5-tropic NL4.3 (Ba-L Env) CA P90A Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid P90A mutation
100137 CCR5-tropic NL4.3 (Ba-L Env) CA N74D Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid N74D mutation
100138 CCR5-tropic NL4.3 (Ba-L Env) CA N57A Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the capsid N57A mutation
100139 CCR5-tropic NL4.3 (Ba-L Env) delta RT (D185E) Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the reverse transcriptase D185E mutation.
100140 CCR5-tropic NL4.3 (Ba-L Env) delta IN (D116N) Full length infectious molecular clone of HIV-1 NL4.3 with Ba-L env containing the integrase D116N mutation
100141 Human CPSF6 expression vector Plasmid expressing human CPSF6
100142 pcDNA3.1 3xFLAG SIV Mnd2 Vpx Vpx sequence from SIV Mnd2 (5440)cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpx gene. Ampicilin resistant.
100143 pcDNA3.1 3xFLAG SIV RCM Vpx Vpx sequence from SIV RCM (NG411) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpx gene. Ampicilin resistant.
100144 pcDNA3.1 3xFLAG SIV Syk Vpr Vpr sequence from an SIVsyk provirus (Hirsch VM, Dapolito GA, Goldstein S, McClure H, Emau P, et al. (1993) A distinct African lentivirus from Sykes’ monkeys. J Virol 67: 1517–1528) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI o
100145 pcDNA3.1 3xFLAG SIV Deb Vpr Vpr sequence from SIV Deb (CM5) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant.
100146 pcDNA3.1 3xFLAG SIV Mus Vpr Vpr sequence from SIV Mus (CM1239) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant.
100147 pcDNA3.1 3xFLAG SIV AGM Vpr Vpr sequence from SIV AGM (Gri677) cloned into pcDNA3.1 vector between NotI site at 5’ end and either XbaI or XhoI site at 3’ end. The vector contains a 3xFLAG tag that is in-frame with the N-terminus of each Vpr gene. Ampicilin resistant.
100148 Hela TRN-SR2 shRNA HeLa cell line stably expressing TRN-SR2 shRNA.
100149 Kenyan TB isolate (TIF0041) Isolated from sputum samples, repromycin sensitive.
100150 Kenyan TB Isolates (TIF2465) Isolated from sputum samples, repromycin sensitive.
100151 Kenyan TB Isolates (TIF0098) Isolated from sputum samples, repromycin sensitive.
100152 Kenyan TB Isolates (TIF0101) Isolated from sputum samples, repromycin sensitive.
100153 Kenyan TB Isolates (TIF0136) Isolated from sputum samples, repromycin sensitive.
100154 Kenyan TB Isolates (TIF0140) Isolated from sputum samples, repromycin sensitive.
100155 Kenyan TB Isolates (TIF0152) Isolated from sputum samples, repromycin sensitive.
100156 Kenyan TB Isolates (TIF0158) Isolated from sputum samples, repromycin sensitive.
100157 Kenyan TB Isolates (TIF0160) Isolated from sputum samples, repromycin sensitive.
100158 Kenyan TB Isolates (TIF0185) Isolated from sputum samples, repromycin sensitive.
100159 Kenyan TB Isolates (TIF0212) Isolated from sputum samples, repromycin sensitive.
100160 Kenyan TB Isolates (TIF0233) Isolated from sputum samples, repromycin sensitive.
100161 Kenyan TB Isolates (TIF0243) Isolated from sputum samples, repromycin sensitive.
100162 Kenyan TB Isolates (TIF0250) Isolated from sputum samples, repromycin sensitive.
100163 Kenyan TB Isolates (TIF0307) Isolated from sputum samples, repromycin sensitive.
100164 Kenyan TB Isolates (TIF0407) Isolated from sputum samples, repromycin sensitive.
100166 Kenyan TB Isolates (TIF0476) Isolated from sputum samples, repromycin sensitive.
100167 Kenyan TB Isolates (TIF0517) Isolated from sputum samples, repromycin sensitive.
100168 Kenyan TB Isolates (TIF0563) Isolated from sputum samples, repromycin sensitive.
100170 Kenyan TB Isolates (TIF0604) Isolated from sputum samples, repromycin sensitive.
100171 Kenyan TB Isolates (TIF0615) Isolated from sputum samples, repromycin sensitive.
100172 Kenyan TB Isolates (TIF0617) Isolated from sputum samples, repromycin sensitive.
100173 Kenyan TB Isolates (TIF0664) Isolated from sputum samples, repromycin sensitive.
100174 Kenyan TB Isolates (TIF0668) Isolated from sputum samples, repromycin sensitive.
100175 Kenyan TB Isolates (TIF0686) Isolated from sputum samples, repromycin sensitive.
100176 Kenyan TB Isolates (TIF0726) Isolated from sputum samples, repromycin sensitive.
100177 Kenyan TB Isolates (TIF0771) Isolated from sputum samples, repromycin sensitive.
100178 Kenyan TB Isolates (TIF0809) Isolated from sputum samples, repromycin sensitive.
100179 Kenyan TB Isolates (TIF0815) Isolated from sputum samples, repromycin sensitive.
100180 Kenyan TB Isolates (TIF0832) Isolated from sputum samples, repromycin sensitive.
100181 Kenyan TB Isolates (TIF0904) Isolated from sputum samples, repromycin sensitive.
100182 Kenyan TB Isolates (TIF0913) Isolated from sputum samples, repromycin sensitive.
100183 Kenyan TB Isolates (TIF0981) Isolated from sputum samples, repromycin sensitive.
100184 Kenyan TB Isolates (TIF0996) Isolated from sputum samples, repromycin sensitive.
100185 Kenyan TB Isolates (TIF1027) Isolated from sputum samples, repromycin sensitive.
100186 Kenyan TB Isolates (TIF1038) Isolated from sputum samples, repromycin sensitive.
100187 Kenyan TB Isolates (TIF1157) Isolated from sputum samples, repromycin sensitive.
100188 Kenyan TB Isolates (TIF1200) Isolated from sputum samples, repromycin sensitive.
100189 Kenyan TB Isolates (TIF1206) Isolated from sputum samples, repromycin sensitive.
100190 Kenyan TB Isolates (TIF1255) Isolated from sputum samples, repromycin sensitive.
100193 Kenyan TB Isolates (TIF1521) Isolated from sputum samples, repromycin sensitive.
100195 Kenyan TB Isolates (TIF1890) Isolated from sputum samples, repromycin sensitive.
100196 Kenyan TB Isolates (TIF1898) Isolated from sputum samples, repromycin sensitive.
100198 Kenyan TB Isolates (TIF2105) Isolated from sputum samples, repromycin sensitive.
100199 HIV-1 isolate cultured in PBMC, CRF08_BC
1002 HIV-1 SAQR 90M HIV-1 Molecular Clone HXB2 with G→V mutation at Position 48 and L→M mutation at position 90 of Proteinase. Derived by co-transfection of MT4 cells with PHXB2deltapro and PHXB2 proteinase coding region containing 2 mutations G→V at position 48, L→M at pos
100200 HIV-1 isolate cultured in PBMC, CRF07_BC
100201 HIV-1 isolate cultured in PBMC, CRF07_BC
100202 HIV-1 isolate cultured in PBMC, CRF07_BC
100203 HIV-1 isolate cultured in PBMC, CRF01_AE
100204 HIV-1 isolate cultured in PBMC, CRF07_BC
100205 HIV-1 isolate cultured in PBMC, CRF07_BC
100206 HIV-1 isolate cultured in PBMC, CRF07_BC
100207 HIV-1 isolate cultured in PBMC, CRF07_BC
100208 HIV-1 isolate cultured in PBMC, CRF07_BC
100209 HIV-1 isolate cultured in PBMC, CRF01_AE
100210 HIV-1 isolate cultured in PBMC, CRF07_BC
100211 HIV-1 isolate cultured in PBMC, CRF08_BC
100212 HIV-1 isolate cultured in PBMC, CRF01_AE
100213 HIV-1 isolate cultured in PBMC, CRF01_AE
100214 HIV-1 isolate cultured in PBMC, CRF07_BC
100215 HIV-1 isolate cultured in PBMC, CRF01_AE
100216 HIV-1 isolate cultured in PBMC, CRF07_BC
100217 HIV-1 isolate cultured in PBMC, CRF01_AE
100218 HIV-1 isolate cultured in PBMC, CRF01_AE
100219 HIV-1 isolate cultured in PBMC, CRF01_AE
100220 HIV-1 isolate cultured in PBMC, CRF07_BC
100221 HIV-1 isolate cultured in PBMC, CRF01_AE
100222 HIV-1 isolate cultured in PBMC, subtype B
100223 HIV-1 isolate cultured in PBMC, CRF07_BC
100224 Mab to HIV-1 gp41 (m66) Broadly neutralising anitbody, from an HIV-1-infected patient with 2F5-like serum Abs. This antibody binds to the D664KW666 core 2F5 epitope but use entirely different germ line V genes from 2F5 and that are significantly less divergent than 2F5 from thei
100226 (+)_JQ-1 (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2).
100227 OTX-015 OTX-015 is a new potent BRD2/3/4 inhibitor with evident anti-proliferative activity.
100228 pcDNA3.1 Zeo V5 Vpx SIVmac WT
100229 pcDNA3.1 Zeo V5 Vpx SIVmac N12A
100230 pcDNA3.1 Zeo V5 Vpx SIVmac E16A
100231 pcDNA3.1 Zeo V5 Vpx SIVrod
100233 Patient PBMCs HIV-1 subtype G (EUR-0002)
100234 Patient PBMCs HIV-1(CRF02_AG) (EUR-0003)
100235 Patient PBMCs HIV-1 (subtype C) (EUR-0004)
100236 Patient PBMCs HIV-1 (subtype C) (EUR-0005)
100237 Patient PBMCs HIV-1 (subtype B) (EUR-0006)
100238 Patient PBMCs HIV-1 (subtype G) (EUR-0009)
100239 Patient PBMCs HIV-1 (subtype B) (EUR-0012)
100240 Patient PBMCs HIV-1 (subtype D) (EUR-0018)
100241 Patient PBMCs HIV-1 (subtype A1) (EUR-0019)
100242 Patient PBMCs HIV-1 (subtype F1) (EUR-0020)
100243 Patient PBMCs HIV-1 (subtype A1) (EUR-0021 )
100244 Patient PBMCs HIV-1 (subtype B) (EUR-0022)
100245 Patient PBMCs HIV-1 (subtype F1) (EUR-0034)
100246 Patient PBMCs HIV-1 (subtype B) (EUR-0035)
100247 Patient PBMCs HIV-1 (CRF02_AG) (EUR-0036)
100248 Patient PBMCs HIV-1 (subtype G) (EUR-0037)
100249 Patient PBMCs HIV-1 (subtype A1) (EUR-0038 )
100250 Patient PBMCs HIV-1 (subtype B) (EUR-0039)
100251 Patient PBMCs HIV-1 (CRF19_cpx) (EUR-0040 )
100252 Patient PBMCs HIV-1 (CRF19_cpx) (EUR-0041 )
100253 Patient PBMCs HIV-1 (subtype A1) (EUR-0042)
100254 Patient PBMCs HIV-1 (subtype B) (EUR-0043)
100255 Patient PBMCs HIV-1 (subtype B) (EUR-0044)
100256 Patient PBMCs HIV-1 (subtype B) (EUR-0045)
100257 Patient PBMCs HIV-1 (subtype B) (EUR-0046)
100258 Patient PBMCs HIV-1 (subtype F1) (EUR-0047)
100259 Patient PBMCs HIV-1 (CRF02_AG) (EUR-0048)
100260 Patient PBMCs HIV-1 (CRF02_AG/B) (EUR-0049)
100261 Patient PBMCs HIV-1 (subtype B) (EUR-0050)
100262 Patient PBMCs HIV-1 (subtype F1) (EUR-0051)
100263 Patient PBMCs HIV-1 (subtype B) (EUR-0052)
100264 Patient PBMCs HIV-1 (subtype B) (EUR-0053)
100265 Patient PBMCs HIV-1 (subtype F1) (EUR-0054)
100266 Patient PBMCs HIV-1 (subtype B) (EUR-0056)
100267 Patient PBMCs HIV-1 (CRF02_AG) (EUR-0057)
100268 Patient PBMCs HIV-1 (subtype F1) (EUR-0058)
100269 Patient PBMCs HIV-1 (subtype A1) (EUR-0059)
100270 Patient PBMCs HIV-1 (subtype B) (EUR-0060)
100271 Patient PBMCs HIV-1 (subtype A1) (EUR-0061)
100272 Patient PBMCs HIV-1 (subtype F1) (EUR-0062)
100273 Patient PBMCs HIV-1 (subtype B) (EUR-0064)
100274 Patient PBMCs HIV-1 (subtype B) (EUR-0065)
100275 Patient PBMCs HIV-1 (subtype C) (EUR-0067)
100276 Patient PBMCs HIV-1 (CRF02_AG/B) (EUR-0001)
100277 Patient PBMCs HIV-1 (subtype F1) (EUR-0010)
100278 Patient PBMCs HIV-1 (subtype C) (EUR-0011)
100279 Patient PBMCs HIV-1 (subtype G) (EUR-0016)
100280 Patient PBMCs HIV-1 (subtype B) (EUR-0017)
100281 Patient PBMCs HIV-1 (subtype B) (EUR-0023)
100282 Patient PBMCs HIV-1 (subtype B) (EUR-0024)
100283 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100284 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100285 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100286 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100287 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100288 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100289 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100290 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100291 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100292 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100293 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100294 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100295 MPB83 (Mb2898) recombinant protein lyophilised
100296 HSP65 (Rv0440) recombinant protein lyophilised
100297 HIV-1 Env gp160 clone (VA-0166) Subtype B HIV-1 Env gp160 clone (VA-0166) subtype B
100298 HIV-1 Env gp160 clone (X-3851) CRF20-BG HIV-1 Env gp160 clone (X-3851) CRF20-BG
100299 HIV-1 Env gp160 clone (VA-0188-02) CRF20-AG HIV-1 Env gp160 clone (VA-0188-02) CRF20-AG
1003 HIV-1 Y115F Derived from HXB2 by in vitro selection with 1592U89. RT mutation Y→F at position 115. Confers low-level resistance (two-fold) to carbocyclic nucleoside (1592U89)
100300 HIV-1 Env gp160 clone (X-3906-02) CRF20-AG HIV-1 Env gp160 clone (X-3906-02) CRF20-AG
100301 HIV-1 Env gp160 clone (EU-0083) CRF20-AG HIV-1 Env gp160 clone (EU-0083) CRF20-AG
100302 HIV-1 Env gp160 clone (VA-0176) SubtypeB HIV-1 Env gp160 clone (VA-0176) subtype B
100303 HIV-1 Env gp160 clone (P-3682-02) SubtypeB HIV-1 Env gp160 clone (P-3682-02) subtype B
100304 HIV-1 Env gp160 clone (N-FU-0171) URF_02_AG/A1 HIV-1 Env gp160 clone (N-FU-0171) URF_02_AG/A1
100305 HIV-1 Env gp160 clone (P-3668-02) SubtypeB HIV-1 Env gp160 clone (P-3668-02) subtype B
100306 HIV-1 Env gp160 clone (P-3459-02) SubtypeB HIV-1 Env gp160 clone (P-3459-02) subtype B
100307 HIV-1 Env gp160 clone (P-3571-03) Subtype G HIV-1 Env gp160 clone (P-3571-03) subtype G
100308 HIV-1 Env gp160 clone (P-3897.02) SubtypeB HIV-1 Env gp160 clone (P-3897.02) subtype B
100309 HIV-1 Env gp160 clone (x-3850) Subtype B HIV-1 Env gp160 clone (x-3850) subtype B
100310 HIV-1 Env gp160 clone (VA-0187-02) SubtypeF1 HIV-1 Env gp160 clone (VA-0187-02) subtype F1
100311 HIV-1 Env gp160 clone (x-3924-02) SubtypeF1 HIV-1 Env gp160 clone (x-3924-02) subtype F1
100312 Patient PBMCs HIV-1 (URF02_AG/A1) (EUR-0025)
100313 Patient PBMCs HIV-1 (subtype B) (EUR-0026)
100314 Patient PBMCs HIV-1 (subtype B) (EUR-0027)
100315 Patient PBMCs HIV-1 (subtype G) (EUR-0068)
100316 Patient PBMCs HIV-1 (subtype F1) (EUR-0069)
100317 Patient PBMCs HIV-1 (subtype C) (EUR-0070)
100318 Patient PBMCs HIV-1 (subtype C) (EUR-0071)
100319 Patient PBMCs HIV-1 (subtype B) (EUR-0073)
100320 Patient PBMCs HIV-1 (subtype B) (EUR_0074)
100321 Patient PBMCs HIV-1 (subtype F1) (EUR-0075)
100322 Patient PBMCs HIV-1 (subtype B) (EUR-0078)
100323 Patient PBMCs HIV-1 (subtype B) (EUR-0080)
100324 Patient PBMCs HIV-1 (subtype F1) (EUR-0081)
100325 Patient PBMCs HIV-1 (CRF02_AG) (EUR-0082)
100326 Patient PBMCs HIV-1 (subtype B) (EUR-0084)
100327 Patient PBMCs HIV-1 (subtype B) (EUR-0085)
100328 Patient PBMCs HIV-1 (subtype B) (EUR-0087)
100329 Patient PBMCs HIV-1 (subtype B) (EUR-0090)
100330 Patient PBMCs HIV-1 (subtype B) (EUR-0096)
100331 Patient PBMCs HIV-1 (subtype B) (EUR-0107)
100332 Patient PBMCs HIV-1 (URF_B/F1) (EUR-0109)
100333 Patient PBMCs HIV-1 (subtype B) (EUR-0112)
100334 Patient PBMCs HIV-1 (subtype B) (EUR-0113)
100335 Patient PBMCs HIV-1 (subtype C) (EUR-0114)
100336 Patient PBMCs HIV-1 (subtype F1) (EUR-0115)
100337 Patient PBMCs HIV-1 (subtype B) (EUR-0116)
100338 Patient PBMCs HIV-1 (subtype B) (EUR-0117)
100339 Patient PBMCs HIV-1 (subtype B) (EUR-0118)
100340 Patient PBMCs HIV-1 (subtype B) (EUR-0121)
100341 Patient PBMCs HIV-1 (subtype G) (EUR-0122)
100342 Patient PBMCs HIV-1 (subtype B) (EUR-0123)
100343 Patient PBMCs HIV-1 (subtype G) (EUR-0126)
100344 Patient PBMCs HIV-1 (subtype B) (EUR-0127)
100345 Patient PBMCs HIV-1 (URF_B/G) (EUR-0128)
100346 Patient PBMCs HIV-1 (subtype B) (EUR-0129)
100347 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100348 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100349 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100350 HIV-1 gp160 clone subtype F1 in pcDNA3.1
100351 HIV-1 gp160 clone subtype B in pcDNA3.1
100352 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100353 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100354 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100355 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100356 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100357 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100358 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100359 HIV-1 gp160 clone CRF63_02A1 in pcDNA3.1
100360 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100361 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100362 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100363 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100364 HIV-1 gp160 clone CRF02_AG in pcDNA3.1
100365 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100366 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100367 HIV-1 Env gp160 clone (KCL100) CRF05_D/F HIV-1 Env gp160 clone (KCL100) CRF05_D/F
100368 HIV-1 gp160 clone subtype A1 in pcDNA3.1
100369 HIV-1 Env gp160 clone (KCL78) G Subtype HIV-1 Env gp160 clone (KCL78) subtype G
100370 HIV-1 Env gp160 clone (KCL62) SubtypeF HIV-1 Env gp160 clone (KCL62) subtype F
100371 HIV-1 Env gp160 clone (KCL123) SubtypeG HIV-1 Env gp160 clone (KCL123) subtype G
100372 HIV-1 Env gp160 clone (KCL133) CRF35_AD HIV-1 Env gp160 clone (KCL133) CRF35_AD
100373 HIV-1 Env gp160 clone (KCL162) SubtypeC HIV-1 Env gp160 clone (KCL162) subtype C
100374 HIV-1 Env gp160 clone (KCL333) CRF03_AB
100375 HIV-1 Env gp160 clone (KCL411) CRF43_02G
100376 HIV-1 isolate cultured in PBMC, CRF01_AE
100377 HIV-1 isolate cultured in PBMC, CRF07_BC
100378 HIV-1 isolate cultured in PBMC, CRF01_AE
100379 HIV-1 isolate cultured in PBMC, CRF07_BC
100380 HIV-1 isolate cultured in PBMC, CRF08_BC
100381 HIV-1 isolate cultured in PBMC, CRF01_AE
100382 HIV-1 isolate cultured in PBMC, CRF01_AE
100383 HIV-1 isolate cultured in PBMC, CRF07_BC
100384 HIV-1 isolate cultured in PBMC, CRF01_AE
100385 HIV-1 isolate cultured in PBMC, CRF07_BC
100386 HIV-1 isolate cultured in PBMC, CRF07_BC
100387 HIV-1 isolate cultured in PBMC, CRF01_AE
100388 HIV-1 isolate cultured in PBMC, CRF01_AE
100389 HIV-1 isolate cultured in PBMC, CRF01_AE
100390 HIV-1 isolate cultured in PBMC, CRF01_AE
100391 HIV-1 isolate cultured in PBMC, CRF01_AE
100392 HIV-1 isolate cultured in PBMC, CRF01_AE
100393 HIV-1 isolate cultured in PBMC, CRF08_BC
100394 HIV-1 isolate cultured in PBMC, CRF55_01B
100395 pNL dNef Compared to the pNL4-3 reference sequence (GenBank: AF324493), this plasmid contains a four nucleotide insertion (TCGA) resulting in a stop codon after amino acid 46 of Nef.
100396 Lamivudine (3TC) Lamivudine is a nucleoside analogue
100397 Stavudine (D4T, 2',3'-didehydro-3'-deoxythymidine Stavudine is a nucleoside analog of thymidine.
100398 2',3'-Dideoxyinosine (DDI) 2’,3’-Dideoxyinosine is a nucleoside analogue that inhibits the HIV-1 reverse transcriptase.
100399 Mab to SIVmac p27 Monoclonal (55-2F12) Anti-SIVmac p27 Monoclonal
1004 HIV-1 K65R Derived from HXB2 by in vitro selection with 1592U89. RT mutation K→R at position 65. Confers low-level resistance (fourfold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC.
100400 Mab to SIVmac251 Nef Monoclonal (17.2) This mAb targets SIVmac251 Nef. Mapped to amino acids 71-80 (-PAEEREKLAY-, SIV)
100401 Mab to SIVmac239 gp41 mAb (4B2) 4B2 binds the highly immunogenic region at the beginning of the cytoplasmic tail of SIVmac gp41 (also known as the Kennedy Epitope). It was isolated from a SIVmac239-infected monkey.
100402 Mab to SIV env gp120 (Purified KK8) Suitable for ELISA, immunoblotting, RIPA and IF
100403 Mab to SIV env gp120 (Purified KK46) Suitable for ELISA, immunoblotting, RIPA and IF
100404 Mab to SIV gag p17 (Purified KK59) Suitable for ELISA and immunoblotting
100405 RepliTope Antigen HCV Ultra
100406 HIV+ sera Gamaleya ER001
100407 HIV+ sera Gamaleya ER002
100408 HIV+ sera Gamaleya ER003
100409 HIV+ sera Gamaleya ER004
100410 HIV+ sera Gamaleya ER005
100411 HIV+ sera Gamaleya ER006
100412 HIV+ sera Gamaleya ER007
100413 HIV+ sera Gamaleya ER008
100414 HIV+ sera Gamaleya ER009
100415 HIV+ sera Gamaleya ER010
100416 HIV+ sera Gamaleya ER012
100417 HIV+ sera Gamaleya ER014
100418 HIV+ sera Gamaleya ER015
100419 HIV+ sera Gamaleya ER016
100420 HIV+ sera Gamaleya ER017
100421 HIV+ sera Gamaleya ER018
100422 HIV+ sera Gamaleya ER019
100423 HIV+ sera Gamaleya ER020
100424 HIV+ sera Gamaleya ER022
100425 HIV+ sera Gamaleya ER023
100426 HIV+ sera Gamaleya ER024
100427 HIV+ sera Gamaleya ER025
100428 HIV+ sera Gamaleya ER026
100429 HIV+ sera Gamaleya ER028
100430 HIV+ sera Gamaleya ER029
100431 HIV+ sera Gamaleya ER030
100432 HIV+ sera Gamaleya ER031
100433 Gameleya ER052 (75)
100434 HIV+ sera Gamaleya ER033
100435 HIV+ sera Gamaleya ER034
100436 HIV+ sera Gamaleya ER035
100437 HIV+ sera Gamaleya ER037
100438 HIV+ sera Gamaleya ER038
100439 HIV+ sera Gamaleya ER039
100440 HIV+ sera Gamaleya ER040
100441 HIV+ sera Gamaleya ER041
100442 HIV+ sera Gamaleya ER047
100443 HIV+ sera Gamaleya ER048
100444 HIV+ sera Gamaleya ER049
100445 HIV+ sera Gamaleya ER051
100446 HIV+ sera Gamaleya ER052
100447 HIV+ sera Gamaleya ER053
100448 HIV+ sera Gamaleya ER054
100449 HIV+ sera Gamaleya ER055
100450 HIV+ sera Gamaleya ER056
100451 HIV+ sera Gamaleya ER057
100452 HIV+ sera Gamaleya ER058
100453 HIV+ sera Gamaleya ER059
100454 HIV+ sera Gamaleya ER060
100455 HIV+ sera Gamaleya ER061
100456 HIV+ sera Gamaleya ER062
100457 HIV+ sera Gamaleya ER063
100458 HIV+ sera Gamaleya ER065
100459 HIV+ sera Gamaleya ER066
100460 HIV+ sera Gamaleya ER068
100461 HIV+ sera Gamaleya ER069
100462 HIV+ sera Gamaleya ER070
100463 HIV+ sera Gamaleya ER071
100464 HIV+ sera Gamaleya ER072
100465 HIV+ sera Gamaleya ER073
100466 HIV+ sera Gamaleya ER076
100467 HIV+ sera Gamaleya ER077
100468 HIV+ sera Gamaleya ER086
100469 HIV+ sera Gamaleya ER087
100470 HIV+ sera Gamaleya ER088
100471 HIV+ sera Gamaleya ER089
100472 HIV+ sera Gamaleya ER090
100473 HIV+ sera Gamaleya ER091
100474 HIV+ sera Gamaleya ER092
100475 HIV+ sera Gamaleya ER093
100476 HIV+ sera Gamaleya ER095
100477 HIV+ sera Gamaleya ER096
100478 HIV+ sera Gamaleya ER097
100479 HIV+ sera Gamaleya ER099
100480 HIV+ sera Gamaleya ER100
100481 HIV+ sera Gamaleya ER101
100482 HIV+ sera Gamaleya ER104
100483 HIV+ sera Gamaleya ER107
100484 HIV+ sera Gamaleya ER108
100485 HIV+ sera Gamaleya ER109
100486 HIV+ sera Gamaleya ER110
100487 HIV+ plasma Gamaleya ER111
100488 HIV+ plasma Gamaleya ER112
100489 HIV+ plasma Gamaleya ER113
100490 HIV+ plasma Gamaleya ER114
100491 HIV+ plasma Gamaleya ER116
100492 HIV+ plasma Gamaleya ER117
100493 HIV+ plasma Gamaleya ER118
100494 HIV+ plasma Gamaleya ER120
100495 HIV+ plasma Gamaleya ER122
100496 HIV+ plasma Gamaleya ER123
100497 HIV+ plasma Gamaleya ER124
100498 HIV+ plasma Gamaleya ER125
100499 HIV+ plasma Gamaleya ER126
1005 HIV-1 Drug resistant L74V/M184V Confers resistance (nine to ten-fold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC.
100500 HIV+ plasma Gamaleya ER127
100501 HIV+ plasma Gamaleya ER128
100502 HIV+ plasma Gamaleya ER129
100503 HIV+ plasma Gamaleya ER131
100504 HIV+ plasma Gamaleya ER138
100505 HIV+ plasma Gamaleya ER140
100506 HIV+ plasma Gamaleya ER141
100507 HIV+ plasma Gamaleya ER142
100508 HIV+ plasma Gamaleya ER143
100509 HIV+ plasma Gamaleya ER144
100510 HIV+ plasma Gamaleya ER145
100511 HIV+ plasma Gamaleya ER146
100512 HIV+ plasma Gamaleya ER147
100513 HIV+ plasma Gamaleya ER148
100514 HIV+ plasma Gamaleya ER149
100515 HIV+ plasma Gamaleya ER150
100516 HIV+ plasma Gamaleya ER151
100517 HIV+ plasma Gamaleya ER152
100518 HIV+ plasma Gamaleya ER153
100519 HIV+ plasma Gamaleya ER154
100520 HIV+ plasma Gamaleya ER155
100521 HIV+ plasma Gamaleya ER156
100522 HIV+ plasma Gamaleya ER157
100523 HIV+ plasma Gamaleya ER158
100524 HIV+ plasma Gamaleya ER159
100525 HIV+ plasma Gamaleya ER160
100526 HIV+ plasma Gamaleya ER161
100527 HIV+ plasma Gamaleya ER162
100528 HIV+ plasma Gamaleya ER163
100529 HIV+ plasma Gamaleya ER164
100530 HIV+ plasma Gamaleya ER165
100531 HIV+ plasma Gamaleya ER167
100532 HIV+ plasma Gamaleya ER168
100533 HIV+ plasma Gamaleya ER185
100534 PBMC HIV+, LTB+ (OT1-TIF2911)
100535 PBMC HIV+, LTB+ (OT1-TIF3176)
100536 PBMC HIV+, LTB+ (OT1-TIF2919)
100537 PBMC HIV+, LTB+ (OT1-TIF2921)
100538 PBMC HIV+, LTB+ (OT1-TIF2929)
100539 PBMC HIV+, LTB+ (OT1-TIF2928)
100540 PBMC HIV+, LTB+ (OT1-TIF2935)
100541 PBMC HIV+, LTB+ (OT1-TIF2938)
100542 PBMC HIV+, LTB+ (OT1-TIF2940)
100543 PBMC HIV+, LTB+ (OT1-TIF2943)
100544 PBMC HIV+, LTB+ (OT1-TIF2948)
100545 PBMC HIV+, LTB+ (OT1-TIF2996)
100546 PBMC HIV+, LTB+ (OT1-TIF3000)
100547 PBMC HIV+, LTB+ (OT1-TIF3014)
100548 PBMC HIV+, LTB+ (OT1-TIF3042)
100549 PBMC HIV+, LTB+ (OT1-TIF3084)
100550 PBMC HIV+, LTB+ (OT1-TIF3068)
100551 PBMC HIV+, LTB+ (OT1-TIF3085)
100552 PBMC HIV+, LTB+ (OT1-TIF3090)
100553 PBMC HIV+, LTB+ (OT1-TIF3114)
100554 PBMC HIV+, LTB+ (OT1-TIF3118)
100555 PBMC HIV+, LTB+ (OT1-TIF3134)
100556 PBMC HIV+, LTB+ (OT1-TIF3136)
100557 PBMC HIV+, LTB+ (OT1-TIF3180)
100558 PBMC HIV+, LTB+ (OT1-TIF3170)
100559 PBMC HIV+, LTB+ (OT1-TIF3173)
100560 PBMC HIV+, LTB+ (OT1-TIF3290)
100561 PBMC HIV+, LTB+ (OT1-TIF3296)
100562 PBMC HIV+, LTB+ (OT1-TIF3302)
100563 PBMC HIV+, LTB+ (OT1-TIF3337)
100564 PBMC HIV+, LTB+ (OT1-TIF3340)
100565 PBMC HIV+, LTB+ (OT1-TIF3403)
100566 PBMC HIV+, LTB+ (OT1-TIF3414)
100567 PBMC HIV+, LTB+ (OT1-TIF3426)
100568 PBMC HIV+, LTB+ (OT1-TIF3394)
100569 PBMC HIV+, LTB+ (OT1-TIF3391)
100570 PBMC HIV+, LTB+ (OT1-TIF3419)
100571 PBMC HIV+, LTB+ (OT1-TIF3489)
100572 PBMC HIV+, LTB+ (OT1-TIF3513)
100573 PBMC HIV+, LTB+ (OT1-TIF3510)
100574 PBMC HIV+, LTB+ (OT1-TIF3528)
100575 PBMC HIV+, LTB+ (OT1-TIF3541)
100576 PBMC HIV+, LTB+ (OT1-TIF3539)
100577 PBMC HIV+, LTB+ (OT1-TIF3567)
100578 PBMC HIV+, LTB+ (OT1-TIF3557)
100579 PBMC HIV+, LTB+ (OT1-TIF3601)
100580 PBMC HIV+, LTB+ (OT1-TIF3616)
100581 PBMC HIV+, LTB+ (OT1-TIF3665)
100582 PBMC HIV+, LTB+ (OT1-TIF3749)
100583 PBMC HIV+, LTB+ (OT1-TIF3748)
100584 Whole blood HIV+, Malaria+ (OT1-TIF0983)
100585 Whole blood HIV+, Malaria+ (OT1-TIF1014)
100586 Whole blood HIV+, Malaria+ (OT1-TIF1121)
100587 Whole blood HIV+, Malaria+ (OT1-TIF1140)
100588 Whole blood HIV+, Malaria+ (OT1-TIF1286)
100589 Whole blood HIV+, Malaria+ (OT1-TIF1486)
100590 Whole blood HIV+, Malaria+ (OT1-TIF1488)
100591 Whole blood HIV+, Malaria+ (OT1-TIF1458)
100592 Whole blood HIV+, Malaria+ (OT1-TIF1504)
100593 HIV-1 isolate cultured in PBMC, CRF02_AG
100594 HIV-1 isolate cultured in PBMC, subtype B
100595 HIV-1 isolate cultured in PBMC, subtype C
100596 HIV-1 isolate cultured in PBMC, subtype B
100597 HIV-1 isolate cultured in PBMC, subtype B
100598 HIV-1 isolate cultured in PBMC, subtype B
100599 HIV-1 isolate cultured in PBMC, subtype F1
1006 HIV-1 Drug resistant K65R/M184V Confers resistance (seven to eight-fold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC.
100600 HIV-1 isolate cultured in PBMC, subtype B
100601 HIV-1 isolate cultured in PBMC, subtype F1
100602 HIV-1 Env gp160 clone (XC2014EU05) CRF07_BC
100603 HIV-1 Env gp160 clone (XC2014EU07) CRF07_BC
100604 HIV-1 Env gp160 clone (XC2014EU11) CRF07_BC HIV-1 Env gp160 clone (XC2014EU11) CRF07_BC
100605 HIV-1 Env gp160 clone (BJ2015EU04) CRF07_BC HIV-1 Env gp160 clone (BJ2015EU04) CRF07_BC
100606 HIV-1 Env gp160 clone (BJ2015EU09) CRF01_AE HIV-1 Env gp160 clone (BJ2015EU09) CRF01_AE
100607 HIV-1 Env gp160 clone (BJ2015EU14) CRF01_AE HIV-1 Env gp160 clone (BJ2015EU14) CRF01_AE
100608 HIV-1 Env gp160 clone (BJ2015EU16) CRF07_BC HIV-1 Env gp160 clone (BJ2015EU16) CRF07_BC
100609 HIV-1 Env gp160 clone (BJ2015EU17) CRF01_AE HIV-1 Env gp160 clone (BJ2015EU17) CRF01_AE
100610 HIV-1 Env gp160 clone (GX2016EU02) CRF08_BC HIV-1 Env gp160 clone (GX2016EU02) CRF08_BC
100611 HIV-1 Env gp160 clone (GX2016EU05) CRF07_BC HIV-1 Env gp160 clone (GX2016EU05) CRF07_BC
100612 HIV-1 Env gp160 clone (GX2016EU07) CRF01_AE HIV-1 Env gp160 clone (GX2016EU07) CRF01_AE
100613 HIV-1 Env gp160 clone (GX2016EU08) CRF07_BC HIV-1Env gp160 clone (GX2016EU08) CRF07_BC
100614 HIV-1 Env gp160 clone (GX2016EU12) CRF07_BC HIV-1 Env gp160 clone (GX2016EU12) CRF07_BC
100615 HIV-1 Env gp160 clone (GX2016EU19) CRF01_AE HIV-1 Env gp160 clone (GX2016EU19) CRF01_AE
100616 pNL4-3 deltaE-EGFP This vector expresses an endoplasmic reticulum (ER)-retained truncated Env-EGFP fusion protein. The EGFP was amplified from the pEGFP-N1 plasmid (Clontech) with primers that introduced the endonuclease sites, a KDEL ER-retention signal and a stop codon at
100617 PepMix HCV (Capsid Protein) Ultra HCV Core Protein, 140 peptides, (15meric) Sequences from European Hepatitis C Virus database (euHCVdb; https://euhcvdb.ibcp.fr/euHCVdb/) average coverage Serotype 1: 94.8 % Serotype 2: 89.1% Serotype 3: 89.4% Serotype 4: 94.2%
100618 PepMix HCV (E1 Protein) Ultra HCV E1 Protein, 200 peptides, (15meric) Sequences from European Hepatitis C Virus database (euHCVdb; https://euhcvdb.ibcp.fr/euHCVdb/) average coverage Serotype 1: 94.8 % Serotype 3: 66.8% Serotype 5: 63.2% Coverage for remaining serotypes <23 %
100619 RepliTope Antigen Collection Malaria Ultra Malaria Microarray, Sequence diversity for all presented antigens was taken from www.malariagen.net. For Pl. Falciparum proteins only mutations with an allele frequncy >0.5 % were considered. For Pl. Vivax proteins all mutations were presented in the pept
100620 Mab to anti-HIV-1 gag p55/p18 (Purified 4H2B1)
100621 Mab to HIV-1 RT (Purified 5B2B2)
100622 Mab to HIV-1 env (Purified CA13)
100623 Mab to SIVmac251 gp160/gp120 (Purified KK45) A monoclonal antibody to SIV gp120, specifically to the V3 region
100624 Entecavir A synthetic analogue of 2'-deoxyguanosine, entecavir is a nucleoside reverse transcriptase inhibito.
100625 HIV-1 plasma (EUR-0119)
100626 HIV-1 plasma (EUR-0120)
100627 HIV-1 plasma (EUR-0121)
100628 HIV-1 plasma (EUR-0122)
100629 HIV-1 plasma (EUR-0123)
100630 HIV-1 plasma (EUR-0124)
100631 HIV-1 plasma (EUR-0125)
100632 HIV-1 plasma (EUR-0126)
100633 HIV-1 plasma (EUR-0127)
100634 HIV-1 plasma (EUR-0128)
100635 HIV-1 plasma (EUR-0129)
100636 HIV-1 plasma (EUR-0130)
100637 HIV-1 plasma (EUR-0131)
100638 HIV-1 plasma (EUR-0132)
100639 HIV-1 plasma (EUR-0133)
100640 HIV-1 plasma (EUR-0134)
100641 HIV-1 plasma (EUR-0135)
100642 HIV-1 plasma (EUR-0136)
100643 HIV+ patient PBMCs (EUR-0119)
100644 HIV+ patient PBMCs (EUR-0120)
100645 HIV+ PBMCs (EUR-0121) PBMCs from HIV+ patients (collected by ISCIII, Spain) same as #100340
100646 HIV+ PBMCs (EUR-0122) PBMCs from HIV+ patients (collected by ISCIII, Spain) same as #100341
100647 HIV+ PBMCs (EUR-0123) PBMCs from HIV+ patients (collected by ISCIII, Spain) same as #100342
100648 HIV+ patient PBMCs (EUR-0124)
100649 HIV+ patient PBMCs (EUR-0125)
100650 PBMCs from HIV+ patients (EUR-0126) PBMCs from HIV+ patients (collected by ISCIII, Spain). Same product as #100343.
100651 PBMCs from HIV+ patients (EUR-0127) PBMCs from HIV+ patients (collected by ISCIII, Spain). Same product as #100344.
100652 PBMCs from HIV+ patients (EUR-0128) PBMCs from HIV+ patients collected by ISCIII, Spain. Same product as #100345.
100653 PBMCs from HIV+ patients (EUR-129) PBMCs from HIV+ patients collected by ISCIII, Spain. Same product as #100346.
100654 HIV+ patient PBMCs (EUR-0130)
100655 HIV+ patient PBMCs (EUR-0131)
100656 HIV+ patient PBMCs (EUR-0132)
100657 HIV+ patient PBMCs (EUR-133)
100658 PBMCs from HIV+ patient (EUR-0134) PBMCs from HIV+ patient collected by ISCIII, Spain
100659 PBMCs from HIV+ patient (EUR-0135) PBMCs from HIV+ patient collected by ISCIII, Spain
100660 PBMCs from HIV+ patient (EUR-0136) PBMCs from HIV+ patient collected by ISCIII, Spain
100661 Mab to gp120 (PGT145) A recombinant, broadly neutralizing monoclonal antibody (bnMAb) to HIV-1 gp120, specifically to the quaternary structure of V1V2 of the HIV-1 envelope protein.
100663 HIV-1 gp160 clone (EUR-0065)Subtype B HIV-1 gp160 clone (EUR-0065)Subtype B
100664 HIV-1 gp160 clone (EUR-0068)Subtype G HIV-1 gp160 clone (EUR-0068)Subtype G
100665 HIV-1 gp160 clone (EUR-0077)Subtype F1 HIV-1 gp160 clone (EUR-0077)Subtype F1
100666 HIV-1 gp160 clone (EUR-0078)Subtype B HIV-1 gp160 clone (EUR-0078)Subtype B
100667 HIV-1 gp160 clone (EUR-0082)Subtype CRF02_AG HIV-1 gp160 clone (EUR-0082)Subtype CRF02_AG
100668 HIV-1 gp160 clone (EUR-0083)Subtype B HIV-1 gp160 clone (EUR-0083)Subtype B
100669 HIV-1 Recombinant gp120 (ADA) Gene cloned from M cell-tropic HIV-1 ADA strain and the full length recombinant envelope gp120 glycoprotein produced in the Baculovirus Expression System.
100670 Recombinant HIV-1 gp120 (sub C) Full length Recombinant HIV-1 C gp120 glycoprotein produced in the Baculovirus Expression System
100671 Recombinant HIV-1 gp120 (YU-2) Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp120 glycoprotein produced in the Baculovirus Expression System
100672 Recombinant HIV-1 p66 (IIIB) Full length Recombinant heterodimeric HIV-1 IIIB p66 (RT) produced in E.coli Full length Recombinant heterodimeric HIV-1 IIIB p66 (RT) produced in E.coli expressionsystem
100673 Mab to tat (Purified NT3/2A4.1) mAb to N-terminal peptide of tat
100674 Mab to SIV gp160/gp120 (Purified KK17) Raised in mice primed with a SIVmac251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaraldehyde-fixed SIVmac11/88 from C8166 cells. Reacts with the SIV env region (aa 8-303). Reacts in WB with gp160/gp120; also reactive in RIPA and surface fl
100675 Mab to SIVgp160/gp32 (Purified KK41) Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 0798.10
100676 Mab to SIV env (Purified KK42)
100677 Mab to SIV p27 (Purified KK64) Suitable for ELISA and immunoblotting
100678 Mab to SIV nef (Purified KK77) Positive in western blot, RIPA, FACScan, reacts with 0777.8
100679 HIV-1 gp160 Clone (EUR0085) Subtype B HIV-1 gp160 Clone (EUR0085) Subtype B
100680 HIV-1 gp160 Clone (EUR0115) Subtype F1 HIV-1 gp160 Clone (EUR0115) Subtype F1
100681 Whole blood from HIV+, Malaria+ (OT1-TIF1494)
100682 Whole blood from HIV+, Malaria+ (OT1-TIF4188)
100683 Whole blood from HIV+, Malaria+ (OT1-TIF1471)
100684 Whole blood from HIV+, Malaria+ (OT1-TIF1832)
100685 Whole blood from HIV+, Malaria+ (OT1-TIF1826)
100686 Whole blood from HIV+, Malaria+ (OT1-TIF1841)
100687 Whole blood from HIV+, Malaria+ (OT1-TIF1919)
100688 Whole blood from HIV+, Malaria+ (OT1-TIF1986)
100689 Whole blood from HIV+, Malaria+ (OT1-TIF1984)
100690 Whole blood from HIV+, Malaria+ (OT1-TIF1989)
100691 Whole blood from HIV+, Malaria+ (OT1-TIF2745)
100692 Whole blood from HIV+, Malaria+ (OT1-TIF2114)
100693 Whole blood from HIV+, Malaria+ (OT1-TIF4189)
100694 Whole blood from HIV+, Malaria+ (OT1-TIF2268)
100695 Whole blood from HIV+, Malaria+ (OT1-TIF2369)
100696 Whole blood from HIV+, Malaria+ (OT1-TIF2267)
100697 Whole blood from HIV+, Malaria+ (OT1-TIF2342)
100698 Whole blood from HIV+, Malaria+ (OT1-TIF2351)
100699 Whole blood from HIV+, Malaria+ (OT1-TIF2368)
1007 HIV-1 Drug resistant K65R/L74V/M184V Confers resistance (tenfold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC.
100700 Whole blood from HIV+, Malaria+ (OT1-TIF2481)
100701 Whole blood from HIV+, Malaria+ (OT1-TIF2001)
100702 Whole blood from HIV+, Malaria+ (OT1-TIF2576)
100703 Whole blood from HIV+, Malaria+ (OT1-TIF2722)
100704 Whole blood from HIV+, Malaria+ (OT1-TIF2728)
100705 Whole blood from HIV+, Malaria+ (OT1-TIF4183)
100706 Whole blood from HIV+, Malaria+ (OT1-TIF4182)
100707 Whole blood from HIV+, Malaria+ (OT1-TIF4181)
100708 Whole blood from HIV+, Malaria+ (OT1-TIF4179)
100709 Whole blood from HIV+, Malaria+ (OT1-TIF4180)
100710 Whole blood from HIV+, Malaria+ (OT1-TIF4184)
100711 Whole blood from HIV+, Malaria+ (OT1-TIF4190)
100712 Whole blood from HIV+, Malaria+ (OT1-TIF4187)
100713 Whole blood from HIV+, Malaria+ (OT1-TIF4177)
100714 Whole blood from HIV+, Malaria+ (OT1-TIF4176)
100715 Whole blood from HIV+, Malaria+ (OT1-TIF4186)
100716 Whole blood from HIV+, Malaria+ (OT1-TIF4185)
100717 HIV-1 CRF08_BC Positive Plasma
100718 HIV-1 CRF07_BC Positive Plasma
100719 HIV-1 CRF07_BC Positive Plasma
100720 HIV-1 CRF07_BC Positive Plasma
100721 HIV-1 CRF07_BC Positive Plasma
100722 HIV-1 CRF07_BC Positive Plasma
100723 HIV-1 CRF07_BC Positive Plasma
100724 HIV-1 CRF07_BC Positive Plasma
100725 HIV-1 CRF01_AE Positive Plasma
100726 HIV-1 CRF07_BC Positive Plasma
100727 HIV-1 CRF07_BC Positive Plasma
100728 HIV-1 CRF07_BC Positive Plasma
100729 HIV-1 CRF07_BC Positive Plasma
100730 HIV-1 CRF07_BC Positive Plasma
100731 HIV-1 CRF07_BC Positive Plasma
100732 HIV-1 CRF07_BC Positive Plasma
100733 HIV-1 CRF01_AE Positive Plasma
100734 HIV-1 CRF07_BC Positive Plasma
100735 HIV-1 CRF08_BC Positive Plasma
100736 HIV-1 CRF01_AE Positive Plasma
100737 HIV-1 CRF01_AE Positive Plasma
100738 HIV-1 CRF07_BC Positive Plasma
100739 HIV-1 CRF01_AE Positive Plasma
100740 HIV-1 CRF07_BC Positive Plasma
100741 HIV-1 CRF01_AE Positive Plasma
100742 HIV-1 CRF01_AE Positive Plasma
100743 HIV-1 CRF01_AE Positive Plasma
100744 HIV-1 CRF07_BC Positive Plasma
100745 HIV-1 CRF01_AE Positive Plasma
100746 HIV-1 subtype B Positive Plasma
100747 HIV-1 CRF07_BC Positive Plasma
100748 HIV-1 CRF01_AE Positive Plasma
100749 HIV-1 CRF07_BC Positive Plasma
100750 HIV-1 CRF01_AE Positive Plasma
100751 HIV-1 CRF07_BC Positive Plasma
100752 HIV-1 CRF08_BC Positive Plasma
100753 HIV-1 CRF01_AE Positive Plasma
100754 HIV-1 CRF01_AE Positive Plasma
100755 HIV-1 CRF07_BC Positive Plasma
100756 HIV-1 CRF01_AE Positive Plasma
100757 HIV-1 CRF07_BC Positive Plasma
100758 HIV-1 CRF07_BC Positive Plasma
100759 HIV-1 CRF01_AE Positive Plasma
100760 HIV-1 CRF01_AE Positive Plasma
100761 HIV-1 CRF01_AE Positive Plasma
100762 HIV-1 CRF01_AE Positive Plasma
100763 HIV-1 CRF01_AE Positive Plasma
100764 HIV-1 CRF01_AE Positive Plasma
100765 HIV-1 CRF08_BC Positive Plasma
100766 HIV-1 CRF55_01B Positive Plasma
100767 RepliTope Antigen Collection HIV Ultra Microarray Array 2, Immunogenic regions of HIV-1 Proteome as reported by LANL. The coverage of the library for all sequences in the respective alignment is for ENV 57%, GAG 72%, NEF 62% and TAT46%.
100768 M7 Cocktail Cocktail of 7 mycobacterium tuberculosis antigens: 19kDa (Rv3763), 85A (Rv3804c), TB10.3 (Rv3019c), 85B, (Rv1886c), (HSP20) Rv0251c, ESAT6 (Rv3875), CFP7 (Rv0288).
100769 MPB70 recombinent Protein the recominant protein with additional N-Terminal his-tag and thrombin cleavage site was expressed in E. coli
100770 HSP70 Recombinant Protein of Mycobacterium TB Recombinent HSP70 protein of Mycobacterium Tuberculosis Alternative names Rv0350, DnaK Homologue, CP70, 70 kDa antigen
100773 HIV-1 Env gp160 clone (EUR-0122) The HIV-1 gp160 sequence derived from a clinical sample collected in Spain has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100774 HIV-1 Env gp160 clone (EUR-0129) The HIV-1 gp160 sequence derived from a clinical sample collected in Spain has been cloned in the pcDNA™3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus
100775 HIV-1 Env gp160 clone (EUR-0133) The HIV-1 gp160 sequence derived from a clinical sample collected in Spain has been cloned in the pcDNA3.1/V5-His TOPO® TA. Transfection of this plasmid in mammalian cells allows the expression of the gp160 protein and can be used to generate pseudovirus.
100789 Purified MAb against SIVp27 (purified #0395) Purified form of 395, Reacts in Immunoblot with SIV lysate
100790 Purified mAb to SIV p27 KK63 (purified #3006) Suitable for ELISA and immunoblotting
100791 Purified MAb against SIVp27 KK60 (purified #3061) Purified form of 3060, Reacts in ELISA, Western blot and RIPA.
100792 Purified MAb against SIVp27 (purified #0392) Purified version of 392, Reacts in Immunoblot with SIV lysate
100793 Purified MAb against SIVp27 (purified #0393) Purified version of 393, Reacts in Immunoblot with SIV lysate
100794 Purified Mab against SIV p27 (purified #0394) Purified version of 394, reacts in Immunoblot with SIV lysate
100795 Purified MAb against SIVp27 (purified #0397) Purified version of 397, Reacts in Immunoblot with SIV lysate
100796 Purified MAb against SIVp27 (purified #0398) Purified version of 398, Reacts in Immunoblot with SIV lysate
100797 Mab to SIVenv KK52
1008 HIV-1 Drug resistant I50V Confers slight resistance (two to three-fold) to protease inhibitors VX-478 & VB-11, 328.
100840 HIV-1 YU2 Infectious Molecular Clone This is the first full length proviral HIV-1 clone derived directly from uncultured material. pYU2 is a replication competent, infectious molecular clone. Virus derived from this clone productively infects primary lymphocytes, primary monocytes and macrop
100841 SIVmac239 gp130-His Recombinant Protein This envelope protein was produced in serum-free HEK-293T cell expression system and purified by Ni-Sepharose/Ion-Exchange/Lectin Affinity/Superdex S-200 chromatography. It contains a 6xHIS-tag. The resulting protein comprises the ectodomain portion of HI
100861 HIV-1 + Plasma Subtype: A1 (EUR-0066) Plasma from a Subtype: A1 Newly diagnosed patient (EUR-0066)
100862 HIV-1 + Plasma Subtype: C (EUR-0067) Plasma from a Subtype: C Newly diagnosed patient (EUR-0067)
100863 HIV-1 + Plasma Subtype: B (EUR-0074) Plasma from a Subtype: B Newly diagnosed patient (EUR-0074)
100864 HIV-1 + Plasma Subtype: B (EUR-0086) Plasma from a Subtype: B patient (EUR-0086)
100865 HIV-1 + Plasma Subtype: B (EUR-0087) Plasma from a Subtype: B patient (EUR-0087)
100866 HIV-1 + Plasma Subtype: F1 (EUR-0088) Plasma from a Subtype: F1 Newly diagnosed patient (EUR-0088)
100867 HIV-1 + Plasma Subtype: B (EUR-0089) Plasma from a Subtype: B Newly diagnosed patient (EUR-0089)
100868 HIV-1 + Plasma Subtype: B (EUR-0090) Plasma from a Subtype: B Newly diagnosed patient (EUR-0090)
100869 HIV-1 + Plasma Subtype: B (EUR-0092) Plasma from a Subtype: B Newly diagnosed patient (EUR-0092)
100870 HIV-1 + Plasma Subtype: B (EUR-0096) Plasma from a Subtype: B Newly diagnosed patient (EUR-0096)
100871 HIV-1 + Plasma Subtype: B (EUR-0097) Plasma from a Subtype: B Newly diagnosed patient (EUR-0097)
100872 HIV-1 + Plasma Subtype: B (EUR-0098) Plasma from a Subtype: B patient (EUR-0098)
100873 HIV-1 + Plasma Subtype: F1 (EUR-0099) Plasma from a Subtype: F1 patient (EUR-0099)
100874 HIV-1 + Plasma Subtype: B (EUR-0100) Plasma from a Subtype: B Newly diagnosed patient (EUR-0100)
100875 HIV-1 + Plasma Subtype: B (EUR-0102) Plasma from a Subtype: B Newly diagnosed patient (EUR-0102)
100876 HIV-1 + Plasma Subtype: B (EUR-0105) Plasma from a Subtype: B Newly diagnosed patient (EUR-0105)
100877 HIV-1 + Plasma Subtype: B (EUR-0106) Plasma from a Subtype: B Newly diagnosed patient (EUR-0106)
100878 HIV-1 + Plasma Subtype: B (EUR-0107) Plasma from a Subtype: B Newly diagnosed patient (EUR-0107)
100879 HIV-1 + Plasma Subtype: unknown (EUR-0108) Plasma from a Subtype: unknown Newly diagnosed patient (EUR-0108)
100880 HIV-1 + Plasma Subtype: BF1 (EUR-0109) Plasma from a Subtype: BF1 Newly diagnosed patient (EUR-0109)
100881 HIV-1 + Plasma Subtype: B (EUR-0112) Plasma from a Subtype: B Newly diagnosed patient (EUR-0112)
100882 HIV-1 + Plasma Subtype: B (EUR-0113) Plasma from a Subtype: B Newly diagnosed patient (EUR-0113)
100883 HIV-1 + Plasma Subtype: C (EUR-0114) Plasma from a Subtype: B Newly diagnosed patient (EUR-0113)
1009 HIV-1 Drug resistant 150V/M46I/I47V Confers slight resistance (twenty fold) to protease inhibitors VX-478 & VB-11, 328.
100941 J-Lat Full length Cells (6.3) This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
100942 J-Lat Full length Cells (8.4) This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
100943 J-Lat Full length Cells (9.2) This jurkat based cell line containing a full length integrated HIV-1 genome that expresses GFP upon Activation. The genone generates incomplete virons due to a frameshift in env.
100944 J-Lat Tat-GFP Cells (A1) These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
100945 J-Lat Tat-GFP Cells (A7) This is a Jurkat-based cell line containing a full-length integrated HIV- genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
100946 J-Lat Tat-GFP Cells (A2) These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
100947 J-Lat Tat-GFP Cells (H2) These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
100948 J-Lat GFP Cells (A72) These Jurkat cells contain a single integration site of a HIV retroviral vector expressing LTR driven GFP expression.
100952 pR8.7
100954 HIV-1 Consensus Group M Env Peptide Pool The 211 peptides (from NIH cat 9487 peptide set) were pooled together and then distributed such that each vial contains 50 µg of each peptide, 10.55 mg total peptide.
100955 pNLGRINFQ Infectious Molecular clone Full-length HIV-1 reverse transcriptase mutant with impaired replication activity.
100956 pNLΔ67+GRINFQ Infectious Molecular clone Full-length HIV-1 reverse transcriptase (RT) mutant. The mutations in RT of this clone lead to resistance to a number of reverse transcriptase inhibitors. The clone replicates as efficiently as wild type HIV-1.
100957 HIV-2 serum (GB 7388)
100958 HIV-2 serum (IC 13509)
100959 HIV-2 serum (GB7329)
100960 HIV-2 serum (GB 7322)
100961 HIV-2 serum (GB 7405)
100962 HIV-2 serum (GB7332)
100963 HIV-2 serum (BS 1295 TH)
100964 HIV-2 serum (BS 2774)
100973 ConM SOSIP.v7 protein A stabilised Native-like Env trimer based on the consensus sequence of HIV-1 group M. Expressed recombinantly in a CHO a host cell line. Efficiently binds with quaternary structure-dependent bNAbs PG16, PGT145, PGT151, and 35O22 and showed decreased bindi
100974 ConSOSL.UFO.664 protein A stabilised soluble Native-like Env trimer based on the consensus sequence of HIV-1 group M. Expressed recombinantly in a CHO a host cell line.
100975 Anti SERINC5 antibody (EVG_S5.2)
100976 pCAGGS_SARS-CoV-2_Spike The sequence of the Spike from Wuhan-Hu-1 isolate (Genbank MN908947.3) has been human codon optimized and cloned in the pCAGGS (SacI-NheI). This plasmid can be used to generate SARSCoV-2 pseudovirus by co-transfection of HEK-293T cells.
100978 VeroE6/TMPRSS2 The VeroE6 cell line has been modified to constitutively express the serine protease TMPRSS2. The resulting VeroE6/TMPRSS2 cells were shown to be highly susceptible to SARS-CoV-2 infection (Matsuyama et al., PNAS, 2020) and can be used to produce large vi
100980 SARS- CoV-2 virus (BetaCoV/Australia/VIC01/2020) SARS-CoV-2 fully infectious virus (strain BetaCoV/Australia/VIC01/2020) grown in VeroE6/TMPRSS2 cell line (CFAR #100978), passage 4. RNA titre (copies / mL, calculated using NIBSC 19/304): 1.10 x 1e10 TCID50/mL in VeroE6: 0.93 x 1e6 TCID50/mL in
100982 SARS-CoV-2 Nucleoprotein SARS CoV-2 Nucleoprotein (full-length, NCBI reference YP_009724397.2) with N-terminal hexahistidine tag, produced by expression in Escherichia coli and purified by Ni2+ affinity, cation exchange, heparin, and size exclusion chromatography.
100985 pCAGGS_SARS_CoV2_D614G_Spike The sequence of the Spike from Wuhan-Hu-1 isolate (Genbank MN908947.3) has been human codon optimized and cloned in the pCAGGS (SacI-NheI). A A1841G (spike numbering) nucleotide mutation was introduced by mutagenesis resulting in the D614G amino acid subs
100986 pCAGGS_SARS_CoV2_Bristol-Deletion_Spike The sequence of the Spike from Wuhan-Hu-1 isolate (Genbank MN908947.3) has been human codon optimized and cloned in the pCAGGS (SacI-NheI). Amino acids 680-687, which include the arginine rich furin cleavage site, have been deleted (Bristol deletion) by m
100987 Inactivated BetaCoV/Australia/VIC01/2020 Inactivated SARS- CoV-2 BetaCoV/Australia/VIC01/2020) #100980, by acetic acid and heat treatments. Can be handled in a BSL2 lab on the bench.
100988 RNA extract(SARS-CoV-2 BetaCoV/Austrlia/VIC01/2020 Nucleic acids have been extracted from SARS-CoV-2 (BetaCoV/Australia/VIC01/2020) grown in VeroE6/TMPRSS2 cell line, passage 4, and inactivated by acetic acid and heat treatment.. RNA titre (copies/mL*):1.64 x 1e10 *calculated using plasmid diluted in ge
100989 pCRII-SARS-CoV-2 (5'UTR-NSP2) Plasmid containing the 5'UTR-NSP2 sequence of SARS-CoV-2. One of a series of nine plasmids containing overlapping fragments covering the whole genome of SARS-CoV-2.
100991 pCRII-SARS-CoV-2 (NSP4-NSP8) Plasmid containing the NSP4-NSP8 sequence of SARS-CoV-2. One of a series of nine plasmids containing overlapping fragments covering the whole genome of SARS-CoV-2.
100992 pCRII-SARS-CoV-2 (NSP9-NSP12) Plasmid containing the NSP9-NSP12 sequence of SARS-CoV-2. One of a series of nine plasmids containing overlapping fragments covering the whole genome of SARS-CoV-2.
100994 pCRII-SARS-CoV-2 (NSP15-NSP16) Plasmid containing the NSP154-NSP16 sequence of SARS-CoV-2. One of a series of nine plasmids containing overlapping fragments covering the whole genome of SARS-CoV-2.
100996 pCRII-SARS-CoV-2 (ORF3a-ORF6) Plasmid containing the ORF3a-ORF6 sequence of SARS-CoV-2. One of a series of nine plasmids containing overlapping fragments covering the whole genome of SARS-CoV-2.
100998 SARS-CoV-2 CVR-GLA1 SARS-CoV-2 fully infectious virus (CVR-GLA 1) grown in Vero h/SLAM cell line, passage 3. Originally isolated and passaged in VeroE6 cell line.
100999 SARS-CoV-2 CVR-GLA2 SARS-CoV-2 fully infectious virus (CVR-GLA 2) grown in Vero h/SLAM cell line, passage 3. Originally isolated and passaged in VeroE6 cell line.
1010 HIV-1 Drug resistant K103N Confers resistance to a selection of non-nucleoside RT inhibitors.
101000 SARS-CoV-2 CVR-GLA3 SARS-CoV-2 fully infectious virus (CVR-GLA 2) grown in Vero h/SLAM cell line, passage 2. Originally isolated in VeroE6 ACE-2/TMPRSS2 cell line (see #101003) and passaged in VeroE6 cell line.
101001 VeroE6-ACE2 The VeroE6 cell line has been transduced to express human ACE2, selected under hygromycin B. This cell line is not derived from a clone but are a pool of hygromycin resistant cells. The resulting VeroE6-ACE2 cells are highly susceptible to SARS-CoV-2 infe
101003 VeroE6-ACE2-TMPRSS2 The VeroE6 cell line has been transduced to express human ACE2, selected under hygromycin B, further transduced to express human TMPRSS2 and selected under geneticin. This cell line is not derived from a clone but are a pool of hygromycin and neomycin res
101004 A549-ACE2-TMPRSS2 The A549 cell line has been transduced to express human ACE2, selected under hygromycin B, further transduced to express human TMPRSS2 under selection of geneticin. This cell line is not derived from a clone but are a pool of hygromycin and neomycin resis
101005 A549-ACE2 Clone 8 The A549 cell line has been transduced to express human ACE2, selected under hygromycin B and cloned. The resulting A549-ACE2 clone 8 cells are highly susceptible to SARS-CoV-2 infection.
101006 A549-ACE2 Clone 8-TMPRSS2 The A549 cell line has been transduced to express human ACE, selected under hygromycin B and cloned. The clone 8 has been further transduced to express human TMPRSS2, selected under hygromycin B and geneticin. This cell line is a pool of hygromycin and ne
101007 SARS-CoV-2 Trimeric Spike Trimeric Spike protein produced from transiently transfected Expi293F cells; Identical 1-530 amino acids to #100979 (NC_045512.2) ,Furin cleavage site (682-685 ‘RRAR’) removed - now GSAS, Amino acid stabilisation changes K986P & V987P, T4 fibritin fol
101008 HEK293T-ACE2-TMPRSS2 HEK 293T/17 cells ɣ-retrovirally transduced to express human ACE2 with HA epitope on a CD8 stalk as a marker; and lentivirally transduced with TMPRSS2 with a puromycin resistant gene for selection.
101009 mAb to SARS-CoV-2 Nucleocapsid protein (CR3009 Hu) A human monoclonal antibody to SARS-CoV-2 Nucleocapsid protein. An antibody formed of CR3009 heavy chain and CR3001 light chain
101010 mAb to SARS-CoV-2 Nucleocapsid protein (CR3018 Hu) A human monoclonal antibody to SARS-CoV-2 Nucleocapsid protein. An antibody formed of CR3018 heavy chain and CR3001 light chain.
101011 mAb to SARS-CoV-2 Nucleocapsid protein (CR3009 Mu) To facilitate working with human serum samples, the Nucleoprotein mAb CR3009 variable region was subcloned into a pre-existing modified version of a mouse IgG1 HC vector. This contains Human CH1-mouse hinge then murine CH2-CH3 and human CR3001 light Chain
101019 SARS-CoV-2 VOC202012/01 (B.1.1.7. lineage) P4 SARS-CoV-2 fully infectious virus (strain VOC202012/01 (B.1.1.7. lineage) P4) grown in Vero/hSLAM cell line, passage 4.
101022 SARS-CoV-2 VOC202012/02 (B.1.351 lineage) P4 SARS-CoV-2 fully infectious virus (strain VOC202012/02 (B.1.351 lineage) P4) grown in Vero/hSLAM cell line, passage 4.
101023 pI.18_SARS-CoV-2-Spike (B.1.1.7) The sequence of the Spike from B.1.1.7 lineage isolate has been human codon optimized and cloned in the pI.18 (Xho-EcoRI). This plasmid can be used to generate SARS-CoV-2 pseudovirus by co-transfection of HEK-293T cells.
101024 pI.18_SARS-CoV-2-Spike (B.1351 The sequence of the Spike from B.1.351 lineage isolate has been human codon optimized and cloned in the pI.18 (Xho-EcoRI). This plasmid can be used to generate SARS-CoV-2 pseudovirus by co-transfection of HEK-293T cells.
101025 4% formaldehyde inactivated SARS CoV-2 BetaCoV/Australia/VIC01/2020 from VeroE6/TMPRSS2 SARS-CoV-2 (BetaCoV/Australia/VIC01/2020) grown in VeroE6/TMPRSS2 cell line, passage 4, has been inactivated by 4% Formaldehyde treatment.
101027 Inactivated SARS-CoV-2Alpha infectious virus (VOC202012/01 (B.1.1.7.lineage) by Acid and heat SARS-CoV-2 VOC202012/01 (B.1.1.7.lineage)grown in Vero/hSLAM cell line, passage 4, has been inactivated by acetic acid and heat treatment.
101029 Nucleic acid extracts from inactivated SARS-CoV-2 VOC202012/01 (B.1.1.7. lineage) Nucleic acids have been extracted from SARS-CoV-2 (VOC202012/01 (B.1.1.7. lineage) grown in Vero/hSLAM cell line, passage 4, and inactivated by acetic acid and heat treatment.
101030 SARS-CoV-2 Delta (VOC21APR-02 (B.1.617.2 lineage)) SARS-CoV-2 Delta fully infectious virus (VOC21APR-02 (B.1.617.2 lineage) passage 1) grown in Vero/hSLAM cell line, passage 2.
101031 SARS-CoV-2 Bristol Variant (VOC-21FEB-02 (B.1.1.7 lineage + E484K)) SARS-CoV-2 (Bristol Variant) fully infectious virus (VOC-21FEB-02 (B.1.1.7 lineage + E484K) grown in Vero/hSLAM cell line, passage
101032 SARS-CoV-2 Kappa (B.1.617.1 lineage) SARS-CoV-2 Kappa (B.1.617.1 lineage) fully infectious virus grown in Vero/hSLAM cell line.
101033 SARS-CoV-2 Delta (AY.1 sub-lineage) SARS-CoV-2 Delta (AY.1 Sub-lineage) fully infectious virus grown in Vero/hSLAM cell line.
101034 SARS-CoV-2 Mu (B.1.621 lineage) SARS-CoV-2 Mu (B.1.621 lineage) fully infectious virus grown in Vero/hSLAM cell line.
101035 Inactivated (acetic acid + heat) SARS-CoV Beta (B.1.351 lineage) SARS-CoV-2 Beta (strain VOC202012/02 (B.1.351 lineage)) grown in VeroE6/hSLAM cell line, passage 4, has been inactivated by acetic acid and heat treatment.
101036 Inactivated (acetic acid + heat) SARS-CoV-2 Delta (B.1.617.2 lineage) Inactivated (acetic acid + heat) SARS-CoV-2 Delta (B.1.617.2 lineage)
101038 0.01% formaldehyde inactivated SARS-CoV-2 Beta (B.1.351 lineage) SARS-CoV-2 Beta (VOC202012/02 (B.1.351 lineage)) grown in VeroE6/hSLAM cell line, passage 4, has been inactivated by 0.01% Formaldehyde treatment.
101039 0.01% formaldehyde inactivated SARS-CoV-2 Delta (B.1.617.2 lineage) SARS-CoV-2 Beta (VOC21APR-02 (B.1.617.2 lineage)) grown in VeroE6/hSLAM cell line, passage 2, has been inactivated by 0.01% Formaldehyde treatment.
1011 HIV-1 Drug resistant Y188H Confers resistance to a selection of non-nucleoside RT inhibitors.
1012 HIV-1 Drug resistant Y188L Confers resistance to a selection of non-nucleoside RT inhibitors.
1013 HIV-1 Drug resistant Y181C Confers resistance to a selection of non-nucleoside RT inhibitors.
1014 HIV-1 Drug resistant G190A Confers resistance to a selection of non-nucleoside RT inhibitors (Loviride & Nevirapine).
1015 HIV-1 Drug resistant V106A Confers resistance to a large selection of non-nucleoside RT inhibitors.
1016 HIV-1 Drug resistant L100I Confers resistance to a large selection of non-nucleoside RT inhibitors.
1017 SE9173 & SE9280 (Subtype J Isolates) Sub-type J isolates, NSI.
1018 SIV SupT1AT-2TX Aldrithiol-2-inactivated virus. Virus treated with Aldrithiol-2. Tested in proliferation assay vs PBLs. Unable to productively infect highly susceptable cells in vitro. 1018.1 = treated virus, 1018.2 = treated microvicles. See 'NOTE' on datasheet
1020 PH969 Cell Line Simian T-cell Lymphotrophic virus cell line. Obtained from PBMC’s of an STLV-3 (formerly STLV-L) infected Erithrean Papio hamadryas (strain PH969). Cocultivated with blood lymphocytes from a seronegative baboon.
1021 PP1664 Cell Line Stable IL-2 dependent Ag producing cell line. Simian T-cell Lymphotrophic virus cell line. Cell line of PBMC’s from an STLV-2 infected Pan paniscus, co-cultivated with human cord blood lymphocytes.
1022 Primary Isolates Djoubouti, Ethiopia Isolated from seropositive individuals in Djibouti, Ethiopia. See datasheet for isolate numbers.
1023 Primary Isolates, Syria. Isolated from seropositive individuals in Syria. See datasheet for isolate numbers.
1024 Primary Isolates, Egypt. Isolated from seropositive individuals in Egypt. See datasheet for isolate numbers.
1025 Primary Isolates Belores. Isolated from seropositive individuals in Belorus See datasheet for isolate numbers.
1026 Primary Isolates, China Isolated from seropositive individuals in China. See datasheet for isolate numbers.
1027 Primary Isolates, India. Isolated from seropositive individuals in India See datasheet for isolate numbers.
1028 Primary Isolates, Israel. Isolated from seropositive individuals in Israel. See datasheet for isolate numbers.
1029 Primary Isolates, Kazachstan. Isolated from seropositive individuals in Kazachstan. See datasheet for isolate numbers.
1030 Pirmary Isolates, Russia Isolated from seropositive individuals in Russia. See datasheet for isolate numbers.
1031 Pirmary Isolates, Senegal. Isolated from seropositive individuals in Senegal. See datasheet for isolate numbers.
1032 Primary isolates, Tanzania Isolated from seropositive individuals from Tanzania. For known Genotype and Phenotype see datasheet.
1033 Primary Isolates, South Africa. Isolated from seropositive individuals in South Africa. See datasheet for isolate numbers.
1034 X-421-2 (B/G CRF14) Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1035 MP255 (F2) MP255 has been placed in the subclade F2
1037 MP1213 (CRF02_AG) A circulating recombinant form similar to the prototype AG recombinant virus IBNG.
1038 MP1307 (CRF11_CPX) A circulating recombinant form with a complex mosaic structure involving subtypes A, G, J, and CRF-01_AE.
1039 USA Primary Isolates ENV subtype B. Subtype B (gag and env determined)
1040 SIVsmE660 Pathogenic, uncloned virus isolate derived from spleen cells. Replicates in primary macaque lymphocytes and macrophages.
1041 SHIV162P3 Co-receptor specificity of SHIV162P3 is CCR5. Virus is transmissible in rhesus macaques by mucosal and parental routes of inoculation.
1042 VI191
1043 VI991
1044 VI997 This sequence was isolated from a Belgian man who had sexual partners in the Democratic Republic of Congo. The virus was isolated 30/04/93. Accession Number AF190128. Full sequence can be seen at http://hiv-web.lanl.gov
1047 96ZM651 (Subtype C) One of very few full length characterised subtype C isolates. Isolated by co-culturing PBMCs from a seropositive individual from Zambia with PHA-stimulated PBMCs from a normal donor. The original virus has been amplified one additional time in PHA-stimula
1048 MN(P) This is a low passage, PBMC-propagated isolate of the HIV-1 MN reference strain originally established by Drs Gallo and Popovic (#0102). It has not been grown in a T-cell line, only on human PBMCs
1049 DU174 Infect 10x106 normal donor PBMCs, previously stimulated for three days with PHA. Exchange 50% of the medium every 3-4 days. Once each week, add 5 x 106 PHA-stimulated normal donor PBMCs. Freeze supernatant 10 days into the co-culture. Propagate in RPMI 16
1050 CM244
1051 NP1525
1052 QH0692
1053 AC10
1054 HIV-2 CDC310319 Primary isolate of HIV-2 subtype B propagated solely on primary human PBMCs; will form syncytia in MT-2 cells.
1055 HIV-2 7312A Phylogenetic analysis of the env and gag regions suggests that this HIV-2 isolate is an A/B recombinant.
1058 KER2018 (00KE_KER2018) Clade A. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1059 KNH1144 (00KE_KNH1144) Clade A.This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists o
1060 BX08 (92FR_BX08) (BX08) Clade B.This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists o
1061 PBL286(696) (02ET_14) Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1062 PBL288(411) (02ET_288) Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1063 TZBD9/11 (01TZ_911) Clade C. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1064 J32228M4 (00UG_J32228M4) Clade D. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1065 NKU3006 (00KE_NKU3006) Clade D. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1066 CAM0002BBY (01CM_0002BBY) CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1067 CAM0013BBY (02CM_0013BBY) CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1068 CAM1970LE (02CM_1970LE) CRF02_AG. This selected isolate is from an International Panel of HIV-1 virus isolates representing six major globally prlent strains of genetically and biologically characterized HIV-1 isolates (Brown, BK et al, J Virology 79(10): 6089, 2005) consists
1069 ES X-1958 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1070 ES X-1959 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1071 ES X2149 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1072 ES X-1980 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1073 ES X-1936 ( C) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1074 ES X-1998 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1075 ES X-2102 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1076 ES P-1261 (CRF02-AG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1077 ES P962 (G) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1078 ES X-2210-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1079 ES X-2363 - 2 ( C) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1080 ES X-2118-2 ( C) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1081 ES P1423 (CRF02-AG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1082 ES X2231 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1083 ES X1870 (CRF14_BG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1084 ES X1628-2 (G) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1085 ES X2425-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1086 ES X2400-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1087 Aldrithiol-2 treated MN ,CL.4 virus/microvesicles Treatment of SIV or HIV-1 with Aldrithiol-2 has shown to inactivate the virus, as assessed by their inability to productively infect highly susceptible cells in vitro. Large doses of Aldrithiol-2 treated SIV (10mg) have been inoculated in monkeys and none
1088 SHIV KU-1 Cellular fraction of CSF from a pig-tailed macaque that developed AIDS. A cell-free virus stock was amplified in PHA-stimulated rhesus macaque PBMCs.
1089 ES X-1608-8 (A1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1090 ES X-2110 (A1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1091 ES X-2456-2 (BG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1092 ES X-845-4 (F1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1093 ES X-1702-3 (C) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1094 ES X-230-10 (CRF02_AG/A1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1095 ES X-1589-2 (CRF14_BG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1096 ES X-963-4 (DG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1097 ES X-772-8 (CRF14_BG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1098 ES X-2457-2 (BF) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1099 ES P-2008 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1100 ES P-1981-2 (G) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1101 99ZACM9 Isolated from an HIV-1 infected female in South Africa in 1999. Patient had cryptococcal meningitis and a CD4 count of 24 cells/µl at the time of virus isolation. HIV-1 subtype C R5X4 isolate that also uses alternate coreceptors. Sequence information ca
1102 ES X-2510-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1103 ES P-2021-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1104 ES X-2432-2 (BF1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1105 ES X-1999-5 (G) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1106 ES P-1751 (CRF02_AG/A3) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1107 ES P-1942 (BF1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1108 ES X-2515-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1109 ES X-2524-2 (CRF12_BF/B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE
1110 ES X-2634-2 (G) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8 Obtained from an acute infection
1111 ES X-2574-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9 Obtained from an acute infection
1112 ES X-2689-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5, X4 (SI); TCID50/ml=10e4.9 Obtained from a newly diagnosed patient
1113 ES P-2149-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8 Obtained from an acute infection
1114 ES X-2556-3 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e5.8 Obtained from an acute infection
1115 ES X-2555-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9 Obtained from a recent infection (2 months after seroconversion)
1116 ES P-2285-2 (B) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9 Obtained from an acute infection
1117 ES X-2632-4 (BF1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e4.9 Obtained from an newly diagnosed patient
1118 ES P2222-2 (CRF02_AG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (SI); TCID50/ml=10e5.4 Obtained from an newly diagnosed patient
1119 ESR23 (A1) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e6 Obtained from chronic infection
1120 ES X531-2 (CRF12_BF) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 (NSI); TCID50/ml=10e6.6 Obtained from chronic infection
1121 ES X 874-9 (F) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. R5 and X4 (SI); TCID50/ml=106 Obtained from chronic infection
1122 93IN905 Subtype C isolate (CCR5). Isolated from seropositive individual in India.
1123 ESR77-2 (CRF20_BG) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Isolate form a newly diagnosed pateint. Subtype CRF20_BG, R5, (NSI); TDCI50/ml=10e5.2
1124 ES R74 (CRF02_AG) These isolates are part of a European Panel of HIV-1 isolates from the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Isolate form a newly diagnosed pateint. Isolate is SI and CXCR4/CCR5 dependant.
1125 CRF04 (BP007048) One of 4 patient samples (#1125-1128). Subtype CRF04. Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece. Virus isolation was performed by Dr Mark Manak at SeraCare Life
1126 CRF04 (BP007049) One of 4 patient samples (#1125-1128). Subtype CRF04. Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece. Virus isolation was performed by Dr Mark Manak at SeraCare Life
1127 CRF04 (BP007052) One of 4 patient samples (#1125-1128). Subtype CRF04. Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece. Virus isolation was performed by Dr Mark Manak at SeraCare Life
1128 CRF04 (BP007053) One of 4 patient samples (#1125-1128). Subtype CRF04. Original plasma was donated by Drs. Angelos Hatzakis and Dimitrios Paraskevis, National and Kapodistrian University of Athens, Greece. Virus isolation was performed by Dr Mark Manak at SeraCare Life
1129 ES X-2730-2 (B) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Subtype B, R5, X4 (SI);TCID50/ml=10e4.8
1130 ES P-2196-2 (G) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Subtype G, R5, X4 (SI); TDCI50/ml=10e6.8
1131 ES X-2759-2 (BF) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. Subtype BF, R5, (NSI); TDCI50/ml=10e4.9
1132 ES P-2420-3 (ADG) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1133 ES X-2757-2 (B) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1134 ES X-2160-2 (G) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1135 HIV-QH0692.42 Envelope Plasmid: QH0692.42, Tier: 2, Clade: B, Country of origin: Trinidad, Fiebig Stage: V, Mode of Transmission: F-M, Accession number: AY835439
1136 HIV-AC10.0.29 Envelope Plasmid: AC10.0.29, Tier: 2, Clade: B, Country of origin: USA, Fiebig Stage: III, Mode of Transmission: M-M, Accession number: AY835446
1137 HIV-SC422661.8 Envelope Plasmid: SC422661.8, Tier: 2, Clade: B, Country of origin: Trinidad, Fiebig Stage: IV, Mode of Transmission: F-M, Accession number: AY835441
1138 HIV-THRO4156.18 Envelope Plasmid: THRO4156.18, Tier: 2, Clade: B, Country of origin: USA, Fiebig Stage: II, Mode of Transmission: M-M, Accession number: AY835448
1139 HIV-TRO.11 Envelope Plasmid: TRO.11, Tier: 2, Clade: B, Country of origin: Italy, Fiebig Stage: IIII, Mode of Transmission: M-M, Accession number: AY835445
1140 HIV-CAP45.2.00.G37 Envelope Plasmid: CAP45.2.00.G3, Tier: 2, Clade: C, Country of origin: S. Africa, Fiebig Stage: IV, Mode of Transmission: M-F, Accession number: DQ435682
1141 HIV-Du422.1 Envelope Plasmid: Du422.1, Tier: 2, Clade: C, Country of origin: S. Africa, Fiebig Stage: V, Mode of Transmission: M-F, Accession number: DQ411854
1142 HIV-ZM53M.PB12 Envelope Plasmid: ZM53M.PB12, Tier : 2, Clade: C, Country of origin: Zambia, Stage of infection: ≤VI, Mode of Transmission: F-M, Accession number: AY423984
1143 HIV-CAP210.2.00.E8 Envelope Plasmid: CAP210.2.00.E8, Tier : 2, Clade: C, Country of origin: South Africa, Stage of infection: IV, Mode of Transmission: M-F, Accession number: DQ435683
1144 HIV-Q23.17 Envelope Plasmid: Q23.17, Tier : 2, Clade: A, Country of origin: Kenya, Stage of infection: VI, Mode of Transmission: M-F, Accession number: AF004885
1145 HIV-Q842.d12 ENVELOPE PLASMID: Q842.d12 Tier : 2 Clade: A Country of origin: Kenya Stage of infection: Acute/Early Mode of Transmission: M-F Accession number: AF407160
1146 HIV-Q769.d22 ENVELOPE PLASMID: Q769.d22 Tier : 2 Clade: A Country of origin: Kenya Stage of infection: Acute/Early Mode of Transmission: M-F Accession number: AF407158
1147 HIV-Q259.d2.17 ENVELOPE PLASMID: Q259.d2.17 Tier : 2 Clade: A Country of origin: Kenya Stage of infection: Acute/Early Mode of Transmission: M-F Accession number: AF407152
1148 HIV-427299.c12 ENVELOPE PLASMID: 427299.c12 Tier : 2 Clade: CRF01_AE Country of origin: Thailand Fiebig Stage: I/II Mode of Transmission: Hetero Accession number: Pending
1149 HIV-816763.c02 ENVELOPE PLASMID: 816763.c02 Tier : 2 Clade: CRF01_AE Country of origin: Thailand Fiebig Stage: I/II Mode of Transmission: Hetero Accession number: Pending
1150 HIV-CM246.c1 ENVELOPE PLASMID: CM246.c1 Tier : 2 Clade: CRF01_AE Country of origin: Thailand Fiebig Stage: >VI Mode of Transmission: Hetero Accession number: Pending
1151 HIV-R3265.c06 ENVELOPE PLASMID: R3265.c06 Tier : 2 Clade: CRF01_AE Country of origin: Thailand Fiebig Stage: >VI Mode of Transmission: Hetero Accession number: Pending
1152 HIV-Bal.26 ENVELOPE PLASMID: Bal.26 Tier: 1 Clade: B Country of origin: USA Fiebig Stage: VI Mode of Transmission: Accession number: Pending
1153 HIV-TV1.21 ENVELOPE PLASMID: TV1.21 Tier: 1 Clade: C Country of origin: S. Africa Fiebig Stage: VI Mode of Transmission: Accession number: Pending
1154 HIV-Bx08.16 ENVELOPE PLASMID: Bx08.16 Tier: 1 Clade: B Country of origin: France Fiebig Stage: VI Mode of Transmission: - Accession number: GQ855765
1155 HIV-SF162.LS ENVELOPE PLASMID: SF162.LS Tier: 1 Clade: B Country of origin: USA Fiebig Stage: VI Mode of Transmission: Accession number: EU123924
1156 SIVmac239CS.23 SIV gp160 clone for use as Env-pseudotyped virus
1157 SVA-MLV MLV Env-pseudotyped virus for negative control in neutralizing antibody TZM-bl assay
1158 ES P-2468-2 (CRF02_AG/CRF06_cpx) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1159 ES P-2317-2 (B) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1160 SIVmac251 Restricted to use by members of the European Vaccines and Microbicides Enterprise and for use within Europe. Only to be used in macaques.
1161 LAI-M184V (3TC-resistant) Produced by electroporation of MT-2 cells with HIV-1 LAI proviral DNA encoding the M184V RT substitution. Highly cytopathic; replicates to high titers (>105 TCID50/ml). The virus is highly resistant to 3TC, with IC50 values >60 µM in HeLa-CD4/LacZ-1 cell
1162 ES P-2392-3 (CRF02_AG) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. NSI phenotype, CCR5 co-repector use.
1163 ES X-2733-2 (A1B) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE. A unique recombinant form A1B genotype NSI phenotype, CCR5 co-repector use.
1164 ESP 2391-3 (CFR02_AG) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1165 ES X2717-2 (B) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterprise. EUROPRISE.
1166 SHIV-A Clade A SHIV
1167 C-HIV-2 KAS
1168 Primary Isolates, Ukraine Isolated from seropositive individuals in Ukraine. See datasheet for isolate numbers.
1169 Primary Isolates, Ivory Coast Isolated from seropositive individuals in the Ivory Coast. See datasheet for isolate numbers
1170 Primary Isolates, Barundi Isolated from seropositive individuals in Barundi. See datasheet for isolate numbers
1171 ES X2546-2 (C) Syncytium inducing phenotype (MT2): NSI Coreceptor use: CCR5 Titration of infectivity (TCID50/ml): 10e4.6 Full-length genome: C This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbi
1172 ES X492-3 (CRF05_DF) Syncytium inducing phenotype (MT2): NSI Coreceptor use: CCR5 Titration of infectivity (TCID50/ml): 10e5.2 Full-length genome: CRF05_DF This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and
1174 P-2606-2 (B) Syncytium inducing phenotype (MT2): NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml): 10e5.2 SUBTYPE: B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpri
1175 X-2432-5 (BF1) Syncytium inducing phenotype (MT2): NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml): 10e5.4 SUBTYPE: BF1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpr
1176 X-2874-2 (F1) Syncytium inducing phenotype (MT2): NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml): 10e5.2 SUBTYPE: F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enterpr
1177 ES X-2899-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e5.2 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines
1178 ES X-2898-2 (F1) Syncytium inducing phenotype (MT2) : SI Coreceptor use: R5 and X4 Titration of infectivity (TCID50/ml) : 10e4.9 Full-length genome : F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and
1179 ES X-2834-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e5.6 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines
1180 ES X-2871-2 (F1) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e4.9 Full-length genome : SUBTYPE F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccin
1181 ES X-2886-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use:R5 and X4 Titration of infectivity (TCID50/ml) : 10e5.2 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vacc
1182 ES P-2593-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e4.6 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines
1183 ES X-2985-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e6.4 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines a
1184 ES X-2922-3 (F1) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: R5 Titration of infectivity (TCID50/ml) : 10e4.2 Full-length genome : SUBTYPE F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccine
1185 ES X-2873-2 (F1) Syncytium inducing phenotype (MT2) : NSI Coreceptor use: CCR5, CXCR4 : R5 Titration of infectivity (TCID50/ml) : 10e5.6 Full-length genome : SUBTYPE F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence Euro
1186 ES P-2418-2 (B) Syncytium inducing phenotype (MT2) : NSI Coreceptor use : R5 Titration of infectivity (TCID50/ml) : 10e6.4 Full-length genome : SUBTYPE B This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines
1187 ES X-3097-2 (F1) Syncytium inducing phenotype (MT2) : NSI Coreceptor use : R5 Titration of infectivity (TCID50/ml) : 10e6.2 SUBTYPE: F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Ent
1188 ES X-3049-2 (BF) Syncytium inducing phenotype (MT2) : NSI Coreceptor use : R5 Titration of infectivity (TCID50/ml) : 10e6.8 SUBTYPE: BF (URF) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbici
1189 ES X-3016-2 (F1) Syncytium inducing phenotype (MT2) : - Coreceptor use : R5 Titration of infectivity (TCID50/ml) : 10e5.6 SUBTYPE: F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides Enter
1190 ES X-3067-2 (BG) Syncytium inducing phenotype (MT2) : NSI Coreceptor use : R5 Titration of infectivity (TCID50/ml) : 10e6.8 SUBTYPE: BG (URF) This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbici
1191 ES X-3070-2 (F1) Syncytium inducing phenotype (MT2) : NSI Coreceptor use : R5 X4 Titration of infectivity (TCID50/ml) : 10e6.6 SUBTYPE: F1 This isolate is part of an European Panel of HIV-1 isolates form the Network of Excellence European Vaccines and Microbicides
1192 SHIV-1157ipEL-p, harvest day 9 SHIV-1157ipEL-p is a tier 1 R5 clade C SHIV. It is a chimera of he "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene w
1193 SHIV-1157ipEL-p, harvest day 11 SHIV-1157ipEL-p is a tier 1 R5 clade C SHIV. It is a chimera of he "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene w
1194 HIV-1 (CRF_02_AG/B) EUR001 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1195 HIV-1 (B) EUR007 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1196 HIV-1 (B) EUR008 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1197 HIV-1 (F1) EUR010 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1198 HIV-1 (C) EUR011 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1199 HIV-1 (URF_BF1) EUR013 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1200 HIV-1 (F1) EUR014 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1201 HIV-1 (G) EUR016 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1202 HIV-1 (B) EUR017 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1203 HIV-1 (B) EUR023 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1204 HIV-1 (B) EUR024 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1205 HIV-1 (URF_02_AG/A1) EUR025 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1206 HIV-1 (B) EUR026 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1207 HIV-1 (B) EUR027 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1208 HIV-1 (B) EUR028 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1209 HIV-1 (URF_BF1) EUR029 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1210 HIV-1 (CRF20_BG) EUR030 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1211 HIV-1 (B) EUR031 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1212 HIV-1 (URF_BF1) EUR032 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
1213 HIV-1 (G) EUR033 SNF Cultured virus from patient plasma. See datasheet for Patient Information, Coreceptor usage, Resistance mutations, CD4 count, Viral load and Genbank numbers.
2002 pCMV-rev Expresses rev in mammalian cells. A 722bp fragment from pCV-1 containing HIV-1 rev cDNA was obtained by Bsu361 digestion. This fragment was blunt end ligated into the BamH1 site of pCMV to generate the 4972 bp plasmid pCMV-rev
2003 pSV-rev Expresses rev in mammalian cells. Contains a cDNA copy of rev positioned between the SV40 late promoter and the rabbit -globin splice and poly-A adenylation signals.
2004 pCV1 Derived from pCV, a 7 Kb mammalian expression vector containing hybrid regulatory sequences. The 1.8Kb insert encodes both rev and tat
2005 pT4B Insert 3 Kb encoding the CD4 receptor of human T-Lymphocytes of which 1.5 Kb is the coding sequence. The cDNA insert has been cloned in eukaryotic expression systems to convert CD4- fibroblasts to the CD4+ phenotype.
2006 pNL4-3 Derived from NY5 (5') and LAV (3') cloned directly from genomic DNA. Full length infection/replication competent chimeric DNA. Upon transfection pNL4-3 directs the production of infectious particles in mouse, monkey and mink cells as well as several non
2007 pSVIII gp160 clone 92UG975.10 Derived from primary isolate Ugandan subtype G, 92UG975.10. HIV-1 gp160 gene produed by PCR of PBMC's
2008 pSVIII gp160 clone 92UG024.2 Derived from primary isolate Ugandan subtype D/D (gag/env), 92UG024.2. HIV-1 gp160 gene produed by PCR of PBMC's
2009 pSVIII gp160 clones Derived from primary isolate Rwanadan subtype A/A (gag/env), 92RW020.5. HIV-1 gp160 gene produed by PCR of PBMC's
2010 pSVIII gp160 clones Derived from primary isolate Brazillian subtype B/F (gag/env), 93BR029.2. HIV-1 gp160 gene produed by PCR of PBMC's
2011 pEE14/tpa/HIV-1 IIIB env PR1-16 series Contains IIIB (BH10) clone env fragments as detailed. When transfected into CHO or BHK cells directs the secreation of gp120/140 into ambient medium.
2012 pEE14/tpa/HIV-2 env ROD Contains HIV-2 ROD env fragment (see 0298.1-2). Directs the secreation of env into the ambient media when transfected into CHO cells.
2013 pSR(alpha)Hcrm1 Contains full length human CRM1 cDNA.
2014 Near Full length Clones of HIV-1 Primary Isolates Set of 10 Near full-length clones, most of which were generated by long PCR technique. Reference clones were derived from non-subtype B isolates. Virus was derived from human PBMC cultures.
2018 pCCR Chemokine Receptor Exp.vectors The inserts were derived from cDNAs encoding CCR-1, CCR-2B, CCR-3, CCR-4, CCR-5, or Fusin. Each cDNA was amplified from activated PBMC RNA using primers hybridizing to the 5’ and 3’ untranslated regions. CCR-1, CCR-2B, CCR-4, and CCR-5 inserts were obtai
2019 Rhesus CXCR4/CCR5 Exp .Vectors These clones contain the rhesus CXCR4 or CCR5 coding regions cloned into the retroviral expression vector pBABE-puro. Expressed CCR5, and CXCR4 can be detected by FACS analysis.
2020 HIV-1 Protease Designer Gene Coding sequences have been modified to utilise codons favoured by yeast and E. coli. Includes the N-terminal Met. The provided sequence of the designer Tat Gene was inserted between the Hindlll and EcoR1 sites of the pUC18 vector. Hindlll, BspM1, and Ncol
2021 HXB2 - env Contains a 2897 bp 5’ Sacl 3’ Xhol HXB2 env fragment from HXB2gpt (env coding sequences are nt 6224-8794). HIV-1 gp 160 is expressed from an SV40 promoter. No other HIV gene products are expressed. Ampicillin-resistant vector. SV40 origin provides high l
2022 LTR-Luciferase plasmids HIV-1 A-G The LTR region was PCR-amplified and the core enhancer-promoter region (position -147 to +63 relative to the transcription start site) was cloned in the pBlue 3’LTR-luciferase plasmid (#2022.2)(Klaver B and Berkhout B, 1994) to replace the sequences of th
2025 pGB8-46R Near full length infectious clone. Transfection of HeLa or 293 T cells yields virus with tropism indistinguishable from the parental virus. Sequence analysis shows clone to be a non recombinant HIV-1 subtype B throughout its genome. Derived as half genome
2027 pEE14/tpa/UG37-08gp140REKR
2030 vP1488 92BR025 gp160, subtype C Cells infected with vp 1488 express HIV-1 Clade C gp160 which is properly processed and transported.
2031 vP1490 Vaccinia IIIB Rev vp1490 infected cells express HIV-1IIIB Rev
2032 vPT135 92UG037 p55 subtype A vaccinia vT135-infected cells express p55 gag precursor. Plasmid contains the vaccinia K1L gene and the HIV-192UG037.1 p55 (subtype A) gag gene under control of the vaccinia 40K promoter.
2033 vT139 92UG037.1 nef, Subtype A vaccinia Cells infected with vT139 express HIV-1 92ug037.1 nef gene (subtype A)
2034 vT143 92UG037.1 pol, subtype A vaccinia Cells infected with vT143 express HIV-192UG037.1 pol gene (subtype A).
2035 vT157 94UG114 gag, subtype D vaccinia Cells infected with vT157 express HIV-1 94ug114.1 gag gene (subtype D)
2036 94UG114 nef, subtype D vaccinia Cells infected with vT158 express HIV-1 94ug114.1 nef gene (subtype D)
2037 94UG114 env subtype D, vaccinia Cells infected with vT173 express the HIV-1 94ug114.1 env gene (subtype D)
2038 vT183 92UG037 env, subtype A vaccinia Cells infected with vT173 express the HIV-1 92ug037.1 env gene (subtype A)
2039 vT198R (92UG037 Env/Gag/Pol, Subtype A) Cells infected with vT198 express HIV-1 92ug037.1 (subtype A) env-,gag-, and pol-encoded polypeptides.
2040 HIV-1 92UG001 (subtype D) full length I Full length infectious clone from 92UG001 (subtype D). Produces dual trophic X4/R5 aggressive, syncytium inducing virus.
2041 pCRll gp160 clones gp160 clones from US isolates.
2042 p96ZM651.8 Near full length molecular clone of a subtype C isolate from Zambia. This genome encodes intact open reading frames for all nine HIV-1 genes.
2043 QH0692, clone 42 Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMCs. Original virus was obtained
2044 AC10.0 clone 29 Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC.
2045 pCAAN5342 clone A2 Expresses functional env/rev and can be used to generate pseudotyped infectious virus for use in neutralization tests. A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a cla
2046 Q23 ENV17 Env clone was derived from PBMCs of an individual approximately one year following HIV-1 acquisition. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype A v
2047 Q168 ENVa2 This envelope clone was directly derived from PBMCs of an individual one week after seroconversion. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype A
2048 Q842 ENVd12 This envelope clone was directly derived from an individual four weeks after seroconversion. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype A viruses.
2049 Q769 ENVd22 The envelope region of HIV-1 was amplified by PCR from PBMC DNA. The PCR product was digested with Mlul/Notl, gel isolated and cloned into Mlul/Notl digested pCI-neo. The coding region present is HIV-1 envelope gp160. Antibiotic resistance markers are
2050 Q259 ENVd2.17 This envelope clone was directly derived from PBMCs of an individual one week after seroconversion. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype A
2051 Q461 ENVe2 This envelope clone was directly derived from PBMCs of an individual four weeks before seroconversion. It is a R5 subtype A virus from Kenya. This clone is useful for screening vaccine sera for neutralizing antibodies that can block transmitted subtype
2052 Du174.15
2053 CM244.ec1 Env clones with inserts in the correct orientation screened for infectivity by co-transfection with an env deficient HIV-1 (SG3env) backbone in 293T cells
2054 MNP.ec3 Env clones with inserts in the correct orientation screened for infectivity by cotransfection with an env deficient HIV-1 (SG3env) backbone in 293T cells
2055 VI 191 Plasmid clone
2056 6535, clone 3 (SVPB5) PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture. T
2057 PVO, clone 4 (SVPB11) A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture.
2058 TRO, clone 11 (SVPB12) A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture.
2059 pWITO4160 clone 33 (SVPB18) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures.
2060 pTRJO4551 clone 58 (SVPB17) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures.
2061 pRHPA4259 clone 7 (SVPB14) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a clade B virus by reverse transcription and nested PCR amplification procedures.
2062 pTHRO4156 clone 18 (SVPB15) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject infected with a clade B virus by reverse transcription and nested PCR amplification procedures.
2063 pREJO4541 clone 67 (SVPB16) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification.
2064 pSG3 delta Env pSG3ΔENV was derived from pSG3.1 , by Spel partial digestion, Klenow filling of the 3’ recessed ends and religation. This introduced a four nucleotide insertion mutation (CTAG) in env and a translation stop codon after amino acid residue 142.
2065 SC422661, clone 8 (SVPB8) A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures.
2066 Std. Ref. Panel of Subtype B HIV-1 Env Clones This reference panel was designed for use as Env-pseudotyped viruses to facilitate standardized Tier 2/3 assessments (Mascola JR. et al. J Virology 79(16):10103, 2005) of neutralizing antibody responses.
2067 pSVIII-92BR025.9 Derived from a patient in Brazil. PCR-derived HIV-1 gp160 gene from primary PBMC culture was cloned into pSVIIIenv (Kpn). The primary isolate env gene was exchanged into the vector in place of the HXB2 env gene, and used in a single round CAT-based virus
2068 92RW009-6 The complete env gene (~2.6 kb) from the p92RW009.6 clone (NIH Cat No. 4006) was PCR amplified using primers containing a Eco RI (sense) respectively Not I (anti-sense) restriction recognition sequence site. Both sites were used for cloning after the Huma
2069 HIV-1 Subtype C Env Clones Reference Panel This clade C reference panel was designed for use as Env-pseudotyped viruses to facilitate standardized Tier 2/3 assessments of HIV-1-specific neutralizing antibodies (Mascola JR. et al. J Virology 79(16):10103, 2005). When co-transfected with an env-dele
2070 pcDNA3.1 APOBEC-V5-6XHis The cloning insert was obtained from Open Biosystems (Huntsville, AL). Insert for human APOBEC3G was cloned into mammalian expression vector pcDNA3 with a V5 epitope tag from SV5 paramyxovirus and a polyhistidine epitope at the C terminus. Plasmid DNA was
2071 HIV-1 SE8131-3 Clade A Clone Full length clade A clone. Accession No: AF107771 in pCRII-TOPO vector.
2072 p93IN905 Virtually full-length HIV-1 genome (lacks 74 bp in the LTR R-U5 region) was amplified from DNA obtained from co-cultured PBMCs infected with HIV-1 93IN905 (Catalog #1122). The primers used were msf5 and msf12 (MO Salminen, et al.). The 9 kb product w
2073 pSVIII-93MW965.26 Derived from a patient in Malawi. PCR-derived HIV-1 gp160 gene from PBMC culture was cloned into pSVIIIenv (Kpn). The primary isolate env gene was exchanged into the vector in place of the HXB2 env gene, and used in a single round CAT-based virus infecti
2074 HIV-1 clone TV1.29 A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. T
2075 p1054.TC4.1499 Env clones of transmitted and early founder HIV-1 subtype B in primary HIV-1 infection (RNA positive, Western blot negative). HIV-1 clade B molecular rev/env clones derived from patient plasma during acute HIV-1 infection. The rev/env genes were PCR am
2077 pNL-845_4-Ren Env clone of virus isolate X-845-4 clade F1 (#1092), from a EUROPRISE panel of isolates.
2078 pNL-962-Ren Env clone of virus isolate P-962 clade G (#1077), from a EUROPRISE panel of isolates.
2079 pNL-1261-Ren Env clone of virus isolate P-1261 clade CRF02_AG (#1076), from a EUROPRISE panel of isolates.
2080 pNL-1423-Ren Env clone of virus isolate P-1423 clade CRF02_AG (#1081), from a EUROPRISE panel of isolates.
2081 pNL-1589_2-Ren Env clone of virus isolate X-1589-2 clade CRF14_BG (#1095), from a EUROPRISE panel of isolates.
2082 pNL-1608_8-Ren Env clone of virus isolate X-1608-8 clade A1 (#1089), from a EUROPRISE panel of isolates.
2083 pNL-1628_2 Env clone of virus isolate X-1628-2 clade G (#1084), from a EUROPRISE panel of isolates.
2084 pNL-1702-3 Env clone of virus isolate X-1702-3 clade C (#1093), an isolate from a EUROPRISE panel of isolates.
2085 pNL-1936-Ren Env clone of virus isolate X-1936 clade C (#1073), from a EUROPRISE panel of isolates.
2086 pNL-2118_2-Ren Env clone of virus isolate X-2118-2 clade C (#1080), from a EUROPRISE panel of isolates.
2087 pNL-2363_2-Ren Env clone of virus isolate X-2363-2 clade C (#1079), from a EUROPRISE panel of isolates.
2088 Panel of Paired Infant and Maternal Env Clones A collection of HIV-1 envelope clones isolated from chronically infected women and their infants who were infected with HIV-1 sometime between birth and 6 weeks post delivery. These clones are useful for the study of paired maternal and infant viruses n
2089 Panel of HIV-1 Envelope Clones Panel of HIV-1 envelope clones isolated from women who acquired HIV-1 sexually. The envelope sequence was cloned from PBMC DNA at 23-100 days post-infection, as described in Blish JV, 83: 7783-7788, 2009 and Long et al. ARHR 18: 567-576, 2002. The envelop
2090 p92NG083.2 Near-full-length clone generated by long PCR technique and cloned into the MluI site of pTZ18Mlu1. Lacks less than 80 bp of LTR sequences. Ampicillin Resistant.
2091 p97CN001.12 Genomic DNA was extracted from PBMC culture and used for PCR amplification. PCR products were cloned directly into vector pTZ18Mlu I at the Mlu I cloning site. This clone is ampicillin resistant. GenBank Accession #AF286226. Sequences in GenBank reflect d
2092 pNL-GFP-RRE(SA) pNL-GFP-RRE was first constructed by complete deletion of all HIV ORFs of pNL4-3 by replacing the 8.1 kb BssHII-BlpI fragment of the HIV-1 genomes with an insert containing the GFP ORF and the HIV-1 Rev-responsive element (RRE) including the HIV-1 sequenc
2093 DuoFluo (R7GEmC) This HIV-1 construct contains two distinct fluorescent proteins under control of independent promotors. EGFP has been inserted in place of nef and is expressed through LTR activation. An EF1a-mCherry transcriptional unit was inserted between EGFP and the
2110 vBD3 (89.6gp160) Cells infected with vBD3 express env glycoprotein from the dual trophic HIV-1 primary isolate 89.6, which uses both CXCR4 and CCR5, and well as a number of other chemokine co-receptors for entry. The gp160 is expressed on the surface of infected cells, an
2111 vNEF2 (NL4-3) (vTFnef) The HIV-1 nef ORF was isolated from the plasmid pNLXho, a pNL432 derivative. A BamHl fragment was blunt end ligated to pSCll (from Dr. Bernard Moss) and cleaved with SmaI to produce the plasmid pTFnef. This clone contains the nef coding sequence under tr
2112 vP1218 rvHIV-1 nef (MN) ABI Contains the HIV-1MN nef gene. The vaccinia virus 13L early/intermediate promoter is cloned upstream of the nef coding sequences. Cells infected with vP1218 express HIV-1MN Nef
2114 Baculovirus HIV-1 HXBC2gp120 Baculovirus expressing HIV-1 HXB2 gp120 with FLAG tail - EFGGDYKDD-DDKGG
2115 Baculovirus HIV-1 Bal gp120 Flag Tailed Baculovirus expressing HIV-1 HXB2 gp120 with FLAG tail - EFGGDYKDD-DDKGG
2116 C2, HIV-1 env gene cassetting system Based on infectious clone NL4-3.C2 env chimearas retain glycoprotein determined phenotype of their parent viruses.
2117 pcDNA3-DC-SIGN DC-SIGN is a C-type lectin, which efficiently binds and transmits HIV-1, HIV-2 and SIV to receptor positive cells. This clone can be used for DC-SIGN expression in mammalian cells. DC-SIGN cDNA was amplified from human dendritic cells and cloned between
2118 pcDNA3-DC-SIGNR DC-SIGNRelated is a C-type lectin that binds ICAM-3 and HIV gp120 and transmits HIV-1, HIV-2 and SIV to receptor cells in the liver and lymph nodes.This clone can be used for DC-SIGN expression in mammalian cells.
2119 HIV-1 p89.6 plasmid Full length infectious molecular clone, full 9.7KB provirus with intact LTR's.
2120 pSHIV-KB9 5' plasmid The KB9 5' construct contains the HindIII-SphI fragment (nt 215-6706) of SIVmac239 in pBS(+) (Stratagene). The insert size is 6.5 kb (total plasmid size is 9.5 kb). Asynthetic polylinker was introduced between the vector EcoRI site and the SIVmac239 cellu
2121 pSHIV KB9 3' plasmid The KB9 3' construct encodes the HIV-1 portions of the chimeric virus. Vector is pSL1180 (Pharmacia).
2122 pSHIV-89.6 5' plasmid The KB9 5' construct contains the HindIII-SphI fragment (nt 215-6706) of SIVmac239 in pBS(+) (Stratagene). The insert size is 6.5 kb (total plasmid size is 9.5 kb). A synthetic polylinker was introduced between the vector EcoRI site and the SIVmac239 cell
2123 pSHIV 89.6 3' plasmid The SHIV-89.6 3' construct encodes the HIV-1 portions of the chimeric virus, cloned into the pBluescript II KS(+) vector (Stratagene). The insert size is 5.9 kb, and the plasmid size is 8.9 kb.
2124 vT183 The HIV-192UG037.1 env gene was modified to introduce silent mutations to remove two internal T5NT sequences encoding vaccinia virus early transcription termination sequences. A plasmid containing the vaccinia K1L gene and the modified env gene under cont
2125 pCAGGS SF162 gp160 Co-transfection of 293T cells with NL4-3 env plasmid yields an HIV-1 pseudotype virus that is R5-tropic and susceptible to neutralization by multiple antibodies.
2126 SV-A-MLV-env Contains the amphotropic murine leukemia virus env gene (nt. 5407- 7846) linked to the MLV LTR. The plasmid also contains the SV40 origin. Ampicillin resistant. Co-transfection of COS cells with SV-A-MLV-env and HIV-gpt yields an HIV/MLV (amphotropic) ps
2127 HIV-1 pSVIII 92UG021.16 Approximate plasmid size 8290bp
2128 pNL4-3.Luc.R-E- Firefly luciferase gene was inserted into the pNL4-3 nef gene. Two frameshifts (5′ Env and Vpr aa 26) render this clone Env- and Vpr-.
2129 rVVgp120Bx08 Vaccinia virus (Western Reserve) recombinant for the codon-optimised gp120 gene from HIV-1(Bx08) expressing gp120 protein in (VERO) cell culture supernatant.
2130 pNL-Env-Ren (Clades A,B,C,D&E) The env gene (complete gp160) of 10 viruses representative of the five primary clades A to E1 was amplified by PCR from viral RNA using specific primers, digested with XbaI and NotI and inserted in the same sites in the pNL-lacZ/env-Ren2 with the resultin
2132 pZM96gp140
3002 Mab to SIV gp41 (KK20a) Suitable for ELISA, immunoblotting , RIPA and IF
3003 Mab to SIV gp120 (KK46) Suitable for ELISA, immunoblotting , RIPA and IF
3004 Mab to SIV p17 (KK59) SIV p55/p17 (reacts with peptide 0775 [.2]). Suitable for ELISA and immunoblotting. Purified antibody also available Cat# 100404.
3005 Mab to SIV p27 (KK64) Suitable for ELISA and immunoblotting
3006 Mab to SIV p27 (KK63) Suitable for ELISA and immunoblotting
3007 Mab to Feline class II MHC Specific to Feline Class II MHC. IgG1
3008 Mab to Feline CD8 Specific to Feline CD8.
3010 Mab to Feline CD4 Specific to Feline CD4. IgG1
3012 Mab to HIV-1 LAI gp120 (4G10) Reacts in ELISA with V3 loop peptide (#0734) and with purified gp160(LAI). Reacts in immunoblot with gp120(LAI) and IFA with infected cells. Inhibits syncitium formation, RT activity and p24 production in vitro (100% inhibition over 20 days)
3013 Mab to HIV-1 LAI gp120 (5F7) Reacts in ELISA with V3 loop peptide (#0734) and with purified gp160(LAI). Reacts in immunoblot with gp120(LAI) and IFA with infected cells. Inhibits syncitium formation, RT activity and p24 production in vitro (partial and retardation over 20 days)
3014 Mab to HIV-1 LAI gp120 (7D8) Inhibits syncitium formation, RT activity and p24 production in vitro. Reacts in ELISA with V3 loop peptide ADP737. Inhibits syncytium formation, RT activity and p24 production in vitro (retardation over 20 days)
3015 Mab to CD4 (Q425) Does not inhibit binding of gp120 or virus to CD4, but blocks infection and syncitium formation by a number of isolates.
3016 Mab to HIV-1 gp120 (Human) Blocks CD4 binding. Neutralises a wide range of strains IIIB, Z84, MN and SA3. Reacts in ELISA/Immunoblot with at least 2 strains of HIV-1
3018 Mab to HIV-1 RT Epitope mapped to aa aa294-319. Can be used in ELISA and IF assays
3019 Mab to HIV-1 RT Reacts with p66/p51. Can be used in ELISA/IF assays
3020 Mab to HIV-1 RT Reacts with p66. Can be used in ELISA and IF assays
3021 Mab to MAb anti HIV-1 tat (ID9D5) Reacts with HIV-1 tat in ELISA and Immunoblot. Epitope mapped to aa 1-20.
3022 Mab to MAb anti HIV-1 tat (J4B4F4) Reacts with HIV-1 tat in ELISA and Immunoblot.
3023 Mab to HIV-1 MN gp120 (Human) 257-D IV Reacts in ELISA/RIPA. Neutralises MN and SF2 but not IIIB
3024 Mab to HIV-1 MN gp120 (Human) 268-D IV Reacts in ELISA/RIPA. Neutralises MN and SF2 but not IIIB
3025 Mab to HIV-1 IIIB gp120 (V3) Neutralises IIIB. Immunoblots/reacts in ELISA with IIIB
3026 Mab to HIV-1 nef Recognises an epitope at the n-terminus of nef, possibly only including the last 6 aa. Suitable in ELISA's and Western blots. It recognises nef from a wide range of strains.
3028 Mab to HIV-1 gp120 (2D7-V4) Reacts in ELISA, Immunoblot and IF
3029 Mab to HIV-2 gp105 Mapped to C1
3030 Mab to HIV-2 gp105 Mapped to C1
3031 Mab to HIV-2 gp105 Mapped to C-terminus
3032 Mab to HIV-2 gp105 Mapped to C2
3033 Mab to HIV-2 gp105 Mapped to C2
3035 Mab to HIV-1 gp120 Neutralises HXB10 clone of HIV-1 IIIB but not HXB2 or IIIB itself. Suitable for ELISA.
3036 Mab to HIV-1 gp120 Virion binding and neutralisation of HIV-1IIB only in the presence of sCD4 Suitable for ELISA and RIA
3037 Mab to HIV-1 gp120 Neutralises IIIB. suitable for ELISA and RIA
3038 Mab to HIV-1 gp120 Neutralises IIIB. suitable for ELISA and RIA
3039 Mab to HIV-1 gp120 Virion binding and neutralisation of HIV-1IIB only in the presence of sCD4 Suitable for ELISA and RIA
3040 Mab to HIV-1 gp120 Vition binding only in the presence of sCD4. Does not neutralise IIIB. Suitable for ELISA and RIA.
3041 Mab to HIV-1 gp120 Neutralises HXB10 clone of HIV-1 IIIB, but not HXB2 or IIIB itself. Binds to virion. Antibody binding to gp120 is inhibited by sCD4.Antibody does not inhibit sCD4 binding to gp120. Suitable for ELISA and RIA.
3042 Mab to SIV gp160/120 (KK66) Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 0774.13
3043 Mab to SIV gp160/gp120 (KK18) Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 0774.1
3044 Mab to SIVgp160/gp32 (KK41) Suitable for ELISA, immunoblotting , RIPA and IF. Reacts with peptide 0798.10
3045 Mab to SIV gp120 (KK9) Suitable for ELISA, immunoblotting , RIPA and IF. Neutralises SIVmac251 at a titre of 1:1920
3046 Mab to HIV-1 IIIB gp120 (IIIB-V3-01) Bind to non-glycosylated denatured IIIB in ELISA, but does not neutralise IIIB, MN, SF2 or RF, or react with cell-surface gp120 expressed IIIB infected Molt-3 cells.
3047 Mab to HIV-1 IIIB gp120 (IIIB-V3-13/IIIB-V3-34) Exhibits strong tpe-specific neutralisation of IIIB and medium to weak neutralisation of SF2, NY5, MFc and two primary isolates. Reacts with native IIIB and SF2 gp120 and denatured IIIB, SF2 and SK gp120.
3048 Mab to HIV-1 IIIB gp120 (IIIB-V3-21) Does not neutralise HIV-1
3049 Mab to HIV-1 gp160/120 Binds weakly to denatured gp120. Binding enhanced by the persence of non-ionic detergent.
3051 Mab to HIV-1 gp160/120 Binds weakly to denatured, but not native gp120.
3053 Mab to p50 subunit of NF-kB Recognises a linear epitope either very close to, or including, the nuclear localisation signal of the p50 protein.
3055 Mab to HIV-1 gp120 (GP68) Human mab suitable for use in ELISA/IRMA, RIPA and IF. Neutralises a wide range of HIV-1 strains
3056 Mab to HIV-1 gp120 (Human) Suitable for use in ELISA/IRMA, RIPA, IF, Western blotting and virus neutralisation
3057 Mab to HIV-1 p17 (Human) Does not recognise linear peptides. Reacts in ELISA/Western blot. Inhibition of syncitia formation in C8166 cell line. Shown to be HIV-1 negative by PCR
3058 Mab to HIV-1 rev Suitable for ELISA , Western blot and IF
3060 Mab to MAb anti HIV-1 rev (Ig10F4) Suitable for ELISA, western blot and IF
3061 Mab to SIV p27 (KK60) Reacts in ELISA, Western blot and RIPA. High titre antibody produced in technomouse.
3063 Mab to HIV-1 gp41 (2F5) Human recombinant mab produced in CHO cells. Neutralises a broad variety of laboratory strains and Primary isolates.
3064 Mab to HIV-1 gp120 (2G12) Human mab neutralises HIV-1 IIIB, RF and a broad variety of primary isolates.
3065 Mab to HIV-1 IIIB gp120 (Human) b12 Obtained as a Fab by selection against gp120 IIIB of an antibody phage display library prepared from bone marrow of a asymptomatic HIV-1 seropositive donor. Was then expressed as a whole antibody in CHO cells in tissue culture. Neutralises field isolates
3066 Mab to SV5-Pk tag May be used for the affinity purification of the SIV-Pk fusion protein from bacterial expression vectors #0282 and 283.
3067 Mab to MAb anti HIV-1 BRU nef Cross reactivity measured by immunoperoxidase staining. Also reacts in ELISA and western blot.
3068 Mab to MAb anti HIV-1 JR-CSF nef 3 mAbs specific to different epitopes of nef.
3069 Mab to MAb anti HIV-1 IIIB tat As IgM is difficult to purify Mab 8.2 (#3069.2) is an enriched fraction from mouse Ascitis (in PBS + 0.1% NaN3). Therefore it is composed of some other proteins which do not cause problems with the antibody specificity. Since IgM is around 0.5mg/ml we adv
3070 Mab to MAb anti HIV-1 IIIB rev 3 mAbs to different epitopes of rev.
3071 Mab to SIV nef 5 mAbs to different epitopes of SIV nef
3072 Mab to SIV rev 4 mAbs to different epitopes of SIV rev
3074 Mab to HIV-1 gp120 (V2) Neutralises molecular clones HXB10 and HXB2. Binds to cell surface expressed oligomeric gp120. Suitable for ELISA.
3075 Mab to HIV-1 gp120 (V2) Crossv reacts with RF. Binds to cell surface expressed oligomeric gp120. Suitable for ELISA.
3076 Mab to HIV-1 gp120 (C1) Binds to rec. gp120 by ELISA. Cross reacts with IIIB, MN and RF.
3077 Mab to HIV-1 gp120 (V2) Neutalises HXB10. Binds to cell surface expressed oligomeric gp120. Binds to rec. gp120 by ELISA.
3078 Mab to HIV-1 gp120 (17b) Human mab neutralises a wide range of isolates, reacts in ELISA and Immunoblot.
3079 Mab to HIV-1 gp120 (48D) Human mab neutralises a wide range of isolates, reacts in ELISA and Immunoblot.
3080 Mab to FIV env Recognises several FIV isolates
3081 Mab to FIV env FIV-petaluma specific
3082 Mab to FIV env FIV-petaluma specific
3083 Mab to HIV-2 gp105 HIV-2 env C1 aa43-54. Positive in ELISA, IF and western blot
3084 Mab to HIV-2 gp105 HIV-2 env V1 aa125-133. Positive in ELISA, and IF
3085 Mab to HIV-2 gp105 HIV-2 env V2 aa140-148. Positive in ELISA, IF and western blot
3086 Mab to HIV-2 gp105 HIV-2 env V2 aa149-154. Positive in ELISA, IF and western blot. Neutralises virus infectivity.
3087 Mab to HIV-2 gp105 HIV-2 env conformational dependant not V1, V2 nor V3. Positive in ELISA
3088 Mab to HIV-2 gp105 HIV-2 env conformational dependant not V1,V2 nor V3. Positive in ELISA, IF and neutralises virus.
3089 Mab to HIV-2 gp105 HIV-2 env conformational dependant not V1, V2 nor V3. Positive in ELISA
3090 Mab to HIV-2 gp105 HIV-2 ROD V3 aa304-311. Positive in ELISA, neutralises virus infectivity
3091 Mab to HIV-2 gp105 HIV-2 ROD V3 aa306-311. Positive in ELISA and western blot
3092 Mab to SIV nef (KK75) Positive in westernblot, FACScan, reacts with 0777.7. Suitable for Immunohistochemistry (formalin-fixed, parafin embedded tissue).
3093 Mab to SIV nef (KK77) Positive in western blot, RIPA, FACScan, reacts with 0777.8
3094 Mab to SIV nef (KK80) Positive in western blot, RIPA, FACScan
3095 Mab to HIV-1 W61D (TH1) Isolate specific. Reacts with #3095.
3096 Mab to HIV-1 W61D (TH3) Clade specific. reacts with #7035.14
3097 Mab to HIV-1 W61D (TH8) Braodly cross reactive.
3098 Mab to HIV-1 W61D (KK86) Broadly cross reactine. Reacts with #7035.42 and 7035.14
3100 Mab to CCR3 Good neutralising ability, works well in immunoassays.
3101 Mab to CXCR4 (12G5) Works well in FACS assay. Partial antagonist of SDF-1
3102 Mab to RANTES Works well in ELISA, westernblot, cell staining and Immuno precipitation
3103 Mab to RANTES Works well in ELISA, westernblot and cell staining Negative for immunoprecipitation.
3104 Mab to RANTES Works well in ELISA, western blot and immunoprecipitation Positive for immunoprecipitation.
3105 Mab to RANTES Works well in ELISA, western blot and immunoprecipitation. Positive for immunoprecipitation.
3106 Mab to HIV-1 nef (1/46a/5d) Works well in ELISA
3107 Mab to HIV-1 nef (1/56/3b) Works well in ELISA
3108 Mab to HIV-1 nef (92/81c/2j) Works well in RIPA and ELISA
3109 Mab to HIV-1 nef (2/90/2k) Works well in ELISA
3110 Mab to CCR2 Specificity to aa24-38 of the human CCR2. IgG2α
3111 Mab to CCR2 Specificity to aa24-38 of the human CCR2. IgG2α
3112 Mab to CCR5 Specificity to aa13-28 of the human CCR5. IgM
3113 Mab to CCR5 Specificity to aa13-28 of the human CCR5. IgM
3114 Mab to CCR5 Specificity to aa13-28 of the human CCR5 receptor
3115 Mab to HIV-1 gp120 (F105) Reacts with a discontinuous or conformational, gp120 epitope. Binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. Neutralises SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10µg/ml.
3116 Mab to HIV-1 vif (TG001) Raised in mice immunised with purified HIV-1 Vif protein derived from E-coli . Recognises Vif in ELISA, Western blot, and RIPA assays. Maps to the C-terminal region (aa 176-192).
3117 Mab to HIV-1 env (CA1) Specific to HIV-1 env subtype A.
3118 Mab to HIV-1 env (CA8) Sub-type A & D specific (92/UG/029, 92/UG/035 & rec IIIB gp120), works in ELISA.
3119 Mab to HIV-1 env (CA13) HIV-1 env sub-type, broadly cross-reactive.
3200 Mab to SIV nef (J5) (KK70) Monoclonal antibody to SIV nef (J5)
3201 Mab to SIV nef (J5 and C8) (KK71) Monoclonal antibody to SIV nef (J5 and C8). Positive in Western blot, RIPA, FACSCAN (SIV J5/C8)
3202 Mab to HIV-1 W61D gp120 7 mAbs to regions V2, V3, C4 and V5/C5 of HIV-1 W61D gp120
3203 Mab to HIV-1 W61D gp120 (68/77a) Conformational dependent epitope (V1V2V3 dependent) preferentially exposed on gp160
3204 Mab to HIV-1 W61D gp120 (68/91) Conformational dependent epitope (V1V2V3 independent) preferentially exposed on gp160.
3205 Mab to HIV-1 W61D gp120 (68/92) Conformational dependent epitope preferentially exposed on gp160.
3206 Mab to HIV-1 env gp120 (63/10) Linear epitope to C1. Recognises peptide #0740.8
3207 HIV-1 env gp120 (63/45a, 69a, 84c, 85a, & 91a) Linear epitope in C1
3208 Mab to HIV-1 env gp120 (63/49) Conformational dependent epitope within V1.
3209 Mab to HIV-1 env gp120 (63/11b) Conformational dependent epitope within V1V2
3210 Mab to HIV-1 env gp120 (63/42) Conformational dependent epitope within C1
3211 Mab to HIV-1 env gp120 (63/45b) Conformational dependent epitope within V2
3214 Mab to CCR5 Specific to aa13-28 of the human CCR5. IgM
3215 Mab to HIV-1 vif (Tg002) Recognises Vif in ELISA and RIPA assays (not reactive in Western blots). Maps to the N-terminal region (aa 34-47)
3218 Mab to HIV-1 gp120 (697D) The epitope spans the region 164-194 of gp120HXB2 and is primarily conformation-dependent with weak reactivity for a linear region between aa 161-180(1). This epitope is common to 75% of clade B primary isolates (2). SincemAb 697-D reacts sporadically wit
3219 Mab to HIV-1 gp120 (447-52D) The antibody neutralises laboratory strains1,2 and clinical isolates3 which contain the GPGR sequence at the apex of the V3 loop. This monoclonal binds to virus-infected cells4, cross-reacts with V3 peptides derived from isolates of various clades5, and
3220 Mab to HIV-1 CD4 (654D) This mAb recognizes a discontinuous epitope on gp 120 and its binding depends on the tertiary protein structure and intact carbohydrates (1). The epitope,though infrequently detected, is expressed on cells infected with various clades (2). MAb 654-D bloc
3221 Mab to HIV-1 gp120 (670D) Core epitope localised to region aa 503-509 of rgp 120LAI based on binding to overlapping C-terminus peptides. MAb 670-D binds to the surface of cells infected with majority of viruses tested from clades A-E (1) and reacts with intact virions from clade
3222 Mab to HIV-1 gp41(50-69D)
3223 Mab to HIV-1 gp41 (98-6D) Reactivity was tested with recombinant proteins (Microgenetics). gp41specificity 644-663
3224 Mab to HIV-1 p24 Obtained from EBV-immortalised peripheral blood Mononuclear cells from HIV-seropositive individuals.This antibody is anti-p24, and reacts with HIV lysate In ELISA. It reacts with the p55 core precursor as well as p24 and several intermediates as determin
3225 Mab to DC-SIGN (DC28) This is a murine lgG2 generated from a mouse immunised with a thioredoxin fusion protein containing the entire DC-SIGN ectodomain. Works by Western blot and FACS analysis. Also works well for immunoperoxidase staining of tissue sections. Directed agai
3226 Mab to RAID 54 67a 2k anti HIV-2 gp105
3227 Mab to RAID 54 3b 1a anti HIV-2 gp105
3228 Mab to RAID 54 77.o.w 12f anti HIV-2 gp105
3229 Mab to RAID 54 64 4a anti HIV-2 gp105
3230 Mab to RAID 54 34a 4e anti HIV-2 gp105
3237 Mab to DC-SIGN (DC6) Anti DC-SIGN specific monoclonal antibody, reacts against an epitope at the C-terminus included within KKSAASCSRDEEQFLSPAPATPNPPPA. Balb/c mice were immunised intradermally 4 times weekly with 100g of bacterial ectodomain of hu-DC-SIGN. Four days followi
3239 Mab to HIV-1 gp41 (4E10) Recombinant human monoclonal antibody to HIV-1gp41 epitope NWFDIT. IgG1 (kappa).
3240 Mab to TriMab (2F5, 2G12 & b12) Consists of equal concentrations of Mabs 2F5, 2G12 and b12 diluted to 1mg/ml in PBS (333μg/ml of each antibody)). The individual monoclonal antibodies are also available separately see 3063 2F5, 3064 2G12, and 3065 b12.
3241 Mab to HIV-1 tat (NT8 8D1.8)
3242 Mab to MAb anti HIV-1 tat (NT2 4D5.24) mAb to C-terminal peptide of tat. Human IgM
3243 Mab to HIV-1 p24 5 antibodies to various epitopes of p24 (see datasheet) Reacts in ELISA, WB, IHC, IF, RIP with HIV-1 native p24 as well as rp24 expressed in bacteria & Cos-7 cells.
3245 Mab to HIV-1 97CN54 gp140 (N03B11) Binds env from 2 geographically distant clade C isolates but not env from other clades
3246 Mab to HIV-1 CN54 gp140 (subtype C) Competition group MH9 = 1 MH10 = 2 MH13 = 4
3248 Mab to SIV tat (MH6) Recognises recombinant SIV tat in Elisa
3249 Mab to CXCR4 Monoclonal antibody to N-terminal of CXCR4
3250 Mab to CD4 region of gp120 (M14) Binds to CD4 region of gp120
3251 Mab to HIV-1 gp120 (P4/D10) Mediates highly efficient antibody-dependent cellular cytotoxicity and virus neutralisation. The reactivity was located to a major neutralising region on gp120 (aa304-323).
3252 Mab to MAb anti tat (NT3/2A4.1) mAb to N-terminal peptide of tat
3253 Mab to MAb anti tat (NT3/5A5.3) mAb to N-terminal peptide of tat
3254 Mab to MAb anti tat (NT7/4A4.8) mAb to tat
3255 Mab to MAb anti tat (NT7/7D5.1) mAb to tat
3256 Mab to MAb anti tat (NT8/6B4.8) mAb to tat
3257 Mab to HIV-1 gp120 (P3B2) Antibody to the HIV V1 region (mAB: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 ΔV2 gp140/V1 gp120, Elisa 0.5 mg/ml).
3258 Mab to HIV-1 gp41 (P4A3) Antibody to the HIV gp41 (mAB: IgG2a kappa, chimera protein A/G binding, used immunogen SF162 gp140/gp41, Elisa 0.5 mg/ml).
3259 Mab to HIV-1 gp41 Antibody to the HIV-1 gp41 region (mAB: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 gp140/SF162 gp41, Elisa 0.5 mg/ml).
3260 Mab to HIV-1 gp120 (P1H6G11) Antibody to the HIV-1 gp41 region (mAb: IgG1 kappa, chimera protein A/G binding, used immunogen SF162 gp140/SF162 gp41, Elisa 0.5 mg/ml.
3261 Mab to Murine Human APOBEC3G High affinity murine Anti-Human APOBEC3G (CEM15) mAb. Binds to native and recombinant human CEM15 in ELISA and Western ELISA.
3262 Mab to Murine Anti-Human TRIM5 Alpha High affinity murine Anti-Human TRIM5a mAb. Binds to native and recombinant human TRIM5 in ELISA and Western ELISA, cross reactive with RhTrim 5 Alpha as determined by ELISA and Immunofluoresence assays.
3263 Mab to HIV-1 env V3 loop region (P3E1F3) Antibody to the HIV env V3 loop region (mAB: IgG2a kappa, chimera protein A/G binding, used immunogen SF162 gp140/V3 gp120. SNF shows strong binding to #7012.2 and #7041 V3 peptides (100ng/well) at a dilution of 1:1000.
3277 HIV-1 anti-idiotypic antibody to 2G12 (M1G1) Murine monoclonal non-inhibiting, anti-idiotypic antibody to HIV-1 antibody 2G12
3278 Mab to HIV-1 gp41 (3D6) Human monoclonal antibody to HIV-1 gp41 epitope GCSGKLICTTAVPW.
3279 Mab to HIV p24 Human Monoclonal antibody to HIV-1 p24
3280 Mab to HIV-1 p24 Murine Monoclonal antibody to HIV-1 p24 epitope GATPQDLNTML
3281 Mab to HIV-1 gp41 (5F3) Recombinant human monoclonal antibody to HIV-1 gp41 epitope AAGSTMGAASMTLTVQARQ
3282 Mab to HIV-1 gp41 (4B3) Human Monoclonal antibody to HIV-1 gp41 epitope SGKLIC
3283 Mab to SIV gp160/gp120 (KK17) Raised in mice primed with a SIVmac251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaraldehyde-fixed SIVmac11/88 from C8166 cells. Reacts with the SIV env region (aa 8-303). Reacts in WB with gp160/gp120; also reactive in RIPA and surface fl
3284 Mab to SIV env (KK42) Raised in mice primed with a SIVmac251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaraldehyde-fixed SIVmac11/88 from C8166 cells. Reacts with the SIV V3 region (aa 321-340). Reacts in WB with gp160/gp120; also reactive in RIPA and surface f
3285 Mab to HIV-1 V3 (2191) Isolated PBMCs taken from a HIV-1 Subtype B infected patient from the USA. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridoma was clo
3286 Mab to HIV-1 V3 (2219) Isolated PBMCs taken from a HIV-1 Subtype B infected patient from the USA. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridoma was clo
3287 Mab to HIV-1 V3 (3869) Isolated PBMCs taken from a HIV-1 (subtype unknown) infected patient from Cameroon. Produced by Epstein-Barr virus transformed peripheral blood mononuclear cells producing V3 specific antibodies fused with heteromyeloma SHM-D33, and the resulting hybridom
3288 Mab to HIV-1 IIIb gp41 (246-D) Reacts in ELISA with a gp41 peptide spanning aa 579-613 of gp160. mAb 246-D binds to overlapping hexapeptides which identified its core epitope as qqLLGIwg (aa 591-598) which is located in the immunodominant region (cluster I) of gp41, just upstream from
3289 Mab to HIV-1 gp120 (VRC03) HIV-1 envelope monoclonal antibody directed towards the CD4-binding site of HIV-1 gp120. Purified by protein A sepharose column chromatography. Broadly neutralizing HIV-1 antibody; active against all major subtypes. No cross-reactivity against host self o
3290 Mab to Mouse Anti-Human CD195 (2D7/CCR5) Raised against CCR5 transfectants. Recognizes the second extracellular domain of CCR5. Works well in flow cytometry and immunohistochemistry. Also works in immunoprecipitat